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The Hedgehog (Hh) pathway is a development pathway with therapeutic potential as a target for treatment 
of cancers and degenerative disorders. Multiple agonists of Hh signaling have been investigated to treat 
degenerative disorders, oxysterols (OHCs) have been the most well studied. Previous studies have shown 
OHCs to bind directly to the cysteine-rich domain of Smoothened in a regio- and stereoselective manner. 
A series of OHC analogues were synthesized with modifications at the C-20 position to further study 
binding. Combined with modeling studies, inverting the C-20 stereochemistry was determined to switch 
the activity of the analogues from agonist to antagonists. Additional studies suggested that inversion 
rigidified the alkyl side chain to increase interactions leading to the activity change. Among the scaffolds 
under investigation as anti-cancer chemotherapeutics and antagonists of Hh signaling is vitamin D3 (VD3). 
Previous structure-activity relationship studies contained both modified A- and seco-B ring motifs, and 
provided potent and selective analogues for Hh signaling. To continue studies on this scaffold, new series 
of compounds were synthesized to explore additional interactions and spatial constraints. While continuing 
to evaluate the usefulness of amine-based seco-B ring motifs, these compounds incorporate functional 
groups of varying size and hydrophobicity at the C-11 position of the C-ring as well as hydroxylations at 
the C-25 position of the alkyl side chain. While large hydrophobic moieties at the C-11 position resulted in 
significant loss of Hh inhibition, smaller or more flexible moieties maintained anti-Hh activity. 
Hydroxylation at the C-25 position significantly increased VDR activation while also increasing anti-Hh 
potency for most analogues. Masking the hydroxyl group as a methyl ether could regain selectivity for Hh 
signaling with minor losses in anti-Hh activity. Mechanism of action studies have been contradictory, but 
suggest the vitamin D receptor (VDR) plays a role in inhibiting Hh signaling. These results call for 
additional and continued studies to identify the binding target and pocket to better understand these 
structure-activity relationships.  
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Chapter 1: 
The Therapeutic Potential of Hedgehog Signaling 
 
  
 2 
Introduction 
The Hedgehog (Hh) signaling pathway plays a crucial role in the embryonic development of many 
tissues and organs. In adult tissues, the pathway is significantly less active with the primary function of 
maintaining homeostasis of stem cell populations, primarily in the skin and central nervous system.1 
Abnormal regulation of the pathway, specifically constitutive activation, through mutations or irregular 
expression, has been linked to a variety of cancers, most notably basal cell carcinoma (BCC) and 
medulloblastoma (MB). Additionally, Hh signaling has been linked to a number of conditions from obesity 
to neurodegenerative disorders.  
I. Canonical Hedgehog Signaling (Figure 1) 
The Hh pathway is primarily regulated by the glioma-associated oncogene (Gli) family of zinc-finger 
transcription factors (Gli1-3) along with two trans-membrane receptor proteins: Patched (Ptch), a 12 trans-
membrane (TM) domain surface receptor, and Smoothened (Smo), a 7TM membrane GPCR-like receptor.  
In mammalian cells, canonical signaling is initiated by binding of one of the Hh ligands – Desert (DHh), 
Indian (IHh) and Sonic (SHh) – to Ptch.  
Before binding occurs, immature Hh proteins undergo multiple post-transcriptional modifications to 
regulate activity and Hh protein dispersion. The immature proteins first undergo autoproteolytic cleavage 
 
Figure 1. Simplified representation of the Hedgehog signaling pathway in (A) 
inactive and (B) active states.2 
 
DOI: 10.1002/cmdc.201300358
Hedgehog Pathway Agonism: Therapeutic Potential and
Small-Molecule Development
M. Kyle Hadden*[a]
Introduction
In cells regulated by the Hedgehog (Hh) pathway, signal trans-
mission is controlled through a cascade of events that ulti-
mately results in a balance between activator (GliA) and re-
pressor (GliR) forms of the glioma-associated oncogene (Gli)
family of transcription factors. As this process has been exten-
sively reviewed elsewhere,[1–3] only a brief description of the
key regulators is described herein. There are three Hh proteins
[Sonic (SHh), Indian (IHh), and Desert (DHh)] that serve as li-
gands to initiate pathway signaling. I the absence of an H
protein, Patched (Ptch), a 12-transmembrane domain protein
located on the cell surface, suppresses the activity of Smooth-
ened (Smo), a 7-transmembrane GPCR-like receptor primarily
located in the membrane of intracellular vesicles (Figure 1A).
Wh n Smo is inactive, Suppressor of Fused (Sufu), a negative
regulator of Gli, forms a heteroprotein complex with Gli pro-
teins in the cytosol. This complex promotes phosphorylation of
the Gli proteins, leading to the generation of N-terminal trun-
cated forms, GliR, that act as repressors of Hh responsive
genes. Binding of an Hh ligand to Ptch results in its internaliza-
tion and abolishes its inhibition of Smo, which undergoes
phosphorylation at its C terminus followed by reciprocal trans-
location to the plasma membrane of non-motile cilia (Fig-
ure 1B). This process prevents the proteolytic processing of Gli
proteins in the cytosol and results in the production of full-
length activator forms of Gli (GliA). Translocation of GliA to the
nucleus stimulates transcription of Hh target genes, including
GLI1 and PTCH1.
Therapeutic Applications of Hh Pathway
Agonists
While the use of small-molecule Hh pathway inhibitors as anti-
cancer chemotherapeutics has been extensively studied, the
therapeutic application of Hh pathway agonists has generated
less interest. Recent years have seen an increase in
publications describing the regenerative role of the
Hh pathway in the central and peripheral nervous
systems, the process of bone formation, and the vas-
culature. Extensive reviews into the nature of Hh sig-
naling in the development and maintenance of these
tissues have been published elsewhere.[4–8] This sec-
tion will highlight key aspects of the Hh pathway in
these systems and provide an overview as to how
modulation of the pathway holds therapeutic poten-
tial within these cellular contexts.
Neurodegenerative disorders
Hh signaling has been identified as an integral com-
ponent for neural system patterning in both the cen-
tral and peripheral nervous systems (CNS and PNS).[9, 10] In the
CNS, SHh signaling regulates the specification of multiple
neural cell types, including motor, dopaminergic, and basal
The Hedgehog (Hh) pathway is a developmental signaling
pathway that plays multiple roles during embryonic develop-
ment and in adult tissues. Constitutive Hh signaling has been
linked to the development and progression of several forms of
cancer, and the application of small-molecule pathway inhibi-
tors as anticancer chemotherapeutics is well studied and clear-
ly defined. Activation of the Hh pathway as a therapeutic strat-
egy for a variety of degenerative or ischemic disorders has also
been proposed; however, the development of small-molecule
Hh agonists has received less attention. The goal of this review
is to highlight the recent evidence supporting the therapeutic
potential of Hh pathway activators and to provide a compre-
hensive overview of small-molecule pathway agonists.
Figure 1. Generalized scheme for the Hh pathway signaling cascade.
[a] Prof. M. K. Hadden
Department of Pharmaceutical Sciences, University of Connecticut
69 North Eagleville Road, Unit 3092, Storrs, CT 06269 (USA)
E-mail : kyle.hadden@uconn.edu
! 2014 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemMedChem 2014, 9, 27 – 37 27
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 3 
allowing for covalent addition of a cholesterol moiety to the N-terminal peptide. Additionally, a palmitic 
acid moiety is attached to the most N-terminal cysteine residue solubilizing the protein and aiding in its 
translocalization and attachment to the cell membrane.3 The mature proteins are secreted as a monomer by 
the transmembrane protein Dispatched (Disp) and the secreted glycoprotein, Scube2.  
Following secretion, Hh ligands spread to target cells. In the absence of these ligands, Ptch is localized 
near and on the primary cilia. This suppresses Hh signaling by inhibiting downstream Smo activity through 
a poorly understood mechanism. A major downstream regulator of Hh signaling is the tumor suppressor 
protein, Suppressor of Fused (SuFu). The primary function of SuFu is the sequestering of Gli proteins in 
the cytoplasm to prevent their translocation to the nucleus.4 Inhibition of Smo prevents the dissociation and 
accumulation of this Gli-SuFu complex in the primary cilium. Accumulation allows for hyper-
phosphorylation of Gli to occur by protein kinase A (PKA), casein kinase 1a (CK1a) and glycogen 
synthase kinase 3b (GSK3b). Phosphorylated Gli then undergoes site specific ubiquitination resulting in 
partial proteasomal degradation of Gli to form repressor Gli (GliR). The proteasome removes the C-terminus 
allowing the N-terminal and DNA binding domain to translocate to the nucleus and repress transcription.3 
Binding of Hh ligands to Ptch activates the signaling cascade. Upon binding, Ptch and the Hh ligand 
are internalized and degraded. Removal of Ptch from the primary cilium allows Smo to localize at the 
primary cilia, a critical component of Hh signaling.5 Smo is then phosphorylated by CK1 and G-protein 
coupled receptor kinase 2 (GRK2) to form the active conformation.6 Kinase protein Kif7, another major 
downstream component, moves to the tip of the primary cilium following pathway activation. Kif7 is then 
able to increase the trafficking of SuFu and Gli proteins to the cilium for the cascade to continue.7 
Additionally, Kif7 has been proposed to control cilium architecture and length, ensuring proper formation 
of functional primary cilium required for Hh signaling.8 The increased accumulation of Hh components 
promotes the dissociation of SuFu and Gli resulting in full length Gli, or activated Gli (GliA). This 
dissociation allows for GliA to translocate to the nucleus and activate the transcription of Hh target genes, 
such as: Ptch1, Gli1, and Gli2.  
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II. Hh Signaling and Cancer 
As previously mentioned, Hh signaling is primarily inactive in adults; however, mutations within the 
pathway may arise over time leading to dysregulation and constitutive activation. This dysregulation can 
ultimately lead to the development of cancers, most notably basal cell carcinoma (BCC) and 
medulloblastoma (MB).  
In 1996, a link between cancer and Hh signaling was discovered where a familial loss-of-function 
mutation in Ptch1 was responsible for the development of Gorlin’s syndrome (nevoid BCC syndrome).9 
Gorlin’s syndrome is an autosomal dominant disease characterized by predisposition to BCCs, 
medulloblastomas and ovarian fibromas.10 Similarly, the most common human cancer, sporadic BCC, is 
driven by aberrant regulation of Hh signaling. This aberrant regulation is associated with UV exposure and 
a high frequency of loss of Ptch function. In total, 85% of BCC cases showed Hh pathway mutations. These 
mutations included inactivating Ptch1 (75%) and SuFu (8%) mutations, and activating mutations in Smo 
(~20%).11  
Another connection between Hh signaling and cancer has been described with MB where 
approximately 30% of cases can be characterized by activating mutations of Hh signaling.12 Constitutive 
activation in granule neuron progenitors in the developing cerebellum leads to proliferation beyond the 
normal development period and the formation of MB.13-14 Mutations of Hh components in MB can be 
broken down into ~45% Ptch1, ~14% Smo and ~14% SuFu. Interestingly, these mutations are attributed to 
disease progression at different stages with Smo mutations highly enriched in adults, and the majority of 
SuFu mutations found in infants (0 - 3 years old).15-16 
Additionally, neuroblastoma (NB) has received attention as another form of cancer where Hh signaling 
plays an important role in disease progression. Neuroblastoma, like medulloblastoma, is a common 
pediatric cancer of the nervous system, specifically the sympathetic nervous system. In 2009, it was shown 
that Hh signaling maintained tumorigenicity of neuroblastoma cells.17 In those studies, inhibition of Hh 
signaling by cyclopamine, a known natural product Smo inhibitor, resulted in apoptosis and cell cycle arrest 
in multiple NB cell lines. An additional study utilized a Gli1 inhibitor, to target downstream of Smo. In this 
 5 
study, treatment of NB cell lines with the inhibitor resulted in down-regulation of Gli1, as well as c-MYC 
and MYCN, and induced apoptosis.18  
To date, multiple specific Smo mutations have been identified through genomic analysis of Hh-driven 
cancers.12 These mutations were further characterized as oncogenic or resistance conferring (Figure 2, 2a 
and 2b respectively). The majority of these mutations are located within the TM region of Smo with the 
exception of a single mutation in the cytostolic tail, R562Q. The most studied oncogenic mutations, W535L, 
is located at at the end of the 7th TM-helix and thought to alter contacts with the extracellular loops to confer 
constitutive activation of Hh signaling.12 Among the resistance driven mutations, D473H was identified in 
a biopsy from a relapsed MB patient, and remains the major functional characterized resistance 
mechanism.12, 19-20 Under normal conditions, the Asp473 residue participates in the formation of a water 
network while also interacting directly with small molecules. Interestingly, it was shown that D473H 
mutant Smo was still susceptible to Ptch inhibition indicating it is a non-oncogenic mutation.19 Follow-up 
studies revealed that any mutation of Asp473 conferred resistance and changing Asp473 to a basic residue 
resulted in constitutive activation.20 
 
(A) (B) 
 
Figure 2. Mutations in Smo found in cancer.12 (A) Mutations in the TM region thought to be oncogenic. 
(B) Mutations in the TM region associated with resistance to small-molecule Smo inhibitors GDC-0449 
(2, black residues) and LDE225 (3, red residues). Reprinted by permission from Macmillan Publishers 
Ltd: Sharpe, H. J.; et al. Nat. Chem. Biol. 2015, 11, 246-255. 
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III. Small Molecule Antagonists of Hh Signaling 
A. Smoothened (Traditional) Inhibitors 
With the vast majority of Hh activating mutations observed in cancers being Ptch inactivating, or loss-
of-function, mutations, much of small molecule development has focused on targeting the downstream 
component, Smo (Figure 3). The first small molecule inhibitor of Smo discovered was the naturally 
occurring alkaloid, cyclopamine (Cyc, 1), that inhibited Hh signaling by direct binding to Smo. Even though 
Cyc has a poor pharmacokinetic profile, it has been utilized to further explore Hh pathway function and 
more specifically, the importance of Smo in tumor growth and progression.21-22 These studies also supported 
the potential for small molecule modulation of Hh signaling as anticancer chemotherapeutics. In recent 
years, two Smo inhibitors have received approval from the Food and Drug Administration (FDA): GDC-
0449 (Vismodegib, 2) and NVP-LDE225 (Sonidegib, 3).  
 
Figure 3. (A) 2D representation of Smo with key domains targeted by small molecules indicated, 
Green = Cysteine rich domain (CRD) and Yellow = Cyclopamine binding site (Cyc-BS); (B) 
Representative small molecule Smo inhibitors. 
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Genentech first reported GDC-0449 as a potent inhibitor of Hh signaling in 2009, and it received FDA 
approval for the treatment of advanced BCC in 2012.23-24 Unfortunately, the point mutation previously 
mentioned, D473H, developed and decreased GDC-0449’s binding affinity by 100-fold.19-20 Since then, 
additional point mutations have been identified that reduce the binding affinity in the TM region. This 
observation highlights a need for further therapeutic development capable of inhibiting wild-type and 
mutant Smo. In 2010, Novartis Institute of Biomedical Research first reported NVP-LDE225, a biphenyl 
carboxamide. LDE225 quickly became a clinical candidate due to its selectivity, potency against Smo, and 
ability to penetrate the blood brain barrier.25 In 2015, LDE225 became the second Hh inhibitor to receive 
FDA approval specifically for locally advanced BCC. Unfortunately, several point mutations in conserved 
Smo residues have been identified in mouse models of MB that confer resistance.12 
Multiple other small molecules are currently undergoing preclinical and clinical development.1, 21 
Among those small molecules, itraconazole (ITZ, 4) has emerged as a potent lead candidate following high-
throughput screening (HTS) of over 2,000 approved FDA and phase 1 compounds for anti-Hh activity.26 
As a commonly used antifungal agent, ITZ has been studied for many years and has a well-known safety 
profile making it a promising drug candidate. Perhaps more importantly, ITZ was shown to inhibit wild 
type and mutant D473H Smo by direct binding to Smo in a distinct manner from cyclopamine and other 
Smo antagonists.21  
Additional small molecule Smo inhibitors (Figure 4) currently in clinical trials include compounds 
from Lilly (LY2940680, taladegib, 5), Pfizer (PF-04449913, glasdegib, 6), and Bristol-Myer Squibb (BMS-
ON
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N N
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Figure 4. Additional Smo inhibitors in clinical and pre-clinical development. 
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833923, 5).21 Multiple other novel scaffolds are under development that directly displace BODIPY-Cyc, 
such as IHR-NAc(8), as well as inhibitors of Smo translocation/accumulation in the primary cilium, such 
as SMANT (9).21  
 
B. Non-traditional Inhibitors 
Multiple components of Hh signaling have been shown to be major contributors or critical for proper 
pathway function. These components include: (1) upstream components, such as Ptch and Kif7, (2) the TM-
protein Smo, and (3) downstream components, such as Gli and PKA.16 Approaches have been taken to 
target components upstream of Smo,1 but the emergence of Smo mutations and resistance to Smo inhibitors 
has led to a focus of targeting downstream components (Figure 5).  The advantage to this approach is not 
only bypassing the level of resistance but the ability to regulate signaling via agonists or antagonists exists. 
An additional advantage to these targets is to bypass SuFu mutations that have been observed. The major 
focus to date has been to target the Gli transcription factors, or the final-step of the signaling cascade.  
In 2007, the first Gli inhibitors, including GANT61 (10), were discovered during a screening assay 
reported at the Karolinska Institutet in Huddinge, Sweden.27 Importantly, GANT61 was able to reduce both 
Gli1 and Hip1 mRNA in SuFu-/- cells whereas traditional Smo inhibitors could not. Characterization of 
GANT61’s mechanism of action in HEK293 cells revealed accumulation of transfected Gli suggesting 
 
Figure 5. Hh inhibitors acting downstream of Smo. 
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inhibition of nuclear Gli, confirmed by electrophoretic mobility shift assays where pretreatment with 
GANT61 reduced the Gli-DNA binding band.27 As the first reported Gli inhibitor, GANT61 has been 
extensively studied and shown to induce growth arrest leading to cell death,28 and evaluated outside of 
traditional Hh-dependent cancers.29 
 Following these reports, the Sanford-Burnham Center for Chemical Genomics at Sanford-Burnham 
Medical Research Institute in collaboration with Stanford University reported another Gli specific inhibitor, 
ML340 (11) in 2012.30 ML-340 provided a novel scaffold for Gli inhibitor development with promising 
characteristics, such as potency, reduced non-specific cytotoxic, high permeability and selectivity. 
However, ML-340 showed high plasma protein binding of ~99% in both mice and humans. Overall, ML340 
could be useful as a selective probe to target downstream of Smo, but additional medicinal chemistry efforts 
are required to improve the preclinical pharmacokinetic properties.  
In a similar approach to the inhibition of Hh signaling at the transcriptional level by Gli inhibitors, 
researchers at Stanford University School of Medicine showed that Hh signaling was modulated by a 
specific bromodomain protein, BRD4, that regulated Gli transcription downstream of Smo and SuFu by 
occupying the Gli1 and Gli2 promoters.31 Additionally, shRNA knockdown of Brd4 resulted in decreased 
Gli1 and Gli2 mRNA levels that could be successfully rescued by the addition of full length Gli. Similarly, 
treatment of both wild type and SuFu-/- mouse embryonic fibroblast (MEF) cells with a known small 
molecule inhibitor of Brd4 (JQ1, 12) could reduce Gli1 and Gli2 expression.31 Inhibition of Brd4 also 
showed promise in combating Smo-inhibitor resistant tumors in cellular and mouse models.  
A cell-based screening effort at the University of Miami for epigenetic modulators of Hh signaling 
identified I-BET151 (13), an inhibitor of several bromodomain containing proteins (BRD2-4).32 Similar to 
JQ1, I-BET151 maintained potent inhibition in SuFu-/- MEFs and decreased the occupancy of BRD4 at the 
Gli1 transcriptional start site. Additional, I-BET151 was able to reduce both tumor volume and tumor 
associated Gli1 expression in in vivo models of Hh-dependent MB.32  
Additional strategies to target Hh activity exist by activating negative regulators downstream of Smo, 
such as CK1a or adenosine receptor/protein kinase A (ADORA/PKA). As previously mentioned, CK1a 
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and PKA serve as negative regulators of Hh signaling by phosphorylating and destabilizing Gli proteins. 
This destabilization leads to their proteasomal degradation and Hh antagonism. Therefore, activation of 
these negative regulators increases Gli phosphorylation to inhibit Hh signaling. Recently, an anti-pinworm 
compound, pyrvinium (14), was identified as a potent allosteric agonist of CK1a and subsequently 
evaluated for anti-Hh activity.33-35 Pyrvinium could attenutate Hh activity in Hh-dependent MEFs and 
maintained activity in SuFu-/- cells, indicating the ability to inhibit downstream of Smo and SuFu.33 
Mechanistic studies indicated that inhibition was dependent on CK1a and direct interactions between Gli1 
and CK1a promoted proteasomal degradation of Gli1. Furthermore, pyrvinium maintained anti-Hh activity 
in the presence of D473H mutant Smo. 
Previous studies in Drosophila suggested that the nucleoside adenosine and its receptors (ADORAs) 
may serve as negative regulators of Hh signaling by promoting the proteolytic cleavage of Gli to GliR.36 
Imquimod (IMQ, 15) is an adenosine analogue developed by Medicis Pharmaceuticals approved by the 
FDA for the topical treatment of a variety of skin disorders, including superficial BCC.21 Multiple 
mechanisms have been implicated as mediators of the biological activity of IMQ, including toll-like 
receptors (TLR7 and TLR8) and several ADORAs.37 Based on connections between its use as a treatment 
option for BCC and its ability to modulate ADORAs, researchers at the University of Salzburg evaluated 
its ability to regulate Hh signaling.38 At higher concentration (42 µM), IMQ decreased Gli1 protein levels 
in Hh-dependent murine BCC cells. Additional studies indicated that the anti-Hh activity was a result of 
Table 1. Anti-Hh activity of small-molecules targeting Hh components. 
Compound Target IC50 Wild-type Smo 
IC50 
D473H Smo Status Reference 
GDC-0449 Smo 3-22 nM Loss of activity Clinically approved 22 
NVP-LDE225 Smo 2.5 nM Loss of activity Clinically approved 25 
Itraconazole Smo 270-690 nM 500 nM Phase 1 26 
GANT61 Gli 5 µM ND Preclinical 27 
ML340 Gli 34 nM ND Preclinical 30 
JQ1 Brd4 50 – 150 nM Activea Preclinical 31 
I-BET151 Brd4 31 nM ND Preclinical 32 
Pyrvinium CK1a ~10 nM Activea Preclinical 33 
Imiquimod ADORA Actviea ND Preclinical 38 
aActive = Specific IC50 value not reported. ND = No data reported.  
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PKA phosphorylation of Gli enhancing the proteolytic process to GliR, mediated through ADORA 
activation.38  
To date, the Hh signaling pathway has been implicated as an anti-cancer target for a variety of human 
cancers, but recent evidence has shown that only BCC and MB are truly dependent on Hh signaling for 
oncogenic transformation and tumor growth. These findings have greatly reduced the therapeutic scope of 
Hh pathway inhibitors. Pathway inhibitors still have the potential to treat a large number of people with 
BCC being the most common human cancer and no targeted therapy existing for MB. The FDA approval 
of GDC-0449 (2) and LDE225 (3) and additional success in clinical and preclinical settings confirmed the 
validity of Smo, and Hh signaling, as a drug target. Taken together with the rise of resistance to GDC-0449 
(2) and other Smo antagonists, the development of Hh pathway inhibitors targeting Smo and downstream 
components continues in both academic and industry settings. As the complexity of Hh signaling continues 
to grow and come into view, reports of enzymes and receptors indirectly regulating Gli expression have 
emerged as potential targets.  The complexity of Hh signaling and the promise of Hh inhibitors ensures that 
development of small molecule Hh inhibitors will continue for the purpose of anti-cancer agents and 
chemical probes to further study the Hh pathway and indirect regulation of signaling. 
 
IV. Hh Signaling and Degenerative Disorders 
As previously mentioned, the evolutionarily conserved Hh pathway is one of the major pathways 
involved during embryonic development. Disruption of Hh signaling has been shown to be an underlying 
contributor to a variety of developmental disorders such as holoprosencephaly and limb abnormalities.16 
Holoprosencephaly is characterized by failure of the embryonic forebrain to sufficiently divide in the two 
lobes of the cerebral hemisphere. Additionally, specific Hh proteins are expressed throughout embryonic 
development controlling everything from hair follicle and eye development to bone growth and smooth 
muscle patterning.39 With this in mind, Hh agonism has been studied for therapeutic potential in a variety 
of disease states. To date, the therapeutic areas that have been studied the most are neuro- and 
osteodegenerative diseases. Signaling in these tissues appears to be primarily regulated by specific Hh 
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protein isoforms with IHh in cartilage and bone, DHh in the peripheral nervous system (PNS) and SHh in 
a variety of cell types.2, 39-40  
 
A. Hh Signaling and Neurodegenerative Disorder  
Overall, Hh proteins act as morphogens, or agents that induce morphogenesis, by regulating the 
expression of families of transcription factors, such as the Gli family that Hh signaling targets, to ensure 
proper development and function. In the nervous system for example, DHh is secreted by Schwann cells, 
which are responsible for the formation of the myelin sheath around neuronal axons. Mice lacking DHh 
develop an abnormal nerve sheath, a leaky blood-nerve barrier, low action-potential conduction rates, and 
behavioral changes.41 These results are suggested to be due to indirect mechanisms by which DHh regulates 
Hh signaling in perineurial cells leading to the secretion of neurotrophic, angiogenic, and growth factors 
that ensure proper development.41-43 
To date, much of the therapeutic strategy for Hh pathway agonism is based on central nervous system 
(CNS) disorders, such as Parkinson’s disease (PD). In the adult nervous system, Hh proteins and signaling 
components are present but the magnitude of signaling appears to be lower and more restricted.44-45 It has 
also been shown that Hh signaling can be reactivated following tissue damage in adults. Reactivation in 
perineurial cells following sciatic nerve damage significantly increased Schwann cell production of SHh 
and DHh mRNA leading to increased Hh response.39 Additionally, viral overexpression of SHh has been 
shown to stimulate neural stem cell proliferation in the hippocampus. Taken together, it has been suggested 
that activation or stimulation of Hh signaling may promote a functional neuroprotective and regenerative 
role in neurodegenerative diseases.  
 Parkinson’s disease is a neurodegenerative disorder characterized by the loss of dopaminergic neurons 
in the substantia nigra, where it is known that SHh is involved in the differentiation of these neurons during 
embryonic development.46 Most animal models of Parkinson’s Disease are generated using 6-
hydroxydopamine (6-OHDA), which is taken up by dopaminergic neurons resulting in decreased 
dopaminergic innervation and loss of function in the substantia nigra.39 In multiple animal models using 
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this method, direct administration of SHh resulted in improved motor function and protected against drug-
induced neurotoxicity.47 Transplantation of SHh-secreting neural progenitor cells into 6-OHDA rat models 
was shown to improve motor function and behavior,48 providing further evidence that Hh stimulation can 
be neuroprotective.  
 
B. Hh signaling and Osteodegenerative Disorders 
The other major area of study for therapeutic activation of Hh signaling is osteodegenerative disorders, 
such as osteoporosis. Osteoporosis is characterized by a decline in bone mass beyond what is expected as 
a function of various factors, such as age and sex, and typically leads to reduced bone strength and higher 
probability of fractures.48 Normal bone remodeling follows a time sequence (~6 months) where 
demineralized space is filled with new bone. During this process, activation of osteoclast precursors 
ultimately leads to the formation of new bone and mature osteoblasts fill the resorption cavity.49  
IHh is expressed in the growth plate and osteoblasts in postnatal humans and rodents, and was shown 
to be involved in limb patterning, intramembranous ossification, and endochondral ossification.50 In one 
study using adult mice,51 it was determined that Hh signaling indirectly induced osteoclast maturation to 
promote bone resorption, where increased Hh activity in the mature osteoblasts upregulated parathyroid 
hormone-related peptide expression promoting RANKL expression. Additional studies have shown that 
IHh and Ptch1 are upregulated during the initial stage of fracture repair,52 and SHh is activated at the 
remodeling site of fractures to regulate osteoblasts and osteoclast formation.53 Similarly, both Ptch1-
deficient mice and osteoblast precursor cells showed increased bone mass and differentiation to osteoblasts 
at accelerated rates as a result of an enhanced response runt-related transcription factor 2 (Runx2) and 
decreased GliR.54 Evidence also suggests that terminal osteoblastic cell fate is determined by canonical 
Wnt/b-catenin signaling induced by IHh signaling.55 
 Overall, activation of Hh signaling shows promise as a therapeutic strategy for osteodegenerative 
disorders; however, contradictory evidence has shown that prolonged pathway activation may lead to 
detrimental side effects, including an increased risk of osteoporosis. In one study, activation of Hh signaling 
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in mature osteoblasts of adult mice led to reduced bone density and fragile long bones.50 This evidence adds 
to a role of Hh signaling in bone formation and regulation, but suggests that a fine balance would be 
required. 
 
V. Small Molecule Agonists of Hh signaling 
Development of small molecules targeting the Hh pathway has primarily focused on the development 
of antagonists as anti-cancer chemotherapeutics, but multiple scaffolds have been studied as Hh agonists. 
These scaffolds can be divided into two major classes: (1) non-sterol and (2) sterol-based compounds 
(Figure 6). 
A. Non-Sterol-Based Agonists  
Purmorphamine (16), and tri-substituted purine derivatives, were discovered following an HTS assay 
to identify inducers of osteogenesis in C3H10T1/2 (C3H) MEFs, a cell line commonly used as a cellular 
model of osteoblast differentiation.56 Additional studies indicated that purmorphamine’s osteoinductive 
effects could be negated by administration of Cyc indicating its effects were a result of Hh activation.57 
Follow-up studies demonstrated that purmorphamine displaced BODIPY-Cyc showing that it directly 
 
Figure 6. Small molecule modulators of Hh signaling; 16 – 17, 20 = agonists, 
19 = antagonist. 
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targeted Smo.58 Multiple other studies have been performed to evaluate the therapeutic potential of  
purmorphamine. In one study, purmorphamine was part of a chemical system capable of promoting 
formation of forebrain GABA interneurons from induced pluripotent stem cells (iPSC).59 Another study 
using iPSCs utilized purmorphamine as part of a four-step protocol to generate spinal motor neurons.60 
Taken together, these experiments demonstrated the therapeutic potential of small molecule Hh agonists 
for neurodegenerative disorders. More importantly, small molecule activation of Smo showed similar 
effects to external administration of Hh protein.  
A second non-sterol series was discovered through an HTS assay in C3H cells stably expressing a 
luciferase reporter plasmid downstream of the Gli1 promoter. This series is the biaryl benzothiophenes, 
such as SAG (17, Smoothened agonist).61 These compounds were shown to potently activate Hh signaling 
following oral administration through direct binding to the transmembrane region of Smo, similar to Cyc.19 
Additional structure-activity relationship (SAR) studies have further increased the potency of this series to 
low nanomolar EC50 values.62 The majority of therapeutic studies with this series have utilized SAG. These 
studies have shown promising results for neurodegenerative disorders as well as diabetes and obesity, where 
Hh signaling has been reported to block or inhibit the formation of fat, specifically white adipose tissue.63 
Treatment of C57BL/6J mice, which are susceptible to diet induced obesity and type-2 diabetes, with SAG 
stimulated insulin-dependent glucose uptake in muscle and brown adipose tissue preventing storage in 
white adipose tissue and fat formation.64  Combination studies with retinoic acid in mouse embryonic stem 
cells induced differentiation of spinal progenitor cells and formation of functional motor neurons.65 
B. Sterol-Based Agonists  
The majority of endogenous and synthetic Hh pathway agonists are sterol like small molecules. The 
first of these scaffolds are the glucocorticoids, including FDA approved glucocorticoids (GCs), such as 
Table 2. Representative Hh pathway agonists. 
Compound EC50 (µM) Reference 
Purmorphamine (16) 0.5 56 
SAG (17) 0.01 61 
Fluticasone propionate (18) 0.1 66 
20(S)-OHC (20) 0.1 71 
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fluticasone propionate (18, Flonase). These compounds were initially identified as Hh pathway agonists 
using a U2OS cell model where overexpressing Smo resulted in b-arrestin2-GFP aggregation.66 The GCs 
identified were able to upregulate Hh signaling at moderate levels by increasing the ciliary accumulation 
of Smo,67 and were able to displace BODIPY-Cyc in a dose-dependent manner, although BODIPY-Cyc 
was not completely displaced (~20% displacement at 10 µM).66 It is important to note that structurally 
related GCs, such as budesonide (19) inhibited Hh signaling at high concentration (IC50 of 40 µM) 
suggesting that this scaffold could provide both agonists and antagonists of Hh signaling.67 
Perhaps the most well studied scaffold of Hh agonists are oxysterols (OHCs), or hydroxylated 
metabolites of cholesterol. Evidence first pointed to the importance of endogenous sterols for Hh signaling 
after the discovery that the covalent linking of a cholesterol moiety to the C-terminus of Hh proteins is 
essential for proper Hh signaling.68 Adding to the importance of sterols, recent studies  attempting to answer 
how Ptch endogenously regulates Smo activity suggested that Ptch influences intracellular cholesterol 
levels by contributing to cholesterol efflux.69 Cholesterol itself has recently been proposed to be the natural 
ligand of Smo to activate downstream Hh signaling.70 These two observations will be discussed in the 
following chapter.  
 Both natural and synthetic OHCs, such as 20(S)-OHC (20), have also been shown to activate Hh 
signaling via direct interactions with Smo.71-73 In a study using M2-10B4 cells, pluripotent mesenchymal 
stem cells and osteogenic progenitor cells, OHCs demonstrated osteoinductive effects while also inhibiting 
adipogenic differentiation further demonstrating therapeutic potential for obesity and osteodegenerative 
disorders.72, 74 The usefulness and potential of endogenous and synthetic OHCs as modulators of Hh 
signaling with be further discussed in the following chapter. 
 
Summary  
As one of the primary embryonic developmental pathways, the Hh signaling pathway has been linked 
to a variety of diseases and disorders from cancer to obesity. With cancers such as BCC and MB resulting 
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directly from constitutive activation of Hh signaling, much of small molecule development has focused on 
the development of inhibitors as anti-cancer chemotherapeutics. The complexity of Hh signaling provides 
multiple potential targets and mechanisms to regulate signaling. To date, the primary target investigated is 
the GPCR-like receptor Smo. Two small molecule inhibitors targeting Smo have received FDA approval, 
GDC-0449 (2) and LDE225 (3), for BCC treatment; however, resistance has emerged due to a specific 
point-mutation in Smo (D473H).22-25 Additional Smo inhibitors are currently being investigated in clinical 
and preclinical settings that show activity against mutant Smo.1,21 As another means to bypass mutant Smo, 
Hh components downstream of Smo are being investigated, such as Gli and Brd4. Compounds targeting 
downstream of Smo, such as 10 – 15, have shown great potential so far and remain in preclinical 
development. Small molecule agonists of Hh signaling have also been developed and explored as means to 
treat a variety of diseases with the majority focusing on degenerative disorders, such as Parkinsons’s disease 
and osteoporosis. Multiple scaffolds have emerged as potent agonists of Hh signaling, but the vast majority 
have been sterol-based small molecules such as glucocorticoids and oxysterols. These compounds have 
shown potent activation of Hh signaling and hold promise as preventative and post-treatment options for 
neurodegenerative and osteodegenerative disorders.     
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Introduction 
Cholesterol is one of the most abundant and important small molecules in the human body. It makes up 
nearly half of the lipid molecules in the plasma membrane,76 and serves as the precursor for steroidal 
hormones and bile acid.77 As trans-membrane receptors, GPCRs are naturally embedded in cholesterol rich 
environments and therefore always in close proximity to cholesterol. It is not surprising that as the role and 
functions of GPCRs has become clearer, cholesterol binding motifs have been identified, and the biological 
functions of cholesterol have grown. As the proposed roles for cholesterol have grown, the roles and 
functions of oxysterols, cholesterol metabolites, have come into view.  
 
I. Endogenous Oxysterols 
Oxysterols can generally be defined 
as oxygenated derivatives of 
cholesterol, containing additional 
carbonyls, alcohols, or epoxide groups. 
Interest in oxysterols has been renewed 
in recent years as the additional 
evidence for the importance of cellular 
cholesterol has come into view.78 
Oxysterols in general are generated 
through non-enzymatic [reactive 
oxygen species (ROS)] and enzymatic 
oxidation reactions [cytochrome p450 (Cyp) enzymes]. With multiple endogenous OHCs identified, their 
specific functions appear to fall under two categories: (1) regulation of cholesterol homeostasis and/or (2) 
interference with normal cellular functions of cholesterol.78 Additional roles have recently been proposed 
including the regulation of immune function.79  
 
Figure 7. (A) The cholesterol numbering system and (B) 
representative endogenous oxysterols. 
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Regulation of cholesterol homeostasis by OHCs was first proposed in 1973 when impure cholesterol 
was able to inhibit cholesterol synthesis while purified cholesterol did not have this ability.80 This was later 
attributed to small amounts of OHCs present, such as 20(S)- (20), 22(S)- (21), and 25-OHC (22), which 
showed the greatest inhibitory potency in subsequent studies.81 Additional studies have shown that 
cholesterol does not need to be hydroxylated or metabolized to suppress its own synthesis.70 Since the first 
isolation of the sterol receptor element binding protein (SREBP) transcription factors in 1993,82 aspects of 
these contradictory studies have been clarified.  
SREBPs are made as membrane-bound precursors in the endoplasmic reticulum (ER) bound to the 
SREBP-cleavage activating protein (SCAP). When cholesterol levels are low in the ER, SCAP guides 
SREBP to the Golgi, where the two proteins are cleaved (Figure 8). This releases SREBP into the nucleus 
to activate gene transcription via binding to sterol response elements (SRE). Interestingly, cholesterol and 
not oxysterols were shown to bind to the membrane region of SCAP, which upon cholesterol binding results 
 
Figure 8. The effect of overall sterol status on the SREBP pathway of cholesterol homeostasis.88 Low 
cholesterol levels are sensed by SCAP which escorts SREBP for cleavage and activation of SREBP gene 
activation via a sterol response element (SRE). OHCs bind to Insig to trigger the same effect. When 
sterol levels are sufficient, the SREBP/SCAP complex remains tethered to the ER by Insig preventing 
gene expression. Reprinted by permission from Macmillan Publishers Ltd: Nature Immunology. Spann, 
N. J.; Glass, C. K. Sterols and oxysterols in immune cell function. Nat. Immunol. 2013, 14, 893-900. 
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in the binding of SCAP to Insig.83 It was later determined that OHCs regulate cholesterol synthesis by direct 
binding to Insig.84 These two studies showed that the binding properties of SCAP and Insig were reciprocal, 
where the presence of a polar (hydroxylated) group on the alkyl-side chain resulted in a change in the 
binding target. Importantly, the overall net effect of reducing SREBP transcriptional activity was observed 
with administration of OHCs or cholesterol.83-84  
OHCs have also been identified as natural ligands for the liver X receptors (LXRa and LXRb), 
providing more evidence that they regulate cholesterol homeostasis. These receptors regulate genes that 
control whole body cholesterol and lipid homeostasis through a heterodimer formed with the retinoid X 
receptor (RXR). Target genes include the genes encoding for the ATP-binding cassette proteins ABCA1 
and ABCG1, which both play an important role in cholesterol efflux.85 Based on X-ray crystallography and 
murine studies, it appears that oxygenation at the 22-, 24-, and 27-positions of the cholesterol scaffold 
(Figure 7, 21) are important for LXR binding.86-87  
Endogenous OHCs have also been proposed to have functions within the immune system.88 Studies 
have shown both LXRs and SREBPs play roles in immune response.88-91 Besides regulating cholesterol and 
fatty acid homeostasis, LXRs regulate genes encoding for anti-inflammatory proteins or molecules that 
promote the synthesis of anti-inflammatory fatty acids, while also suppressing genes controlled by the pro-
inflammatory transcription factors NF-kB and AP-1.88 Studies in macrophages have also indicated that 
SREBPs, SREBP1a specifically, activates the Nlrp1a gene, which encodes a core component of the NLRP1 
inflammasome.92 Endogenous LXR ligands are expected to promote anti-inflammatory activities of LXRs 
while suppressing the processing of SREBPs to decreases the activation of genes involved in the 
inflammatory response.88  
One specific OHC proposed to have immune functions is 25-OHC (23). In in vitro and in vivo studies, 
LXRs have been linked to innate immune responses to bacterial and protozoan pathogens, where increases 
in the production of 25-OHC were observed.88 The treatment of macrophages with type 1 interferons to 
stimulate the immune response as well as viral infection itself, showed rapid upregulation of cholesterol 
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25-hydroxylase (CH25H), the enzyme responsible for 25-OHC production. In additional studies, 25-OHC 
showed broad inhibitory activity against enveloped viruses and CH25H-deficient mice were more 
susceptible to infection.93  
Another proposed role of OHCs is the regulation of B cell functions. For example, stimulation of 
macrophage toll-like receptors (TLRs) induced CH25H expression and 25-OHC production. This resulted 
in a decrease in immunoglobulin A (IgA),94 suggesting that 25-OHC suppresses immunoglobulin class 
switching of naïve B cells. Another oxysterol with the C25 hydroxylation, 7a,25-OHC (24) is a potent 
ligand with sub-nanomolar potency for the GPCR EBI2 (GPR183), which is required for B cell migration 
and differentiation into antibody-secreting plasma cells.95-96 As other immune cells express EBI2, this 
suggests that local concentrations of oxysterols may coordinate the innate and adaptive immune responses 
via interactions with EBI2.  
 
II. Endogenous Regulation of Smo 
As previously mentioned, Smo is one of two trans-membrane receptors that regulate Hh signaling and 
is a member of the Frizzled class (class F) of G-protein coupled receptor (GPCR)-like proteins. Similar to 
other GPCRs, Smo possesses stereotypical structural features, including seven-TM domains, an amino-
terminal cysteine rich domain (CRD), extra- and intracellular loops, and a carboxy-terminus tail (CT) that 
can undergo a number of post-translational modifications (PTMs), including phosphorylation as previously 
discussed. The specific mechanism, or mechanisms, that lead to activation and inhibition of Smo by Ptch 
under natural conditions remains elusive, but multiple hypotheses do exist (Figure 9).97  
These hypotheses are based on the significant evidence already presented on the inherent druggability 
and ability to regulate Smo by both synthetic and naturally occurring small molecules, such as Cyc and 
OHCs. It is known that inhibition, or repression, of Smo by Ptch is indirect with no evidence of direct 
contact,98 but instead one Ptch molecule is estimated to regulate up to 50 Smo.99 Additionally, Ptch shares 
homology with an ancient class of bacterial transporters that transports lipophilic toxins and contains a 
sterol sensing domain.100 Combining these observations, it has been proposed that Ptch functions by 
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regulating the availability of a sterol-like Smo regulator,100 such as OHCs.71-73 One hypothesis is that Ptch 
pumps agonists outside of the cell to repress Smo activity. Binding of Hh protein to Ptch then: (1) prevents 
removal of the agonist from the cell, allowing the agonist to interact with Smo and initiate signaling, or (2) 
increases the extracellular concentration of the agonist which in turn binds to Smo upon its translocation to 
the primary cilium to initiate signaling. Contradictory evidence to this theory is that deletion or absence of 
Ptch results in constitutive activation of Hh signaling, suggesting that the small molecule regulated by Ptch 
is an antagonist.101 In a similar matter, Ptch would then be able to sequester or efflux the antagonist.  
 
Figure 9. Models of Ptch regulation of Smo activity.97 (A) Ptch (yellow) pumps-out an antagonistic 
small molecule that binds to Smo preventing accumulation and signaling. (B) Ptch pumps-out a 
Smo agonist out of the cell, or sequesters it (B’), where it is unable to activate Smo. (C) Ptch 
controls a lipid regulator that blocks the accumulation of lipid species in microdomains, such as 
the primary cilium, that regulate Smo accumulation. Models A and B can also be utilized for the 
opposite small molecule species where a theoretical agonist could be pumped out to activate Smo 
or an antagonist could be sequestered intracellularly to prevent signaling. Reprinted from Trends 
in Pharmacological Sciences, 37, Arnesdorf, A.; et al. Smoothened Regulation: A Tale of Two 
Signals, 62-72, 2016, with permission from Elsevier. 
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As evident by these hypotheses, the endogenous small molecule that may regulate Smo remains in 
question. Recent evidence attempting to answer this question suggests that cholesterol itself regulates 
Smo.70 Cholesterol is necessary for Hh signaling beyond the cholesterol modification of Hh proteins. 
Treatment of chick embryos with cyclodextrin, a cyclic oligosaccharide that forms non-covalent complexes 
with sterols, resulted in facial defects similar to those observed with a Hh pathway antagonist, and high 
concentrations of cyclodextrin decreased Hh activity to levels comparable to Cyc.102 It was further 
determined that the decreased Hh response occurred at sterol levels sufficient for normal auto-processing 
and cholesterol modification of Hh protein. This suggests that cholesterol plays a role in regulating Hh 
signaling beyond the modification of Hh proteins.  
 
III. Cholesterol Derivatives and Hh signaling  
In the last few years, it has been proposed that cholesterol may be involved in Ptch regulation of Smo 
and may be the natural Smo ligand.70 As a GPCR, it is not surprising that cholesterol and its derivatives 
have been shown to bind to Smo. The importance of cholesterol to GPCRs has become clear in recent years 
with multiple cholesterol sensing, or recognition, sites being identified in multiple GPCR familes.77  
To date, multiple cholesterol binding motifs have been identified in GPCRs that show a range of one 
to six cholesterol molecules per binding interface and all were located within a trans-membrane domain 
with high preference and occurrence of hydrophobic residues.77 In multiple cases, it was also shown that 
cholesterol aids in stabilizing the receptors against thermal, extreme pH, and proteolytic degradation.103-104 
Besides direct binding of cholesterol to GPCRs, the modulation of cholesterol concentrations can alter the 
physical properties of the membrane leading to conformational changes of the proteins and modified 
function.105-106 Combining these studies on other GPCRs with the proposed methods for Smo regulation, it 
is not surprising that studies have shown direct interactions between cholesterol, and its oxysterol 
derivatives, and Smo.70-73 
Oxysterols were first identified as agonists for Hh signaling in 2006,71 but it was not until 2012 that 
their binding site was determined to be the Smo-CRD.73,107 Comparing the naturally occurring 20(S)-OHC 
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(20) with its diastereomer, 20(R)-OHC (25), and enantiomer (26), indicated that the OHC Smo-CRD 
binding interaction was stereoselective in nature. (Figure 10).73 In these studies, 20 was the only compound 
of the three to potently activate Hh signaling and induce ciliary accumulation of Smo (Figure 10e). For 
follow-up studies, 20 was covalently attached to agarose beads via a polyethylene glycol (PEG) linker (20-
beads). Binding of murine Smo (mSmo) to 20-beads was observed while free 20 was capable of displacing 
mSmo from the beads.107 In similar studies with the CRD region deleted (mSmoDCRD), no binding of 20-
beads was observed indicating that the CRD region is required for OHC binding (Figure 10f). 
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Figure 10.73,107 Stereoselective activation of Hh signaling. (a) Structures of 20-OHCs. (b) Gli reporter 
activity in NIH 3T3 cells treated with OHCs as fold change relative to ethanol alone. (c) 
Immunoblotting results of Gli reporter assay. (d) Quantitative real-time PCR (qRT-PCR) analysis 
confirming immunoblotting and reporter activity. (e) Quantification of ciliary Smo fluorescence in 
NIH 3T3 cells with 10 µM OHC. (f) Binding of cherry-tagged mSmo and mSmoDCRD to 20(S)-OHC 
beads indicates that the CRD region is required for binding. Reprinted by permission from Macmillan 
Publishers Ltd: Nachtergaele, S.; et al. Nat. Chem. Biol. 2012, 8, 211-220; and Nedelcu, D.; et al. Nat. 
Chem. Biol. 2013, 9, 557-564. 
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Follow up studies performed in the Hadden lab further confirmed the stereoselective nature of the 
Smo-OHC interaction.108 In these studies, a variety of OHCs with hydroxylated side chains were 
synthesized to study the regioselective nature of OHC binding (Figure 11) and evaluated in C3H MEFS 
(Table 3). The ability of the OHCs to activate Hh signaling was determined 24 h following administration 
to the cells. After 24 h of incubation, mRNA was collected from the cells using the commercially available 
Fast Taqman Cells-to-Ct Kit (ThermoScientific). The mRNA was quantified via quantitative real time-PCR 
(qRT-PCR). 
Similar to previous reports, significant changes in activity were observed with inversion of the hydroxyl 
groups, such as 28 and 29. Comparing the activities indicated that binding to Smo may be regioselective as 
well.  Another important observation can be seen comparing 22 and 27, where activation of LXR, 
determined through mRNA expression of ABCA1, shows stereoselective preferences. It should be noted 
that in general, 27 is recognized as a selective endogenous LXR agonist.108-109 The di-hydroxylated side 
chain of 30 was unable to synergize the agonistic activity of 22 and 23, but resulted in essentially a loss in 
all activity. Interestingly, oxidation of the 22-position (31) yielded activity comparable to 27, selective for 
LXR over Hh signaling. This suggests that LXR binding is regio- and steroselective where the carbonyl of 
31 is oriented similarly to 27 and not 22 within the binding site.  
 
Figure 11. Representative OHCs from initial SAR 
studies.107 
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Table 3. In vitro evaluation of OHCs.107 
OHCa Gli1b ABCA1b Selectc 
20 92 ± 6 13 ± 2 7.1 
22 53 ± 1 2.3 ± 0.1 23 
23 70 ± 3 9.8 ± 1 7.1 
27 4.7± 0.4 24 ± 2 -- 
28 87 ± 0.8 4.9 ± 0.2 18 
29 32 ± 0.1 3.6 ± 1 8.9 
30 9.9 ± 0.2 2.9 ± 0.1 3.3 
31 6.0 ± 0.3 22 ± 2 -- 
aOHCs evaluated at 5 µM in C3H MEFs. 
bValues represent mRNA expression 
compared to DMSO (set to 1.0). cSelectivity 
for Gli1:ABCA1. 
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Taken together, it is clear that synthetic and endogenous OHCs bind directly to the Smo-CRD to induce 
Hh signaling in multiple cellular models. This binding is both regio- and stereoselective in nature with 
significant changes in activity and selectivity observed by inversion of the hydroxylated side chains.    
 
IV. C-20 Modified OHCs110 
Multiple studies (discussed above) have indicated highly regio- and stereoselective binding between 
OHCs and the Smo-CRD; however, a few questions still remained to fully characterize this interaction. 
First, the importance of the C-21 methyl moiety has yet to be determined. In previous studies, the loss in 
activity when the C-20 stereocenter was inverted from S to R (20 to 25, respectively) combined with the 
loss in activity with the 20(S)-OHC enantiomer 23, suggests that the C-21 methyl may play a role in 
determining activity. A second question remaining is whether binding is more regio- or stereoselective, 
meaning if the C-20 stereochemistry is inverted on an active OHC, such as 28, would Hh agonistic activity 
remain. To evaluate these questions, a series of OHC analogues were designed in which the C-21 methyl 
group was removed (26 and 27) or inverted in the 23-OHC scaffold, 34 and 35 (Figure 12).  
A. Synthesis of C-20 modified OHCs 26-29 
Preparation of both analogue families began with the tetrahydropyran (THP) protection of 
commercially available starting materials following previous observations that the incorporation of an 
additional stereocenter in the THP group allowed for easier separation of isomers. For analogues with the 
C-21 methyl moiety removed (des-methyl OHCs, 32 and 33, Scheme 1), 21-acetoxypregnenolone (36) was 
 
Figure 12. Target C-20 modified OHCs. 
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utilized as the starting material. Following THP protection, lithium aluminum hydride-mediated reduction 
of the ester and ketone functionalities yielded the 1,2-diol 37. Oxidative cleavage of 37 with sodium 
periodate yielded aldehyde 38, which underwent Grignard addition with in situ generated isopentyl 
magnesium bromide to provide a mixture of THP-protected C-20 secondary alcohols, 39 and 40. Separation 
of 39 and 40 by column chromatography followed by removal of the THP group by acid deprotection 
yielded S- and R-isomers 32 and 33. Assignment of the C20 stereochemistry was performed by comparative 
1H NMR analysis and Mosher ester analysis of the THP-protected isomers 39 and 40 (See Appendix).110  
Similarly, C-21-inverted OHC analogues 34 and 35 were synthesized from pregnenolone (41), Scheme 
2. A secondary goal of this series was to shorten and improve the yield of 23(S)-OHC (28). Previously, 
synthesis of 28 was twelve steps from commercially available hyodeoxycholic acid with a low overall yield 
of 1.8%. The revised synthetic route started with THP protection of 41. Following a previously reported 
procedure,111 Grignard addition of vinyl magnesium bromide gave a mixture (1:9) of the tertiary allylic 
alcohols.  Treatment of the mixture with pyridinium chlorchromate (PCC) resulted in oxidative 
rearrangement of the allylic alcohol to yield an 80:20 E:Z mixture of b-substituted-a,b-unsaturated 
aldehydes (enal), 42a and 42b. Following unsuccessful attempts to selectively hydrogenate the enal system, 
we turned to the iminium catalysts previously developed in the MacMillan laboratory. This reaction was of 
particular interest due its ability to convert both E and Z alkenes to a single β-stereogenic aldehyde.112 
 
Scheme 1. Synthesis of 20-des-methyl OHC analogues.109 (a)3,4-dihydropyran, p-TsOH, THF, 96%; 
(b) LAH, THF, 3h, 96%; (c) NaIO4, THF, 1h, 92%; (d) Mg, Isopentyl bromide, THF, 55%; (e) 2N HCl, 
MeOH:THF, 96%. 
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Utilizing the Hantzsch ester as 
hydride source and the (S)-
imidazolidinone, the mixture of 
42a:42b was converted to 
aldehyde 43 [20(R) 
configuration] in good overall 
yield with no formation of 
stereoisomer 44. Performing the 
same protocol on the 42a:42b 
mixture with the (R)-
imidazolidinone provided 44 
[20(S) configuration] in good 
yield as the singular reduction product.   
Following unsuccessful asymmetric Grignard attempts to prepare 23(S)-OHC (28) from aldehyde 43, 
standard Grignard addition of isobutyl magnesium bromide to either aldehyde 43 or 44 provide the 
corresponding 23(S)- and 23(R)-OHC analogues as a 1:1 mixture that was easily separable via standard 
silica gel chromatography. Finally, deprotection of the THP group afforded the 23-hydroxylated OHCs, 28-
29 and 34-35. Overall, this revised synthetic route provided 23(S)-OHC, 28, in six steps with a yield of 
14.2% from pregnenolone (41), and 28.3% overall for both isomers 28-29. Previous assignments of the 
stereochemistry at C-23 were based on a combination of thin-layer chromatography, 1H and 13C NMR, and 
circular dichroism analysis.108 We utilized crystal structure analysis of 4 and 13 to both unambiguously 
assign the stereochemistry of the C-23 hydroxyl and utilize as a base for assigning the stereochemistry of 
28 and 29 (See Appendix).  
 
 
 
 
Scheme 2. Synthesis of 23-hydroxylated OHC analogues.110 (a) 3,4-
dihydro-2H-pyran, p-TsOH, THF, 96%; (b) Vinyl magnesium 
bromide, THF, 97%; (c) PCC, NaOAc, DCM, 64%; (d) MacMillan 
catalyst, Hatzsch ester, CHCl3, 60 - 64%; (e) Iso-butyl magnesium 
bromide, THF, 72%; (f) 2N HCl, MeOH:THF, 96%.  
O
HO THPO
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R2
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B. Biological activity of C-20 modified OHCs    
The C-20 modified OHC analogues were initially evaluated in the same manner as previously described 
in M2-10B4 cells, a multipotent murine bone stromal cell line previously utilized as a model to evaluate 
small molecule Hh agonists. The ability of each analogue to up-regulate known Hh (Gli1) or LXR (ABCA1) 
target genes was measured. All OHC analogues were evaluated at 5 µM where values in Table 4 represent 
fold increase in mRNA expression over DMSO levels (set to 1.0). The ability of both 28 and 29 to up-
regulate Gli1 mRNA closely mirrored that reported from OHCs prepared through our previous synthetic 
route.108 Interestingly, inversion of the C-21 methyl on the 23-hydroxylated OHCs (34 and 35) completely 
abolished their ability to up-regulate Gli1 expression. This was particularly interesting for analogue 34, 
which loses all Hh agonism compared to 23(S)-OHC, when the C-21 methyl is inverted, suggesting that 
inversion of the C-21 methyl actively prevents the OHC scaffold from binding the Smo CRD. This result 
is supported by a previous study demonstrating that inversion of the C20-hydroxy group to 20(R)-OHC 
resulted in complete loss of Hh agonism compared to natural 20(S)-OHC.107  
Interestingly, removal of the C-21 methyl moiety of 20(S)-OHC, as in OHC 33, completely abolished 
the ability of the scaffold to up-regulate Gli1 expression. Removal of the C-21 methyl for 20(R)-OHC 
resulted in OHC 32, which demonstrated potent agonism of Hh signaling, an unexpected result considering 
that 20(R)-OHC is a poor activator of Hh signaling.108 Taken together, these results strongly suggest 
Table 4. Initial activity of OHC analogues in M2-10B4 cells.110 
OHC[a] Gli1[b] ABCA1[b] Selectivity[c] 
DMSO 1.0 1.0 -- 
20 20 ± 0.7b 18 ± 0.2 1.1 
28 18 ± 0.6 6.2 ± 0.3 2.9 
29 8.7 ± 0.1 3.6 ± 0.1 2.4 
32 24 ± 0.8 2.4 ± 0.1 10 
33 1.3 ± 0.01 1.3 ± 0.4 -- 
34 1.3 ± 0.3 1.0 ± 0.3 1.3 
35 0.7 ± 0.01 0.7 ± 0.2 -- 
aAll OHCs tested at 5 µM. bValues represent fold mRNA 
upregulation ± SEM. cSelectivity for Hh signaling determined as 
Gli1/ABCA1. Data is average of at least three separate experiments 
performed in triplicate. 
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stereoselective interactions between the side chain of the OHC scaffold and its binding site in the Smo CRD 
are essential for its ability to activate Hh signaling.  
Based on its comparable potency and improved selectivity, we evaluated OHC 32 in a series of 
secondary assays to further probe its ability to activate the Hh signaling cascade. Dose-dependent evaluation 
of OHC 32 demonstrated that its ability to up-regulate the key Hh target genes Gli1 and Ptch1 was 
approximately two-fold less than both 20 and 28 (Table 5). In addition, the EC50 value for up-regulation of 
ABCA1 by 32 was comparable to that obtained for the Hh pathway target genes, suggesting removal of the 
C-21 methyl also affects its ability to selectively activate Hh signaling. To confirm that GLI1 up-regulation 
with 32 is mediated through the Hh pathway, a competition study was performed with cyclopamine (Cyc), 
potent Hh-selective inhibitor known to attenuate Gli1 expression induced by OHCs.72-73,108 As expected, 
co-administration with Cyc (5 µM) abolished Gli1 up-regulation, indicating OHC 32 functions through Hh 
activation (Figure 13d).  
When the Hh pathway is functionally activated in M2-10B4 cells, osteogenic differentiation is 
promoted, resulting in mature osteoblastic cells.113-114 This is possible because M2-10B4 cells possess stem-
like characteristics with the ability to differentiate into bone, cartilage, adipocytes, and hematopoietic 
supporting tissues. This differentiation process can be followed by measuring the early- (osterix, OSX) and 
late-stage (alkaline phosphatase, ALP) transcriptional markers of osteogenesis. Following previously 
utilized procedures, OHCs 20 and 32 were evaluated for osteogenic activity. Cells were treated with either 
OHC at 5 µM for 24, 48, or 96 hours to compare mRNA expressions of Gli1, OSX, and ALP (Figure 13a-
c).  
Table 5. Concentration dependent pathway activation in M2-10B4 cells.110 
OHC Gli1 Ptch1 ABCA1 
20 0.52 ± 0.04a 0.72 ± 0.2 4.7 ± 0.9 
28 0.57 ± 0.1 0.65 ± 0.06 1.5 ± 0.2 
32 1.3 ± 0.1 1.3 ± 0.01 2.8 ± 0.1 
aValues are in mM ± SEM. Data is the average of at least three separate 
experiments performed in triplicate. 
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Both 20 and 32 demonstrated comparable Gli1 up-regulation after 24 and 48 hours; however, 20 
continued to increase Gli1 up to 96 hours post-treatment. After 24 hours, both compounds induced modest 
OSX and ALP expression. Interestingly, only 20 significantly increased OSX up to 96 hours. In addition, 
increased ALP expression, denoting mature osteoblasts, was observed at both 48 and 96 hours for 15, but 
not until 96 hours for 32. Taken together, this data supports the ability of both OHCs to terminally 
differentiate precursor cells via Hh activation, while also suggesting that 32 mediates its osteogenic 
differentiation through a mechanism distinct from osterix. One possible mechanism to be evaluated utilizes 
Runx2, runt-related transcription factor 2. Runx2 is a known as a master regulator of osteoblast 
differentiation115 and has been shown to have a relationship with IHh expression.116  
Figure 13. Induction of osteogenic differentiation by OHCs at 24, 48, or 96 hr. Up-regulation of Gli1 
(A), OSX (B), and ALP (C). Statistical analysis, two-way ANOVA with Bonferroni post-test performed 
using GraphPad Prism5; ***p<0.001, compared with DMSO control; ns, not statistically significant 
compared with DMSO control; #, p<0.001, compared with OHC 32. (D) Attenuation of 32-mediated 
Gli1 up-regulation with Cyc co-administration in M2-10B4 cells. OHC and Cyc evaluated at 5 µM. Data 
are from a representative experiment performed in triplicate. Statistical analysis, one-way ANOVA with 
Tukey post-test performed using GraphPad Prism5; ***p<0.001, compared with corresponding DMSO 
control; ## p<0.001, #p<0.01compared with corresponding OHC alone. 
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In addition, the ability of OHCs to induce osteogenesis may provide a novel method for therapeutics 
for diseases, such as osteoporosis; however, more mechanistic studies as to how stimulation of Hh signaling 
induces osteogenesis.   
 
V. Predicting OHC Activity117  
Following the unexpected results described above with the des-methyl analogues, a modeling approach 
was taken to explain these results and to develop a method for determining possible activities prior to 
testing.  A homology model of the human Smo CRD (hCRD) was generated by a postdoctoral researcher 
in the Hadden lab, Dr R. C. Dash, using the crystal structure of the zebrafish CRD (zCRD, PDB ID: 4C79, 
resolution 2.3Å) as the template (Figure 14).116, 117 Similar to other CRD structures found in Fz-type 
 
Figure 14. Average binding conformations of OHCs 20 and 35.117 (A) Comparison of average binding 
conformation generated from MD of compound 20 (yellow) and 35 (blue) at the oxysterol binding site 
of the hCRD (B) Average binding conformation of 20. (C) Average binding conformation of 35. 
Hydrogen bonds are indicated by the yellow dashed lines. Compounds are represented as ball and stick 
while oxysterol binding residues are represented in sticks. (D) The molecular surface area of the hCRD 
colored as per the hydrophobicity of the residues with the predicted OHC binding site encircled. Green, 
hydrophobic; white, neutral; red, hydrophilic. 
(D) 
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receptors, the probable OHC binding site is located on the surface of the domain between the three core α-
helices and is lined with hydrophobic residues (Figure 14d).  
Docking studies were performed via the Schrodinger Suite package and AutoDock v4.2. The docking 
study demonstrates favorable steric and electrostatic interactions between 20 and the hCRD, where the 
tetracyclic core occupied the hydrophobic pocket formed by the α1 and α3 helices. Additionally, this 
conformation orientated the two methyl groups (C-18 and C-19) in a way that they became buried deeply 
in the hydrophobic cavity, and the 3b-hydroxyl group formed a hydrogen bond (H-bond) with the carbonyl 
of glycine 112 (G112) (Figure 14b). The remaining OHCs were docked to the hCRD model in a similar 
fashion (Table 6). 
Interestingly, all compounds showed predicted binding energies that would suggest biological activity, 
regardless of Gli1 upregulation values, and the predicted binding energies and cell-based Hh activities were 
inversely correlated. Based on these results, the 23-hydroxylated OHC analogues 34 and 35 were evaluated 
as antagonists (Table 7).   
Initially, OHCs 34 and 35 were evaluated in the M2-10B4 cell line and compared to the known 
cholesterol-based Hh pathway inhibitor, 22-NHC.106 In this assay, multiple up-regulation methods were 
utilized to activate Hh signaling: (1) 23(S)-OHC (28), (2) recombinant SHh ligand (rSHh), and (3) SAG 
Table 6. Comparison of OHC cellular activity and predicted binding. 
OHCa Gli1 mRNAb Docking Scored DGbindinge              
DMSO 1.0 NA -- 
20 19.9 ± 0.7 -9.04 -11.81 
22 16.2 ± 2.5 -8.91 -6.69 
23 1.6 ± 0.4 -9.42 -14.87 
28 18.2 ± 0.6 -9.59 -7.72 
29 8.7 ± 0.1 -8.80 -6.35 
32 24.3 ± 0.8 -9.61 -0.72 
33 1.3 ± 0.01 -10.14 -14.31 
34 1.3 ± 0.3 -8.86 -12.03 
35 0.7 ± 0.01 -9.26 -19.59 
22-NHC  NAc -9.16 -15.65 
aAll OHCs evaluated at 5 µM. bValue represents mRNA upregulation 
compared to DMSO (set to 1.0). cKnown Hh antagonist, Ref 106. dDocking 
scores represent predicted binding energy generated by Autodock 4.0. 
eGbinding = Total predicted binding energy in kcal/mol. 
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(17). These three methods were chosen to fully characterize any antagonistic activity where each method 
targets Hh signaling differently. Specifically, rSHh activates Ptch to induce signaling whereas SAG (17) 
and 28 bind at different locations of Smo to induce signaling. These OHCs were further evaluated for 
antagonistic activity in ASZ001 cells, an Hh-dependent murine BCC model with a Ptch deficiency, kindly 
provided by Dr. Ervin Epstein at the Children’s Hospital Oakland Research Institute. These cells were 
obtained from BCC tumors that arose in irradiated Ptch1+/-  mice, and have lost the Ptch1 allele.118 
Inhibitory activity of 35 and 22-NHC were comparable in M2-10B4 cells against all three activation 
methods; however, 22-NHC was slightly more active with sub-micromolar potency in ASZ001 cells. This 
difference in potency may be due to greater permeability or decreased metabolism in ASZ cells for 22-
NHC.  
Molecular dynamic studies were performed by Dr Radha Dash to try to explain the differences in 
activity between 28 and 35, where inverting the C-21 methyl orientation results in opposite Hh activity 
(agonist to antagonist). The major difference was observed when snapshots of 20, 28, and 35 were overlaid 
and the C17-C20-C22-C23 dihedral angles were plotted (Figure 15). Inversion of the C-21 methyl group, 
found in 35, appears to rigidify the iso-octyl side chain (Figure 15b), presumably due to interactions 
between the C-18 and C-21 methyl groups preventing complete rotation and flexibility. In turn, this leads 
to a synclinal orientation that orients the 23-hydroxyl group into the protein surface allowing for an 
Table 7. Inhibition of Hh signaling by OHCs 34-35 compared to 22-NHC.117 
OHC Hh activation method in M2-10B4 MEFsa 
IC50 (µM)b 
M2-10B4 ASZ001 
34 
23(S)-OHC (28) >20 
>20 rSHh >20 
SAG (17) >20 
35 
23(S)-OHC (28) 3.7 ± 0.9  
2.9 ± 0.8 
 
rSHh 5.2 ± 0.01 
SAG (17) 4.4 ± 2  
22-
NHC 
23(S)-OHC (28) 5.3 ± 0.1 
0.71 ± 0.3 rSHh 4.7 ± 2 
SAG (17) 6.0 ± 0.6 
aAgonists administered at following concentrations: 28 at 5 µM, 17 at 400 nM, 
and rSHh at 0.5 ng/µL. bIC50 values are Mean ± SEM of at least two separate 
experiments performed in triplicate. 
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additional H-bond to form with aspartate-96 (D96) compared to 20 and 28 that show an anti-periplanar 
dihedral angle that orients the 23-hydroxyl group away from the protein surface and D96. This suggests 
that the additional binding interaction with D96 increases the binding affinity enough for 35 to become an 
Hh antagonist.  
 
Conclusion 
As described above, the natural endogenous ligand for Smo and the specific mechanism for Ptch 
regulation of Smo remain to be defined. Among the candidates for endogenous ligands are cholesterol and 
 
Figure 15. OHC dihedral profile.117 (A) Two-dimensional representations of 20, 28, and 35. (B) An 
overlay of 500 snapshot geometries for 20, 28 and 35 from the OHC-hCRD Molecular Dynamic (MD) 
simulation, showing both the localized geometries of the iso-octyl side chain and the significant 
orientation of the hydroxyl group. Alignment of these snapshot geometries is based on the atoms of the 
tetracyclic ring of the average MD geometry. (C) Distribution of dihedral angles between the C-17, C-
20, C-22 and C-23 atoms over a simulation time of 5 ns. 
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oxysterols (OHCs), oxygenated metabolites of cholesterol. In recent years, the binding of OHCs and to Smo 
has been greatly characterized suggesting both highly regio- and stereoselective binding preferences. 
Adding to these studies, a series of OHC analogues (32 – 35) were designed and synthesized to study the 
importance of the C-20 stereochemistry and specifically the C-21 methyl group. Interestingly, removal of 
the C-21 methyl group yielded an active analogue (32) where the hydroxyl group was oriented in the same 
direction as the inactive 20(R)-OHC (25) suggesting that removal of the methyl group allows for the C20-
hydroxyl group to occupy the same special arrangement and orientation as the active 20(S)-OHC (20).109 
Additionally, it was determined that changing the C20 stereochemistry (OHCs 34-35) can completely 
change the activity of the compound from agonist to antagonist (28 to 35). Molecular dynamic studies 
revealed that inversion of the C20 stereocenter allowed for the 23-hydroxyl group to interact with the D96 
residue in the CRD, increasing the binding affinity significantly to result in this activity change.117 Taken 
together, these results were surprising but follow a trend observed with glucocorticoids where both agonists 
and antagonists have been identified with very similar overall structures.2 It has also been reported that 
endogenous B-ring oxysterols inhibit Hh signaling at the level of Smo distinct from the side-chain OHC 
binding site.120 
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Experimental Section109, 117 
General Information. Pregnenolone and 21-acetoxypregnenolone were purchased from Sigma-Aldrich. 
All other reagents were purchased from commercial sources (Fisher Scientific or Sigma-Aldrich) unless 
otherwise stated. Column chromatography was performed using silica gel purchased from Sorbtech 
(Sorbent Technologies). All 1H and 13C NMR data was performed on a Bruker AVANCE 500 spectrometer 
and analysis with MestReNova version 9.1.0. HRMS data was analyzed at the Mass Spectrometry Facility 
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at the University of Connecticut, performed by Dr. You-Jun Fu. FT-IR analysis was performed on a Bruker 
Alpha Platinum ATR instrument using OPUS software (v 7.2). 
 
3-THP,21-acetoxypregnenolone (36-THP). To a solution of 21-acetoxypregnenolone (10.8 g, 31.6 mmol) 
in anhydrous DCM (150 mL) under argon, 3,4-dehydro-2H-furan (39.5 mmol, 3.6 mL) and a catalytic 
amount of p-toluenesulfonic acid were added. The mixture stirred for 12 hr at RT, washed with saturated 
sodium bicarbonate (2 X 75 mL), saturated sodium chloride (2 X 75 mL), dried over sodium sulfate, and 
concentrated. The mixture was purified via column chromatography (SiO2, 10% EtOAc in Hex) to give 36-
THP as a white solid in excellent yield (13.9 g, 95%). 1H (500 MHz, CDCl3) d 5.37 (m, 1H), 4.73 (m, 2H), 
4.56 (d, 2H), 3.94 (m, 1H), 3.54 (m, 2H), 2.53 (m, 1H), 2.38 (m, 1H), 2.24 (m, 1H), 2.19 (s, 3H), 2.06 (m, 
2H), 1.88 (m, 3H), 1.73 (m, 3H), 1.64 (m, 1H), 1.58 (m, 7H), 1.49 M, 1H), 1.42 (m, 1H), 1.31 (m, 1H), 
1.21-1.07 (2H), 1.03 (s, 3H), 0.99 (m, 1H), 0.69 (s, 3H). 13C NMR (126 MHz, CDCl3) d 203.7, 170.2, 141.1, 
121.1, 96.9, 75.9, 69.2, 62.8, 59.3, 57.1, 49.9, 44.7, 40.2, 38.6, 37.4, 37.2, 36.8, 31.9, 31.3, 29.6, 27.9, 25.5, 
24.6, 22.8, 21.0, 20.5, 20.0, 19.4, 13.1. IR (ATR FTIR): 2936, 1745, 1722, 1417, 1370, 1229, 1198, 1112, 
1074, 1056, 1029, 975, 904, 837.  [M+H]+, calc. 459.3111, obs. 459.3186. 
 
1-((3S,10R,13S,17S)-10,13-dimethyl-3-((tetrahydro-2H-pyran-2-yl)oxy)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethane-1,2-
diol (37). A solution of THP-36 (1.0 g, 2.18 mmol) in anhydrous THF (20 mL) under argon was cooled to 
0°C. Lithium aluminum hydride (1.0 M in THF, 8.8 mmol) was added drop-wise and the mixture stirred 
for 4 hr at 0°C. The reaction was diluted with EtOAc, quenched with cold water and filtered. The filtrate 
was washed, where the organic layer was collected and concentrated. Purification via flash chromatography 
(SiO2, 30% EtOAc in Hex) afforded 37 as a white solid in excellent yield (1.02 g, 96%). 1H NMR (500 
MHz, CDCl3) δ 5.36 (m, 1H), 4.74 (s, 1H), 3.94 (m, 1H), 3.67 (d, 2H), 3.51 (m, 2H), 3.38 (m, 1H), 2.38 
(m, 1H), 2.22-2.11 (m, 3H), 2.00 (m, 1H), 1.87 (m, 3H), 1.74 (m, 2H), 1.66 (m, 2H), 1.55-1.47 (m, 10H), 
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1.27-1.11 (4H), 1.04 (s, 3H), 0.81 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 141.2, 121.3, 96.9, 75.9, 74.6, 
66.5, 62.8, 55.9, 52.4, 50.2, 42.5, 40.2, 39.7, 38.8, 37.2, 36.8, 31.9, 31.8, 31.3, 29.7, 27.9, 25.5, 24.6, 20.9, 
20.1, 19.4, 12.4. IR (ATR FTIR): 3338, 2931, 1438, 1351, 1305, 1199, 1135, 1114, 1060, 1027, 972, 909, 
868 cm-1. HRMS: [M+H]+, calc. 419.3161, obs. 419.3139. 
  
(3S,10R,13S,17S)-10,13-dimethyl-3-((tetrahydro-2H-pyran-2-yl)oxy)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-17-carbaldehyde 
(38). To a solution of 37 (0.75 g, 1.79 mmol) in 2:1 THF:H2O (45 mL) was added sodium periodate (1.2 g, 
5.61 mmol) and the mixture stirred at RT for 1 hr. The mixture was extracted with EtOAc (3 X 50 mL) and 
the organic layer was dried over sodium sulfate and concentrated. Purification via flash chromatography 
(10% EtOAc in Hex) afforded 38 as a white solid (0.64 g, 92%). 1H NMR (500 MHz, CDCl3) δ 5.37 (s, 
1H), 4.74 (s, 1H), 3.94 (m, 1H), 3.54 (m, 2H), 3.38 (m, 1H), 2.35 (m, 2H), 2.04 (m, 2H), 1.88 (m, 3H), 1.76 
(m, 3H), 1.29 (m, 1H), 1.15 (m, 2H), 1.04 (s, 3H), 0.79 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 204.9, 141.1, 
121.2, 96.9, 75.9, 62.84, 56.5, 50.2, 44.7, 40.2, 38.3, 37.2, 36.8, 31.8, 31.5, 29.7, 27.9, 25.5, 24.9, 21.1, 
20.6, 20.1, 19.4, 13.7. IR (ATR FTIR): 2938, 2695, 1719, 1438, 1352, 1260, 1198, 1112, 1054, 1021, 973, 
911, 866 cm-1. HRMS: [M-H]+, calc. 385.2743, obs. 385.2742; [M+H]+, calc. 387.2899, obs. 387.2867 
  
Grignard Addition to 38. To a suspension of acid activated Mg turnings (0.360 g, 14.8 mmol) in anhydrous 
THF (5 mL) under argon at RT was catalytic amount of Br2Et (3 drops) and heated to 35°C. The suspension 
was stirred until bubbling of the Mg turnings was observed. A solution of bromo-4-methylpentane (1.6 mL, 
10.9 mmol) in anhydrous THF (6 mL) was added drop-wise over 20 min to the Mg suspension and heated 
to 55°C. After stirring for 2 hr, the mixture was cooled to 0°C. A solution of 28 (0.700 g, 1.81 mmol) in 
anhydrous THF (6 mL) was added and stirred 0°C for 2 hr. The reaction was quenched with saturated 
ammonium chloride (15 mL) and washed with ether (2 X 25 mL). The combined organic layers were dried 
over sodium sulfate and concentrated. Purification via flash chromatography (10% EtOAc in Hex) afforded 
39 and 40 as easily separable white solids (55% overall conversion).  
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(1S)-1-((3S,10R,13S,17S)-10,13-dimethyl-3-((tetrahydro-2H-pyran-2-yl)oxy)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-5-
methylhexan-1-ol (39). Rf 0.28 in 10:1 Hexanes:Ethyl acetate. 1H NMR (500 MHz, CDCl3) δ 5.40 (s, 1H), 
4.76 (s, 1H), 3.97 (m, 1H), 3.58 (m, 3H), 2.41 (m, 2H), 2.13 (m, 1H), 2.02 (m, 1H), 1.91 (m, 3H), 1.76 (m, 
1H), 1.68 (m, 2H), 1.57 (m, 13H), 1.40-1.20 (m, 12H), 1.06 (s, 3H), 1.00 (m, 1H), 0.92 (d, J = 7.5 Hz, 6H), 
0.82 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 141.2, 121.3, 96.8, 76.0, 74.4, 62.8, 56.7, 56.2, 50.2, 42.4, 
40.3, 40.0, 39.1, 37.3, 37.2, 36.8, 31.9, 31.8, 31.3, 28.03, 25.54, 25.50, 24.6, 22.9, 22.7, 22.5, 21.0, 20.1, 
19.4, 12.4. IR (ATR FTIR): 3466, 2933, 1464, 1376, 1364, 1259, 1134, 1112, 1093, 1077, 1057, 1022, 973, 
910, 867 cm-1. HRMS: [M+H]+, calc. 473.3995, obs. 473.4140. [M-OH]+, calc. 455.3889, obs. 455.3848. 
 
(1R)-1-((3S,10R,13S,17S)-10,13-dimethyl-3-((tetrahydro-2H-pyran-2-yl)oxy)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-5-
methylhexan-1-ol (40). Rf 0.23 in 10:1 Hexanes:Ethyl acetate. 1H NMR (500 MHz, CDCl3) δ 5.39 (s, 1H), 
4.76 (s, 1H), 3.96 (m, 1H), 3.58 (m, 3H), 2.38-2.24 (2H), 2.13 (m, 1H), 2.02 (m, 1H), 1.91 (m, 5H), 1.75-
1.19 (30H), 1.05 (s, 3H), 0.92 (d, 6H), 0.74 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 140.9, 121.5, 97.0, 76.0, 
73.2, 62.9, 56.6, 56.3, 50.3, 41.7, 40.3, 39.1, 38.8, 37.5, 37.2, 36.9, 31.9, 31.6, 31.3, 29.7, 28.1, 25.5, 24.8, 
24.2, 23.2, 22.7, 22.6, 20.8, 20.1, 19.4, 12.7. IR (ATR FTIR): 3500, 2923, 1460, 1384, 1353, 1260, 1199, 
1109, 1053, 1020, 973, 911, 864 cm-1. HRMS: [M+H]+, calc. 473.3995, obs. 473.4028; [M-OH]+, calc. 
455.3889, obs. 455.3873.  
 
(3S,10R,13S,17S)-17-((S)-1-hydroxy-5-methylhexyl)-10,13-dimethyl-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol (32). The THP 
group was removed from OHC 39 by stirring in 2N HCl (10 mL) until completion (16 h). The acid was 
quenched with 2 M NaOH (15 mL) and extracted with EtOAc (3 x 20mL). Purification via flash 
chromatography (SiO2, 20% EtOAc in Hex) afforded 32 as a white solid in excellent yield (0.063 g, 96%). 
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1H NMR (500 MHz, CDCl3) δ 5.40 (s, 1H), 3.60 (m, 2H), 2.30 (m, 2H), 2.15 (m, 1H), 2.02 (m, 1H), 1.89 
(m, 2H), 1.69 (m, 2H), 1.56 (m, 8H), 1.43 (m, 2H), 1.30-1.14 (12H), 1.07 (s, 3H), 0.92 (d, 6H), 0.82 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 140.9, 121.6, 77.3, 77.0, 76.8, 74.4, 71.8, 56.7, 56.2, 50.2, 42.4, 42.3, 
40.0, 39.1, 37.3, 37.2, 36.6, 31.9, 31.8, 31.7, 28.0, 25.5, 24.6, 22.9, 22.7, 22.5, 21.0, 19.4, 12.4. IR (ATR 
FTIR): 3298, 2925, 1729, 1463, 1373, 1351, 1260, 1056, 1023, 954, 912 cm-1. HRMS: [M+NH4]+ calc. 
406.3685, obs. 406.3661; [M-OH]+, calc. 371.3314, obs. 371.3302.  
 
(3S,10R,13S,17S)-17-((R)-1-hydroxy-5-methylhexyl)-10,13-dimethyl-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol (33). The THP 
group was removed from OHC 33 as described above for the preparation of 32. Purification via flash 
chromatography (SiO2, 20% EtOAc in Hex) afforded 33 as a white solid in excellent yield (0.031 g, 95%). 
1H NMR (500 MHz, CDCl3) δ 5.40 (s, 1H), 3.60 (m, 2H), 2.31 (m, 2H), 2.04 (m, 1H), 1.90 (m, 4H), 1.68 
(m, 2H), 1.56 (m, 9H), 1.42 (m, 4H), 1.30-1.12 (8H), 1.06 (s, 3H), 0.92 (d, 6H), 0.75 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 140.8, 121.6, 77.3, 77.0, 76.8, 73.2, 71.8, 56.6, 56.2, 50.2, 42.3, 41.7, 39.1, 38.8, 37.3, 
37.2, 36.6, 31.9, 31.7, 31.6, 28.1, 24.8, 24.2, 23.2, 22.7, 22.6, 20.8, 19.4, 12.8. IR (ATR FTIR): 3290, 2926, 
1715, 14622, 1378, 1365, 1320, 1238, 1058, 1028, 953, 936 cm-1. HRMS: [M+NH4]+, calc. 406.3685, obs. 
406.3658; [M-OH]+, calc. 371.3314, obs. 371.3300. 
 
1-((3S,10R,13S,17S)-10,13-dimethyl-3-((tetrahydro-2H-pyran-2-yl)oxy)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)ethanone, 
THP-pregnenolone (41-THP). To a solution of pregnenolone (10.0 g, 31.6 mmol) in anhydrous DCM 
(150 mL) under argon, 3,4-dehydro-2H-furan (39.5 mmol, 3.6 mL) and a catalytic amount of p-
toluenesulfonic acid were added. The mixture stir for 12 hr at RT, washed washed with saturated sodium 
bicarbonate (2 X 75 mL), saturated sodium chloride (2 X 75 mL), dried over sodium sulfate, and 
concentrated. The mixture was purified via column chromatography (SiO2, 10% EtOAc in Hex) to give 41-
THP as a white solid (12.2 g, 96%). Characterization matched that previously described.119 1H NMR (500 
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MHz, CDCl3) δ 5.37 (m, 1H), 4.75 (m, 1H), 3.93 (m, 1H), 352 (m, 2H), 2.56 (m, 1H), 2.39 (m, 1H), 2.21 
(m, 1H), 2.15 (s, 3H), 2.08-2.00 (2H), 1.88 (m, 3H), 1.77-1.64 (5H), 1.59-1.47 (11H), 1.29-1.09 (3H), 1.04 
(s, 3H), 0.66 (s, 3H).  
 
(Z)-3-((3S,10R,13S,17S)-10,13-dimethyl-3-((tetrahydro-2H-pyran-2-yl)oxy)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-
methylbut-2-enal (42a) and (E)-3-((3S,10R,13S,17S)-10,13-dimethyl-3-((tetrahydro-2H-pyran-2-
yl)oxy)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-2-
methylbut-2-enal (42b). A solution of 41-THP (5.00 g, 12.5 mmol) in THF (100 mL) was cooled to -78°C 
under argon. Vinylmagnesium bromide (0.7 M in THF, 44.8 mL, 31.4 mmol) was added drop wise. Upon 
complete addition, the mixture was stirred for 1 hr at -78°C and then warmed to RT over 12 hr. The mixture 
was re-cooled to 0°C and quenched with saturated aqueous ammonium chloride and washed with ether (3 
X 60 mL). The organic layers were combined and washed with saturated sodium chloride (1 X 100 mL), 
dried with sodium sulfate and concentrated. Purification with flash chromatography (SiO2, 12% EtOAc in 
Hex) afforded a 1:9 mixture of alcohols as a white solid (5.2 g, 97%) that was utilized without additional 
separation. 1H NMR (500 MHz, CDCl3) δ 6.01 (dd, 1H), 5.37 (s, 1H), 5.17 (d, 1H), 4.99 (d, 1H), 4.75 (s, 
1H), 3.94 (s, 1H), 3.53 (m, 2H) 2.30 (m, 2H), 2.13 (m, 1H), 1.99 (m, 1H), 1.89 (m, 3H), 1.76-1.64 (m, 5H), 
1.58-1.39 (m, 14H) 1.36 (s, 3H), 1.28 (m, 1H), 1.13 (m, 2H), 1.04 (s, 3H), 0.96 (m, 1H), 0.86 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 146.14, 140.98, 121.43, 121.27, 110.22, 96.99, 96.85, 75.92, 75.73, 63.76, 
62.90, 62.81, 59.48, 56.95, 56.83, 50.13, 44.03, 42.85, 40.21, 38.89, 37.47, 37.23, 36.84, 31.89, 31.55, 
31.37, 29.71, 28.78, 28.01, 25.53, 24.51, 23.84, 23.22, 22.86, 20.90, 20.09, 19.40, 13.82, 13.24. IR (ATR 
FTIR): 3516, 2933, 1467, 1453, 1336, 1260, 1200, 1140, 1111, 1055, 1021, 976, 911, 866 cm-1. HRMS: 
[M+NH4]+, calc. 445.3634, obs. 446.3667. 
To a suspension of pyridinium chlorochromate (5.2 g, 24.1 mmol) and sodium acetate (4.9 g, 59.7 mmol) 
in CH2Cl2 (45 mL) under argon, was added the mixture of alcohols (5.2 g, 12.13 mmol). The mixture was 
stirred at RT for 12 hr. The mixture was filtered through Celite, followed by copious rinsing with CH2Cl2 
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and concentrated. Purification with flash chromatography (SiO2, 10% EtOAc in Hex) provided an 80:20 
E:Z mixture of 42a:42b as a white solid (3.3 g, 64%). 1H NMR (500 MHz, CDCl3) δ 10.10 (d, 1H), 10.00 
(d, 0.2H), 6.06 (d, 0.2H), 5.95 (d, 1H), 5.39 (m, 1H), 4.92 (m, 0.2H), 4.75 (m, 1H), 4.05 (m, 0.2H), 3.95 
(m, 1H) 3.53 (m, 2H), 3.25(m, 0.2H), 2.4-2.26 (m, 2H), 2.23 (s, 3H), 2.01 (m, 2H), 1.87 (m, 6H), 1.75 (m, 
4H), 1.61-1.40 (m, 15H), 1.39-1.28 (m, 3H), 1.24-1.08 (m, 3H), 1.04 (s, 3H), 0.72 (s, 0.6H) 0.64 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 191.3, 190.7, 164.3, 140.9, 131.5, 127.9, 121.2, 96.9, 75.9, 62.8, 60.2, 56.8, 
56.2, 51.4, 50.2, 46.3, 45.1, 40.2, 38.7, 38.6, 37.4, 37.2, 36.8, 32.2, 31.8, 31.3, 29.6, 27.9, 25.5, 24.9, 24.4, 
21.0, 20.0, 19.4, 19.3, 13.9, 13.1. IR (ATR FTIR): 2930, 1714, 1656, 1434, 1376, 1354, 1254, 1230, 1197, 
1130, 1112, 1060, 1022, 972, 910, 864 cm-1. HRMS: [M+H]+, calc. 427.3112, obs. 427.3211.   
 
(3R)-3-((3S,10R,13R,17R)-10,13-dimethyl-3-((tetrahydro-2H-pyran-2-yl)oxy)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)butanal (43). 
A solution of 42a:42b (0.300 g, 0.706 mmol) in CHCl3 (10 mL) was cooled to 0°C. The trichloroacetic acid 
salt of (S)-(+)-2-(tert-butyl)-3-methylimidazolin-4-one (0.038 g, 0.14 mmol) and Hantzsch ester (0.215 g, 
0.85 mmol) were added and the mixture stirred at 0°C until the starting material was consumed as evidenced 
by continuous TLC analysis (~ 16 hr). The solution was concentrated and directly purified via flash 
chromatography (SiO2, 10% EtOAc in Hex) to yield 43 as a white solid (0.195 g, 64%). Characterization 
matched that previously reported by the Hadden Lab.11 
 
(3S)-3-((3S,10R,13R,17R)-10,13-dimethyl-3-((tetrahydro-2H-pyran-2-yl)oxy)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)butanal (44). 
A solution of 42a:42b (0.300 g, 0.706 mmol) in CHCl3 (10 mL) was cooled to 0°C. The trichloroacetic 
acid salt of (R)-2-(tert-butyl)-3-methylimidazolin-4-one (0.038 g, 0.14 mmol) and Hantzsch ester (0.215 g, 
0.85 mmol) were added and the mixture stirred at 0°C until the starting material was consumed as evidenced 
by continuous TLC analysis (~ 16 hr). The solution was concentrated and directly purified via flash 
chromatography (SiO2, 10% EtOAc in Hex) to yield 44 as a white solid (0.180 g, 60%). 1H NMR (500 
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MHz, CDCl3) δ  9.80 (s, 1H), 5.37 (m, 1H), 4.76 (m, 1H), 3.85 (m, 1H), 3.55 (m, 2H), 2.72 (m, 1H), 2.41-
2.26 (m, 3H), 2.04 (m, 2H), 1.91 (m, 5H), 1.75 (m, 1H), 1.64 (m, 2H), 1.57 (m, 6H), 1.51 (m, 2H), 1.37 (m, 
1H), 1.27- 1.12 (m, 5H), 1.05 (s, 3H), 0.97 (d, 3H), 0.76 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 203.3, 
140.9, 121.4, 96.9, 75.9, 62.9, 56.6, 55.6, 49.9, 42.4, 40.2, 39.7, 38.8, 37.4, 37.2, 36.8, 31.8, 31.3, 30.6, 
29.7, 27.8, 25.5, 24.0, 21.0, 20.1, 19.9, 19.4, 12.3. IR (ATR FTIR): 2930, 1715, 1439, 1372, 1258, 1199, 
1135, 1112, 1056, 1021, 974, 912, 867 cm-1. HRMS: [M+H]+, calc. 429.3368, obs. 429.3360.   
 
Preparation of 23- OHCs 28 and 29. A solution of iso-butylmagnesium chloride (2.0M in THF, 0.84 mL, 
1.68 mmol) was cooled to 0°C in THF (5 mL) under argon. A solution of 43 (0.090 g, 0.210 mmol) in THF 
(5 mL) was added drop-wise and the mixture stirred at 0°C for 90 min. The reaction was quenched with 
saturated aqueous ammonium chloride and washed with ether (2 X 25 mL). The organic layers were dried 
sodium sulfate and concentrated. Purification via flash chromatography (SiO2, 8% EtOAc in Hex) provided 
two separable isomers as white solids (80% overall total yield of both isomers). Characterization of fraction 
1 [THP-23(S)-OHC, Rf 0.39 in 8:1 Hexanes:Ethyl acetate] and fraction 2 [THP-23(R)-OHC, Rf 0.29 in 8:1 
Hexanes:Ethyl acetate] were as previously described.107 
 
23(S)-hydroxycholesterol (28). Fraction 1 (0.050 g, 0.103 mmol) was dissolved in 5:1 MeOH:THF (6 
mL), to which 2N HCl (2 mL) was added dropwise. The mixture was stirred at RT for 3 hr. The reaction 
was quenched with water (5 mL) and washed with EtOAc (2 X 20 mL). The organic layers were dried over 
sodium sulfate, concentrated, and purified as previously described to afford 22 as a white solid (0.040 g, 
97%). Characterization matched that previously published.107 1H NMR (500 MHz, CDCl3) δ 5.37 (m, 1H), 
3.79 (m, 1H), 3.54 (m, 1H), 2.27 (m, 2H), 2.02 (m, 2H), 1.85 (m, 4H), 1.61-1.43 (11H), 1.28 (m, 4H), 1.20-
1.07 (4H), 1.03 (s, 3H), 0.98 (d, 3H), 0.94 (dd, 6H), 0.71 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 140.8, 
121.7, 71.8, 68.7, 56.9, 56.7, 50.2, 46.5, 45.2, 42.4, 42.3, 39.8, 37.3, 36.5, 33.9, 31.9, 31.6, 28.5, 24.5, 24.3, 
23.9, 21.7, 21.1, 19.43, 19.42, 11.9. 
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23(R)-hydroxycholesterol (29). The THP group was removed from fraction 2 as described above for the 
preparation of 28. Purification via flash chromatography (SiO2, 20% EtOAc afforded) 29 as a white solid 
in excellent yield (0.025 g, 94%). Characterization matched that previously published.107 1H NMR (500 
MHz, CDCl3) δ 5.37 (m, 1H), 3.80 (m, 1H), 3.54 (m, 1H), 2.28 (m, 2H), 2.04 (m, 1H), 2.00 (m, 1H), 1.86 
(m, 3H), 1.77 (m, 1H), 1.67 (m, 1H), 1.61-1.39 (11H), 1.28 (m, 2H), 1.20 (m, 2H), 1.12-1.05 (4H), 1.03 (s, 
3H), 0.99 (d, 3H), 0.93 (dd, 6H), 0.74 (s, 3H).  13C NMR (126 MHz, CDCl3) δ 140.77, 121.67, 71.8, 67.0, 
56.84, 56.78, 50.1, 48.0, 44.5, 42.4, 42.3, 39.8, 37.3, 36.5, 32.5, 31.9, 31.7, 28.5, 24.7, 24.3, 23.3, 22.3, 
21.1, 19.4, 18.7, 11.9. 
 
Preparation of 34 and 35. Grignard addition of iso-butylmagnesium chloride to 44 was analogous to that 
described above for addition to 43. Purification via flash chromatography (SiO2, 8% EtOAc in Hex) 
provided two separable isomers as white solids (72% overall total yield of both isomers). 
(2S,4S)-2-((3S,10R,13R,17R)-10,13-dimethyl-3-((tetrahydro-2H-pyran-2-yl)oxy)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-6-
methylheptan-4-ol (THP-34). Rf 0.41 in 8:1 Hexanes:Ethyl acetate. 1H NMR (500 MHz, CDCl3) d 5.39 
(m, 1H), 4.76 (m, 1H), 3.96 (m, 1H), 3.81 (m, 1H), 3.55 (m, 2H), 2.41 (m, 1H), 2.24 (m, 1H), 2.01 (m, 2H), 
1.93-1.73 (7H), 1.66-1.45 (11H), 1.30 (m, 5H), 1.19-1.07 (5H), 1.05 (s, 3H), 0.97(dd, 6H), 0.90 (d, 3H), 
0.73 (s, 3H). 13C NMR (126 MHz, CDCl3) d 141.1, 121.5, 97.0, 76.0, 68.6, 62.9, 56.5, 50.2, 46.1, 44.8, 
42.4, 40.3, 39.9, 38.8, 37.5, 37.2, 36.8, 32.6, 31.9, 31.3, 29.7, 28.0, 27.5, 25.5, 24.5, 24.9, 21.7, 21.0, 20.1, 
19.4, 18.9, 12.3. IR (ATR FTIR): 3519, 2931, 1465, 1375, 1260, 1113, 1075, 1055, 1019, 909, 868.  HRMS: 
[M+H]+, calc. 487.4151, obs. 487.4145; [M-OH]+, calc. 469.4046, obs. 469.4045. 
 
(2S,4R)-2-((3S,10R,13R,17R)-10,13-dimethyl-3-((tetrahydro-2H-pyran-2-yl)oxy)-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-6-
methylheptan-4-ol (THP-35). Rf 0.30 in 8:1 Hexanes:Ethyl acetate.1H NMR (500 MHz, CDCl3) d 5.38 
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(m, 1H), 4.75 (m, 1H), 3.96 (m, 1H), 3.83 (m, 1H), 3.52 (m, 2H), 2.39-2.32 (2H), 2.01 (m, 2H), 1.88 (m, 
4H), 1.76 (m, 4H), 1.63-1.35 (11H), 1.29-1.07 (9H), 1.04 (s, 3H), 0.96 (d, 6H), 0.92 (d, 3H), 0.74 (s, 3H). 
13C NMR (126 MHz, CDCl3) d 140.9, 121.5, 97.0, 76.01, 67.4, 62.8, 56.8, 50.2, 48.1, 44.0, 42.4, 40.1, 38.8, 
37.5, 37.2, 36.8, 31.9, 31.3, 29.7, 28.1, 28.0, 25.5, 24.7, 24.2, 23.4, 22.3, 21.1, 20.1, 19.4, 18.5, 12.2. IR 
(ATR FTIR): 3491, 2931, 1465, 1374, 1261, 1140, 1110, 1056, 1018, 978, 864.  HRMS: [M+H]+, calc. 
487.4151, obs. 487.4082; [M-OH]+, calc. 469.4046, obs. 469.4035 
 
(3S,10R,13R,17R)-17-((2S,4S)-4-hydroxy-6-methylheptan-2-yl)-10,13-dimethyl-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol (34). The THP 
group was removed from OHC THP-34 as described above for the preparation of 28. Purification via flash 
chromatography (SiO2, 20% EtOAc afforded) 34 as a white solid in excellent yield (0.035 g, 95%). 1H 
NMR (500 MHz, CDCl3) δ 5.39 (m, 1H), 3.82 (m, 1H), 3.57 (m, 1H), 2.30 (m, 2H), 2.03 (m, 2H), 1.88 (m, 
3H), 1.79 (m, 1H), 1.62 (m, 3H), 1.58-1.48 (6H), 1.34 (m, 3H), 1.30 (s, 2H), 1.24-1.09 (4H), 1.05 (s, 3H), 
0.97 (dd, 6H), 0.91 (d, 3H), 0.73 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 140.80, 121.65, 71.81, 68.61, 
56.76, 56.54, 50.17, 46.09, 44.83, 42.41, 42.32, 39.89, 37.27, 36.54, 32.57, 31.91, 31.69, 29.72, 27.46, 
24.50, 24.13, 23.97, 21.69, 21.06, 19.41, 18.92, 12.30. IR (ATR FTIR): 3247, 2928, 1463, 1435, 1373, 
1140, 1112, 1056, 1019 cm-1. HRMS: [M+NH4]+, calc. 420.3842, obs. 420.3801; [M-OH]+, calc. 385.3470, 
obs. 385.3434  
 
(3S,10R,13R,17R)-17-((2S,4R)-4-hydroxy-6-methylheptan-2-yl)-10,13-dimethyl-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol (35). The THP 
group was removed from OHC THP-35 as described above for the preparation of 28. Purification via flash 
chromatography (SiO2, 20% EtOAc in Hex) afforded 35 as a white solid in excellent yield (0.034 g, 96%). 
1H NMR (500 MHz, CDCl3) δ 5.40 (m, 1H), 3.84 (m, 1H), 3.56 (m, 1H), 2.30 (m, 2H), 2.05 (m, 2H), 1.88 
(m, 3H), 1.76 (m, 3H), 1.64-1.32 (m, 11H), 1.24-1.12 (m, 7H), 1.05 (s, 3H), 0.96 (d, 6H), 0.93 (d, 3H), 0.76 
(s, 3H). 13C NMR (126 MHz, CDCl3) δ 140.8, 121.7, 77.3, 77.0, 76.8, 71.8, 67.4, 56.9, 56.8, 50.1, 48.0, 
47 
  
44.0, 42.4, 42.3, 40.1, 37.3, 36.5, 31.9, 31.8, 31.7, 28.1, 24.7, 24.2, 23.4, 22.3, 21.1, 19.4, 18.5, 12.2. IR 
(ATR FTIR): 3332, 2936, 1460, 1433, 1382, 1305, 1055, 952 cm-1. HRMS: [M+NH4]+, calc. 420.3842, 
obs. 420.3839; [M-OH]+, calc. 385.3470, obs. 385.3434.  
 
Biological Assay Protocols:109 
Cell Culture and Reagents: The murine cell line, M2-10B4, was purchased from American Type Culture 
Collection (ATCC). M2-10B4 cells were cultured in RPMI Medium 1640 (Gibco) supplemented with 10% 
FBS and 1% penicillin/streptomycin. Cells were maintained using the media described above (denoted 
“growth” media). Media denoted as “low FBS” contained 0.5% FBS and the same percentage of other 
supplements as specified for growth media. Cells were grown in Corning Cell Culture, canted neck T75 or 
T150 flasks (Fisher Scientific) in an Autoflow IR water-jacket CO2 incubator. Experiments were performed 
in BD Falcon sterile 24-well tissue culture treated plates. Dimethyl sulfoxide (DMSO) was used as solvent 
to prepare all drug solutions and the final DMSO concentration did not exceed 0.3%. 20(S)-
hydroxycholesterol was purchased from Sigma-Aldrich. Cyclopamine was purchased from LC Labs.  
 
General Procedure for analysis of Hh target gene regulation:  
A) Agonist assay: M2-10B4 cells were grown to confluence in T75 flasks. Once cells reached 
confluence, they were plated into 24-well plates at concentration of 50,000 cells/500 µL per well in growth 
media. After 24 h, growth media was removed and replaced with low FBS media (500 µL/well). Cells were 
treated with corresponding compound- DMSO, OHC, or OHC and cyclopamine. Cells were incubated 
(37°C, 5% CO2) for noted time period, at which time mRNA was isolated and evaluated as described 
previously. 
B) Antagonist assay: M2-10B4 cells were cultured and grown under same conditions as agonist assay. 
After 24 h in the plates, growth media was removed and replaced by low-FBS assay media. Specific 
upregulation method was administered for a final concentration of: (S)-OHC, 5 µM; SAG, 400 nM; rSHh, 
0.5 ng/µL. For ASZ001 cells, cells were plated at concentration of 10,000 cells/well in a 96 well plate and 
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100uL media. After 24 h, media was removed and replaced with low-FBS media and drugged 24 h later. 
After 48 h, mRNA was isolated and evaluated.  
 
General Procedure for RT-PCR analysis: Following treatment and incubation, total RNA was extracted 
using Ambion® by Life Technologies Taqman® Fast Cells-to-CTTM kit following manufacturer’s 
instructions. Synthesis of cDNA was performed using a BioRad MyCycler. Quantitative PCR was 
performed on an ABI 7500 system using the following Taqman Gene Expression Primer/Probe solutions 
(ABI): mouse ActB (Mm00607939_s1), mouse GLI1 (Mm00494645_m1), mouse PTCH1 
(Mm00436926_m1), mouse ABCA1 (Mm00442646_m1), mouse Alp1 (Mm00475834_m1), mouse sp7 
(Mm04209856_m1). Relative gene expression levels were computed via the ∆∆Ct method. Values 
represent mRNA expression relative to DMSO control (vehicle; set to 1.00). Data was analyzed using 
GraphPad Prism 5 and IC50 and EC50 values represent mean ± SEM for at least two separate experiments 
performed in triplicate.  
 
Computational Methods117 
Homology modeling of hCRD 
The amino acid sequence of full length human Smo was extracted from the UniProt database (Accession 
number: Q99835). The amino acid sequence corresponding to the hCRD (63-179) was truncated from the 
full length human Smo receptor sequence. A homology model of hCRD was generated using the crystal 
structure of the zCRD (PDB ID: 4C79, resolution 2.3 Å) as the template. Sequence alignment between the 
hCRD and zCRD was performed in ClustalX2 using PAM350 matrix with penalties of 10 and 0.05 for gap 
opening and gap elongation, respectively. The hCRD homology model was prepared by submitting the 
sequence alignment to MODELLER v9.16, which generates the three-dimensional structures of proteins 
by converting the sequence alignment into a large number of spatial restraints. These spatial restraints are 
further optimized by the molecular Probability Density Function (molPDF), which uses conjugate gradients 
and molecular dynamics with a simulated annealing procedure. Through this process, one hundred distinct 
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models of the hCRD were generated. The molPDF, DOPE, and GA341 scoring functions were used to 
identify the ten most probable hCRD models. The top model was selected by utilizing the PROCHECK 
server to assess the stereochemical quality of the minimized protein structure. The model chosen for our 
subsequent docking and molecular dynamics studies demonstrated high quality stereochemical parameters 
with an excellent distribution of Ψ and φ angels as determined by the Ramachandran plot. 
 
Molecular Docking  
The hCRD model was prepared for docking with the protein preparation wizard module from Schrödinger 
(Suite 2015). All ligand structures were built using the Maestro module of the Schrödinger Suite package 
and energy minimized using Macromodel with the OPLS_2005 force field. AutoDock v4.2 and its graphical 
user interface AutoDockTools v1.5.6 were used for the docking study and visualization of docked results. 
The R161 residue of the hCRD was kept flexible during the molecular docking. The three-dimensional 
affinity and electrostatic grid boxes were generated with AutoGrid v 4.2 to provide a gridcenter that covers 
the entire active site (− 14.126X, 14.481Y, and − 3.31Z) [26]. The number of grid points in the X, Y, Z axis 
was 40 × 40 × 40 with each point separated by 0.375 Å. Lamarckian genetic algorithm (LGA) was used as 
a search algorithm and a maximum number of 2.5 ∗ 106 energy evaluations was set. Ten docking runs were 
performed and the best scoring conformations were saved for analysis. The remaining parameters were left 
at their default settings. The reliability of the docking results was evaluated by comparing the root-mean-
square deviations (RMSDs) of the conformations and grouping similar orientations into “clusters”. From 
our ten docking runs of OHC 20, nine conformations were oriented in the binding site in the manner 
described below. Similar results were obtained from the docking runs with OHCs. As the primary 
orientation closely matched the docking studies described previously we utilized this orientation for our 
molecular dynamics studies. 
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Molecular Dynamics 
The starting structures for molecular dynamics (MD) were obtained from the docking of OHCs in complex 
with hCRD. The atomic partial charges of all the OHC analogues were derived by semiempirical AM1 
geometry optimization using the general AMBER force field (GAFF). To neutralize the charge of the 
system, sodium counter ions were placed to grids with the largest negative coulombic potentials around the 
protein, and the whole system was immersed in the rectangular box of TIP3P water molecules. The water 
box extended 8 Å away from any solute atoms. In molecular minimization and molecular dynamics 
simulations, particle mesh Ewald (PME) was employed to treat the long-range electrostatic interactions. 
Before MD simulations, the complexes were gradually relaxed using 10,000 cycles of minimization 
procedure (500 cycles of steepest descent and 9500 cycles of conjugate gradient minimization). After 
minimization, MD simulations in the NPT ensemble with a target temperature of 298 K and a target pressure 
of 1 atm were performed. The SHAKE procedure was employed to constrain all hydrogen atoms and the 
time step was set to 2.0 Fs. Before the actual MD simulations, the system was gradually heated in the NVT 
ensemble from 10 K to 298 K over 50 ps. Initial velocities were assigned from a Maxwellian distribution 
at the starting temperature. MD samplings at 5 ns were performed for all complexes. 
 
MM/GBSA Calculations117 
In MM/GBSA calculations, the affinity of a ligand binding to a protein can be estimated by two protocols: 
(1) evaluate all terms using separate trajectories of complex, protein, and ligand (separate trajectory 
protocol) or (2) evaluate the snapshots from a trajectory of the complex (single trajectory protocol). The 
single trajectory protocol was used in our studies because it is a more rapid procedure and the calculation 
is based upon straightforward energy equations. For specific equations please see Reference 117. 
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Introduction  
As discussed in previous chapters, the Hedgehog (Hh) signaling pathway may be modulated by a 
number of small molecule scaffolds from sterols to larger multi-cyclic compounds like itraconazole (4). 
Development of small molecule modulators of Hh signaling has primarily focused on the design of 
inhibitors as anti-cancer chemotherapeutics. With the importance of cholesterol and oxysterols to Hh 
signaling, it is not surprising that another sterol scaffold, vitamin D (Figure 16) regulates Hh signaling.  
I. Vitamin D Metabolism 
The vitamin D metabolism pathway (Figure 16) is a highly regulated and complex process leading to 
activation of the vitamin D receptor (VDR) by its natural ligand, calcitriol (48). Production of calcitriol 
starts with the cholesterol precursor, 7-dehydrocholesterol (pro-vitamin D3, pro-VD3, 45). In the skin, 
ultraviolet (UV) light, specifically UV-B, promotes the opening and isomerization of the B-ring of 45 in a 
two-step process to form vitamin D3 (cholecalciferol, VD3, 46) in a temperature sensitive and non-catalytic 
 
Figure 16. Vitamin D pathway and metabolism. VD3 is produced in the skin from 7-DHC under UV-
B light from the sun and further hydroxylated at the C-25 position by Cyp2R1 (or Cyp27A1) in the liver 
to 25-OH VD3. Cyp27B1 further metabolizes 25-OH VD3 in the kidney to the biologically active 
metabolite calcitriol, which regulates a variety of genes through the vitamin D receptor (VDR), 
including Cyp24A1 which ultimate degrades calcitriol to calcitroic acid for removal. Blue=enzymatic 
activity, Red=Cyp hydroxylation. 
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process.121 Vitamin D3 can also be obtained through diet and supplementation, which is important with 
inconsistent production throughout the year due to varying UV-B intensity from the sun and protection 
from clothing and melanin in the skin.122 A hydroxyl group is then added to the C-25 position by Cyp27A1 
or Cyp2R1, where Cyp27A1 is the only mitochondrial 25-hydroxylase found throughout the body and 
Cyp2R1 is only found in the liver and testes.123-124 It does appear that Cyp2R1 is the major 25-hydroxylase 
utilized but multiple knockout studies have suggested that other enzymes possessing 25-hydroxylase 
activity may be utilized with no complete reduction observed in circulating levels of 25-hydroxyvitamin 
D3 (25-OH VD3, calcifediol, 47).124 Calcitriol is further metabolized by Cyp24A1 and undergoes oxidative 
truncation to calcitroic acid (48). Importantly, Cyp24A1 is the only 24-hydroxylase shown to participate in 
vitamin D metabolism and is a key target gene of the vitamin D receptor (VDR), denoting a primary 
function of regulating cellular levels of calcitriol.122  
  
II. Vitamin D and Hh signaling   
With no reports of biological activities for the other metabolites, calcitriol (48) was long considered the 
biologically active metabolite, mediating its activity through VDR. In 2006, 7-DHC (45) was initially 
proposed to be an endogenous regulator of Hh signaling.125 These studies were initially designed to identify 
and study the mechanism by which Ptch represses Smo activation through Ptch1 small interfering RNA 
and transfection. The researchers compared the ability of media from the Ptch1-transfected cells and media 
of control-transfected cells to inhibit Hh signaling in reporter cells. The observed strong inhibitory effects 
on Gli activation for the Ptch1-transfected medium. When the media was analyzed, elevated levels of 3b-
hydroxysteroids were observed in the Ptch1-transfected media. Furthermore, Ptch1 siRNA decreased levels 
of 3b-hydroxysteroids and increased Gli reporter activity. These observations suggested that a 3b-
hydroxysteroid may be an endogenous inhibitor of Hh signaling. In follow-up studies, VD3 (46) was 
identified as the hydroxysteroid scaffold responsible for inhibition of Hh signaling. This was based on 
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endogenous addition of VD3 being more efficient in inhibiting Gli reporter activity than the Ptch1-
transfected medium.125-126  
Since these studies, VD3 has been shown to inhibit Hh signaling in multiple in vitro and in vivo models. 
At moderate concentrations (5 and 10 µM), VD3 inhibited proliferation and reduced Gli1 expression in 
murine models of BCC (ASZ001, Ptch-deficient)118 and MB, which both exhibit upregulated Hh 
signaling.127 Accumulation of VD3, through inhibition of Cyp2R1 or exogenous addition, has been shown 
to antagonize Hh signaling by proposed direct interaction with the extracellular region of Smo.128  
Based on these findings and observations that VD3 was capable of activating VDR activity, presumably 
through in vitro metabolism, multiple series of VD3 analogues were designed and synthesized by previous 
Hadden lab members to probe and selectively target Hh signaling (Figure 17, Table 8).125,127,129-133  These 
studies were aimed at probing the structural requirements of the A- and seco-B rings, and alkyl-side chain, 
and provided the representative analogues 51 - 57. 
The initial studies performed by former lab members demonstrated that the northern region of VD3 
(CD-rings and alkyl side chain) was required to inhibit Hh signaling, as Grundmann’s alcohol (50) 
maintained anti-Hh activity comparable to VD3. Grundmann’s alcohol also showed reduced activation of 
VDR, measured by Cyp24A1 mRNA expression.129 To quickly study the effects that A-ring modifications 
 
Figure 17. Representative A- and seco-B ring analogues previously developed.125,127,129-133 
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had on activity, a variety of A-ring mimics were coupled to 50 through an ester seco-B ring (synthesized 
by a former postdoctoral researcher, Dr Albert M. DeBerardinis).131 These studies indicated that the 
incorporation of an aromatic A-ring, specifically a phenol (51) greatly increased anti-Hh potency from ~4 
mM to ~700 nM in C3H MEFs. Unfortunately, 51 showed little consistency across cell lines with ~7-fold 
loss in potency between C3H and ASZ cells. Taken together with potential metabolic instability due to the 
ester seco-B, analogue 52 was synthesized with an amide seco-B to potentially increase stability. Analogue 
52 showed similar potency in C3H cells but also showed improved consistency and potency in ASZ cells 
with ~2-fold loss in potency.133  
The stereochemistry of the CD-rings and alkyl side chain is preset for analogue development by the 
synthetic approach taken, as will be discussed later in this chapter; however, Dr DeBerardinis was able to 
invert the orientation of hydroxyl position of 50 to give ester 53.133 Comparison of 51 and 53 suggested that 
the stereochemistry of the seco-B region may not be important as the Gli1 IC50 values in ASZs were 
comparable. It was also determined by a former graduate student, Dr Upasana Banerjee, that the “natural” 
alkyl side chain is the most favorable, as 54 was the most potent analogue in the alkyl side chain studies 
and only showed activity comparable to 51.132 To further investigate the seco-B region, a variety of 
functionalities were incorporated with the phenolic A-ring.133 Out of these compounds, the most potent 
Table 8. Inhibition of Hh signaling by lead VD3 analogues. 125,127,129-133   
 
C3H MEFs ASZ (BCC model) 
Hh Activitya Cyp24A1b IC50  (Gli1, µM)c 
IC50  
(Gli1, µM)c Cyp24A1
b 
VD3 (46) 36 ± 0.3 8,300 ± 38 4.1 ± 0.3 1.1 ± 0.01 2,200 ± 200d 
50 46 ± 4 3.6 ± 0.5 3.1 ± 0.2 > 10 2.4 ± 0.9 
51 1.9 ± 0.5 22 ± 5 0.74 ± 0.1 5.2 ± 0.2 1.9 ± 0.1 
52 2.5 ± 0.1 7.0 ± 0.9 0.98 ± 0.04 1.8 ± 0.3 1.8 ± 0.2 
53 31 ± 3 3.0 ± 0.5 3.9 ± 0.8 6.3 ± 1 1.6 ± 0.2 
54 2.9 ± 0.3 2.8 ± 0.03 1.1 ± 0.6 1.6 ± 0.2 ~10e 
55 12 ± 0.01 17 ± 4 1.0 ± 0.1 1.7 ± 0.1 1.8 ± 0.1 
56 0.7 ± 0.2 45 ± 20 0.40 ± 0.02 0.67 ± 0.02 2.7 ± 0.7 
57 1.3 ± 0.6 21 ± 3 0.32 ± 0.06 0.57 ± 0.2 3.0 ± 0.8 
aValues represent % Gli1 mRNA expression compared to OHC control (set to 100) at 5 µM. bValues 
represent relative Cyp24A1 mRNA expression compared to DMSO control (set to 1.0) at 5 µM. cValues 
represent average of at least two separate experiments performed in triplicate. dCompound tested at 2.5 µM, 
eEstimate based on figure (ref 132).  
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analogues were the single atom nitrogen seco-B (amine) analogues 55-57. One important observation from 
this series was the consistency across cell lines and increased potency compared to the esters and two atom 
seco-B analogues.  Additionally, the amines followed the same trend as the ester analogues where the 
stereochemistry of the seco-B region was not important for the amine analogues as 56 and 57 showed 
comparable activities across cell lines.  
Based on these results and observations, additional analogue series were designed to continue SAR 
studies. With the specific mechanism of action for inhibition of Hh signaling by vitamin D unclear, these 
series were also aimed at probing the mechanism of action. These analogue series were broken down into 
three categories: (1) C-11 modified, (2) amine seco-B, and (3) C-25 functionalized analogues.  
 
III. Design and Synthesis of Vitamin D Analogues   
A. C-11 Modified Analogues134  
With the primary mechanism of action for inhibition of Hh signaling by vitamin D analogues unclear, 
a focus was made on developing probes that could be modified by a biotin or fluorescent tag to identify the 
protein targets. Based on previous studies indicating that the CD-rings and alkyl side chain were required 
to maintain anti-Hh activity, a new series of analogues were designed with additions to the C-ring.  These 
analogues were designed to (1) probe the binding pocket for additional interactions and spatial requirements 
and (2) determine if this position is suitable for label attachment.  
The C-11 position was chosen for this series primarily because synthetic routes to append functional 
groups at this position are well-characterized and straightforward.  Utilizing standard procedures, 
Grundmann’s ketone (58) can be obtained in high yield from VD3 in two steps via global ozonolysis with 
a reductive workup and oxidation of 50 (Scheme 3). α,β-unsaturation of the ketone was achieved through 
Saegusa-Ito oxidation of the silyl enol ether intermediate to give enone 59. A slight modification to the 
published route to access 59,135 addition of p-benzoquinone as a co-oxidant to regenerate Pd (II), resulted 
in an increased yield. The desired alkyl functionalities were added to the C-11 position via 1,4-
organocuprate addition. In situ formation of the organocuprate from the corresponding Grignard reagent 
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provided a one-pot reaction to obtain the desired ketones (60a–e) in a stereoselective fashion. Standard 
sodium borohydride reduction followed by esterification and deprotection provided the desired esters 
(61a,c–e). The C-11 stereochemistry was determined by analysis of the 1H NMR spectra in which the C-18 
proton peak demonstrates a characteristic shift, similar to that previously reported.135-136 Due to A1,3-strain 
in the C-ring, an 
interaction between the 
C-11 substituent and 
the C-18 methyl group 
would result in a 
downfield shift of the 
C-18 singlet, similar to 
what is observed 
when 52 is reduced to 
Grundmann’s alcohol. 
Following the 1,4-
addition to 59, the C-18 
methyl peak was 
observed at 0.6–0.8 ppm for 60b–60e, indicating the α-orientation. For 60a, an interaction with the C-18 
methyl peak (1.1 ppm) was observed, indicating the β-orientation.  
It is well-established that the reduction of 58 to Grundmann’s alcohol with sodium borohydride is a 
highly stereoselective process that results in the β-alcohol due to the concavity and sterics of the CD-ring 
system favoring backside hydride addition.137 We believe that the cuprate addition works in a similar 
fashion and the steric bulk of the 60b–e C-11 substituents results in α-addition to minimize the A1,3-strain. 
The smaller ethyl substituent, in comparison to the larger ring systems, decreased the favorability for the 
α-orientation by reducing the potential A1,3-strain between the C-11 substituent and the C-18 methyl 
groups, resulting in β-substitution. 
 
Scheme 3. Reagents and conditions: (a) i. O3, pyridine, DCM:MeOH; ii. 
NaBH4; 90% (b) PDC, DCM; 94% (c) i. LDA, THF; ii. TMSCl; (d) 
Pd(OAc)3, p-benzoquinone, MeCN; 78% over two-steps; (e) R-MgBr, CuI, 
THF; 62–90% (f) NaBH4, MeOH; (g) 3-OMOM-benzoic acid, DCC, DMAP, 
DCM; (h) (±)-CSA, MeOH; 17–32% over three-steps. 
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In addition to incorporating hydrophobic functionalities, we also sought to append a hydroxyl moiety 
at C-11 to not only probe its effects on Hh inhibition, but also to provide a chemical handle for attaching a 
terminal alkyne. Analogues incorporating a terminal alkyne hold potential as probes to identify cellular 
proteins that bind the VD3 scaffold and mediate its anti-Hh effects. Hydroboration of the terminal olefin 
in 60b with 9-borabicyclo(3.3.1)nonane (9-BBN) and reduction of the resulting aldehyde provided 
diol 62 (Scheme 4).136 Selective protection of the primary alcohol at C-11, followed by esterification at the 
secondary alcohol and global deprotection provided analogue 63.  
To incorporate the terminal alkyne, selective oxidation of the secondary alcohol in 62 with 2-
iodoxybenzoic acid (IBX)138 afforded ketone 64, allowing for esterification of the C-11 side chain hydroxyl 
 
Scheme 4. Synthesis of C-11 modified analogues: (a) i. 9-BBN, THF; ii. NaOH, H2O, H2O2, MeOH; 
90% (b) TBSCl, imidazole, DCM; 88% (c) 3-OMOM-benzoic acid, DCC, DMAP, DCM; 55% 
(d) CSA, MeOH 65%. 
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Scheme 5. Synthesis of C-11 modified analogues: (a) IBX, tetrabutylammonium bromide, 
DCM:H2O; 75% (b) 4-aminophenol, NaBH(OAc)3, AcOH, DCE; 12% (c) 4-pentynoic acid, 
DCC, DMAP, DCM; 91% (d) NaBH4, MeOH; 67% (e) 3-OMOM-benzoic acid, DCC, 
DMAP, DCM; 60% (f) CSA, MeOH; 15%. 
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(66, Scheme 5). Reduction of the ketone carbonyl followed by esterification and deprotection of the 
phenolic 3-hydroxy A-ring yielded ester 67 in low yield. The low yield can be partially attributed to the 
deprotection step, which also partially cleaves the side chain ester. As noted above, our most potent VD3 
analogue, 56, incorporates a single atom amine seco-B between the CD-ring/side chain and the aromatic 
A-ring. Ketone 58 provided an opportunity to synthesize an amine linked analogue of 59 to see if the same 
SAR trend would be observed. Using a previously described and utilized reductive amination method with 
sodium triacetoxyborohydride,139 analogue 65 was obtained from 64 as a single isomer.  
 
B. Amine Seco-B Analogues  
One of the most notable observations from previously developed analogues was a switch in the 
preferred A-ring hydroxyl position. When the seco-B region was shortened from two atoms (ester 51) to a 
single atom (amines 55 - 56), the para-position (56) was favored over the meta (55). This resulted in a ~2.5-
fold difference in potency with IC50 values of 0.40 – 0.67 µM and 1.0-1.7 µM for 56 and 55 respectively. 
In the ester series, there was a 4-fold difference in potency in C3H cells favoring the 3-hydroxyl position 
with IC50 values of 0.74 
and 2.8 µM for the 3- 
hydroxyl (51) and 4-
hydroxyl esters 
respectively.131 A second 
notable observation was 
that there was little 
difference between the 
standard a-orientation 
(56) and b-orientation of 
the seco-B region (57). 
 
Scheme 6. Synthesis of amine seco-B analogues: (a) NaBH(OAc)3, AcOH, 
R-amine, DCE; 20 – 65% (b) PPh3Cl(MeOMe), NatBuO, THF; 89% (c) 2N 
HCl, MeOH; 75%. 
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Taken with similar results for ester analogues 51 and 53, it suggests that preference for a specific C-8 
stereoisomer may not exist. With these differences observed, we designed a new series of analogues: (1) 
further evaluate if any other previous observations from the initial ester series131 were altered with the 
shortening of the seco-B region, and (2) determine how lengthening of the nitrogen seco-B region back to 
two atoms by the addition of a methylene (CH2) group would affect the inhibitory activity. 
Synthesis of the nitrogen seco-B analogues is centered around the one pot reductive amination of the 
desired amine with Grundmann’s ketone (58) or the methylene extended aldehyde (73). Reductive 
amination of 58 with sodium triacetoxy borohydride and the desired anilines yielded amines 68 – 72 
(Scheme 6). To extend the seco-B region, 73 was obtained as a single isomer in high yield following 
hydrolysis of the enol ether obtained through a Wittig reaction with sodium tert-butoxide and 
methyoxymethyl triphenylphosonium chloride, as previously described.133 The same reductive amination 
procedure was applied to give 74 – 75. 
 
C. C-25 Functionalized Vitamin D Analogues  
After VD3 was shown to inhibit Hh signaling in 2006,124 follow-up studies indicated that differences 
existed between the vitamin D metabolites.126 It appears that as you move down the metabolic pathway 
from VD3 to calcitriol, the metabolites are more active against Hh signaling following the addition of 
hydroxyl groups to the alkyl side chain (C-25, 47) and the 1a-position of the A-ring (48), Figure 16. With 
calcitriol being the biologically active metabolite and a decrease in potency previously observed with 
dihydroxylated analogues,131 we designed a new series of analogues based on 25-OH VD3 (47) in which a 
C-25 hydroxyl group was incorporated.  In anticipation of inducing higher VDR activation, additional 
analogues with a C-25 methyl ether were designed.  
Using Grundmann’s ketone (58) as a starting material, introduction of the C-25 hydroxyl moiety 
was performed using ruthenium (III) chloride and sodium periodate to generate ruthenium tetroxide in-situ 
(Scheme 7).140 Due to steric hindrance and interactions throughout the molecule, such as those between the 
C-18 methyl and C-20 group, selective hydroxylation at the C-25 position was observed to give 76 in 
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moderate yield (67%). Amines 
77 – 78 were then obtained in 
one-step via the sodium 
triacetoxy borohydride 
reductive amination method 
previously utilized.  Ether-
ification at the C-25 position 
was performed using methyl 
iodide and sodium hydride to 
give 79 in low yield due to a-
methylation at C-9. It is believed that a - methylation occurs following the desired etherification due to the 
presence of 79 and the “di-methylated” byproduct 80, which showed both C-25 etherification and a-
methylation. Only C-9 a-methylation was not observed. Reductive amination of 79 provided 81 in moderate 
yield.  
To synthesize C-25 hydroxylated versions of 74 – 75, a similar approach was taken where Wittig 
addition followed by enol ether hydrolysis yielded aldehyde 82 as a single isomer, Scheme 8. Reductive 
 
Scheme 7. Synthesis of C-25 functionalized amine analogues: (a) 
RuCl3, NaIO4, pyridine, MeCN:H2O; 67% (b) NaBH(OAc)3, AcOH, 
R-amine, DCE; 15 – 35 % (c) MeI, NaH, DMF; 25 %. 
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Scheme 8. Synthesis of C-25 functionalized extended amines. (a) PPh3Cl(MeOMe), 
NatBuO, THF; 89 % (b) 2N HCl, MeOH; 60 - 75% (c) NaBH(OAc)3, AcOH, R-amine, 
DCE; 32 – 59 % (d) MeI, NaH, DMF; 62%. 
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amination of 82 provided amines 83 – 84. Since a-methylation was observed in the C-25 etherification of 
58, etherification of the C-25 hydroxyl group was performed on the enol ether intermediate, 85, in moderate 
yield. Following hydrolysis of 85 to the corresponding aldehyde (86), reductive amination yielded amine 
87.  
Ketone 76 provided the starting material for the synthesis of esters 89 - 90. Protection of the C-25 
hydroxyl group with triethyl silane (TES) followed by sodium borohydride reduction gave alcohol 88 
(Scheme 9). Triethyl silane provided a useful protecting group due to the ability to remove both the C-25 
TES-group and the MOM-protecting group in a single reaction with camphor sulfonic acid (CSA). 
Following esterification with 3-OMOM-benzoic acid, both the C-25 TES- and phenolic MOM-groups were 
removed in moderate yield to give ester 89. Similarly, ester 90 was obtained in three steps from ketone 79.   
 
IV. Biological Evaluation of Vitamin D Analogues  
Each of the synthesized analogues were evaluated in the C3H10T1/2 (C3H) mouse 
embryonic fibroblast (MEF) cell line to determine their ability to inhibit Hh signaling. Their ability to 
modulate Hh activity was measured through qPCR quantification of the Hh target gene, Gli1. In this cell 
 
Scheme 9. Synthesis of C-25 functionalized ester analogues. (a)TES-Cl, imidazole, 
DMF; 94% (b) NaBH4, MeOH:DCM; 88 - 92% (c) 3-OMOM-benzoic acid, DCC, 
DMAP, DCM; 52 - 70% (d) CAS, MeOH; 60 - 75% (e) MeI, NaH, DMF; 35%.  
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line, activation of Hh signaling via the addition of known Hh agonists (OHCs 20 and 22 at 5 µM each) 
results in reproducible Gli1 mRNA up-regulation that is attenuated by inhibitor co-administration. For 
these studies, Gli1 mRNA expression was normalized to oxysterol controls (set to 100) and all compounds 
were initially evaluated at 5 µM (Tables 9 - 11). To measure the selectivity of each compound for Hh 
signaling over canonical VDR signaling, the VDR target gene Cyp24A1 was also quantified. The ability of 
more potent analogues to inhibit Hh signaling was further evaluated in ASZ001 cells, a murine Hh-
dependent BCC cell line. Similar to evaluation of OHCs in Chapter 2, the mRNA was extracted using the 
commercially available Cells-to-Ct (ThermoScientific) and quantified by qPCR.  
 
A. Evaluation of C-11 Modified Analogues (60 – 67) 
 Interestingly, the only hydrophobic C-11 substitution that retained the anti-Hh activity of 51 was 61a, 
in which the smaller ethyl substituent is in the α-orientation (Table 9). By contrast all of the analogues with 
Table 9. Inhibition of Hh signaling by C-11 modified VD3-analogues.134 
 
C3H MEFsa ASZ Cellsa 
Hh Activityb Cyp24A1c IC50 (Gli1, µM) IC50 (Gli1, µM)b Cyp24A1c 
OHCs 100 --- --- --- --- 
DMSO --- 1.0 --- --- 1.0 
GDC-
0449 0.88 ± 0.01 1.0 ± 0.02 0.082 ± 0.007 0.040 ± 0.01 0.9 ± 0.2 
VD3 (46) 36 ± 0.3 8,300 ± 40 4.1 ± 0.3 1.1 ± 0.01 2,200 ± 200d 
51d 1.9 ± 0.5 22 ± 5 0.74 ± 0.1 5.2 ± 0.2 1.9 ± 0.1 
56d 0.7 ± 0.2 45 ± 20 0.40 ± 0.02 0.67 ± 0.2 2.7 ± 0.7 
60b 28 ± 5.0 19 ± 3 --- --- --- 
61a 2.0 ± 0.9 3.6 ± 3 0.92 ± 0.1 5.2 ± 0.5 1.3 ± 0.3 
61c 92 ± 3 2.8 ± 1 --- --- --- 
61d 71 ± 10 2.3 ± 0.6 --- --- --- 
61e 85 ± 10 3.6 ± 1 --- --- --- 
62 39 ± 4 17 ± 1 4.7 ± 0.3 --- --- 
63 8.7 ± 2 9.0 ± 4 2.0 ± 0.2 4.1 ± 2.4 1.1 ± 0.1 
65 1.1 ± 0.6 7.2 ± 2 2.7 ± 0.2 1.0 ± 0.01 2.0 ± 0.4 
67 16 ± 2 4.8 ± 2 6.3 ± 3 7.5 ± 2 0.96 ± 0.2 
aValues represent Mean ± SEM for at least two separate experiments performed in triplicate. bValues represent % 
Gli1 mRNA expression relative to oxysterol control (set to 100). Analogues evaluated at 5 µM. cValues represent 
Cyp24A1 mRNA expression compared to DMSO control (set to 1.0). Analogues evaluated at 5 µM. dValues for 
previously published analogues are from Reference 133. 
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a hydrophilic b-substituent (62-63, 65, 67) maintained activity, suggesting that larger and more 
rigid functional groups, such as the cyclohexyl and benzyl groups of 61c and 61e respectively, prevent full 
access of the compound to the binding pocket when they are in the b-conformation. When the lead 
analogues 51 and 56 were compared to their C-11 functionalized counterparts (61a, 63 and 65) the 
functionalization increases selectivity for Hh signaling over canonical VDR. Compounds that inhibited Hh 
signaling at a level equal to or greater than VD3 at 5 µM were evaluated for their ability to inhibit Hh 
signaling in this cell line in a concentration-dependent fashion (61a, 62–63, 65, and 66). 
Each of these analogues demonstrated moderate concentration-dependent inhibition of Hh signaling 
with IC50 values between 0.92 and 6.3 µM. Notably, incorporation of the primary alcohol at the C-11 
position (63, 65) resulted in an approximately 6.5-fold loss in Hh inhibitory activity. In addition, there was 
only a moderate loss in activity for the terminal alkyne (67), suggesting its potential as a chemical probe for 
studying VD3-mediated inhibition of Hh signaling. Next, we evaluated the ability of several of these 
analogues to inhibit Hh signaling in ASZ001 cells, a murine Hh-dependent BCC cell line. Similar to 
previous studies with VD3 analogues,131 a modest loss in potency was observed for the ester analogues 
(61a, 63, 67) in the ASZ001 cells (Table 9). With minimal up-regulation of Cyp24A1 observed across 
either cell line compared to 46, these results support the hypothesis that VD3 analogues act independent of 
VDR to inhibit Hh signaling. The decrease in Cyp24A1 expression compared to 51 and 56, suggests that 
even small additions to the C-ring is enough to disrupt binding within the narrow ligand binding domain of 
VDR and reduce activation of canonical VDR signaling. 
 
B. Evaluation of Amine seco-B Analogues (68 – 75) 
Similar to previous observations with a series of ester analogues,131 removal or masking of the aromatic 
hydroxyl group (68 – 71) resulted in complete loss of anti-Hh activity (Table 10). More intriguing results 
were observed when the seco-B region was extended back to two atoms. Compared to 56, amine 72 showed 
a moderate loss in anti-Hh activity and a slight gain in selectivity over VDR activation in C3H cells. In 
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ASZ cells, 72 had improved activity and selectivity, and became the most potent and selective analogue. 
When the arrangement of the seco-B atoms was switched, 74 – 75, the location of the hydroxyl group 
became more of a contributing factor as 75 (4-OH) showed greater potency compared to 74 (3-OH), a trend 
similar to the ester series as well.131 A second noticeable result was the comparable activities for 56 and 75 
in both cell lines. Comparing the activities of 56, 72, and 75 suggests that the aromatic A-ring may play a 
role in aligning the NH- group of the seco-B region and the northern region for binding interactions. 
 
C. Evaluation of C-25 Functionalized Vitamin D Analogues (77 – 90) 
Differing results were obtained by the incorporation of the C-25 hydroxyl group or methyl ether (Table 
11). Compared to the non-hydroxylated versions 55 – 56, the single atom seco-B analogues 77 – 78 showed 
a slight increase in anti-Hh activity in ASZ cells along with significant upregulation of Cyp24A1 mRNA to 
levels comparable to vitamin D metabolites. Masking the C-25 hydroxyl as a methyl ether (81) was able to 
Table 10. In vitro evaluation of amine seco-B analogues. 
 
C3H MEFsa ASZ Cellsa 
Hh Activityb Cyp24A1c IC50 (Gli1, µM) IC50 (Gli1, µM) Cyp24A1c 
OHCs 100 --- --- --- --- 
DMSO --- 1.0 --- --- 1.0 
GDC-0449 0.88 ± 0.01 1.0 ± 0.02 0.082 ± 0.007 0.040 ± 0.01 0.9 ± 0.2 
VD3 (46) 36 ± 0.3 8,300 ± 40 4.1 ± 0.3 1.1 ± 0.01 2,200 ± 200 e 
51d 1.9 ± 0.5 22 ± 4 0.74 ± 0.1 5.2 ± 0.2 1.9 ± 0.1 
55d 12 ± 0.01 17 ± 4 1.0 ± 0.1 1.7 ± 0.1 1.8 ± 0.1 
56d 0.7 ± 0.2 45 ± 20 0.40 ± 0.02 0.67 ± 0.2 2.7 ± 0.7 
68 98 ± 10 1.2 ± 0.1 >10 -- -- 
69 110 ± 10 1.9 ± 0.5 >10 -- -- 
70 73 ± 7 2.4 ± 0.9 >10 -- -- 
71 110 ± 1 6.1 ± 3 >10 -- -- 
72 4.6 ± 0.1  24 ± 0.8 3.1 ± 0.1 0.34 ± 0.02  1.1 ± 0.7 e  
74 13 ± 8 13 ± 5 3.8 ± 0.7 1.2 ± 0.07 7.8 ± 2 e 
75 1.9 ± 1 8.9 ± 2 0.59 ± 0.2 0.56 ± 0.08 5.8 ± 4 e 
aValues represent Mean ± SEM for at least two separate experiments performed in triplicate. bValues represent % 
Gli1 mRNA expression relative to oxysterol control (set to 100). Analogues evaluated at 5 µM. cValues represent 
Cyp24A1 mRNA expression compared to DMSO control (set to 1.0). Analogues evaluated at 5 µM. dValues for 
previously published analogues are from Reference 133. eAnalogue evaluated at 2.5 µM. 
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significantly reduce the Cyp24A1 upregulation compared to 77, from >30,000 to 100 (C3H) and 11,000 
(ASZ). Importantly, 81 was able to maintain a slight increase in potency compared to 55 in ASZ cells. 
Surprisingly, the addition of the C-25 hydroxyl group to the extended seco-B analogue 74 (83) had little 
effect on anti-Hh potency and Cyp24A1 levels in either cell line. Again, little difference was seen following 
hydroxylation of 75 (84), expect for a slight increase in Cyp24A1 expression in ASZ cells (140 compared 
to 6-fold). Even though no major differences were observed following C-25 hydroxylation, masking of the 
C-25 hydroxyl of 83 (87) yielded interesting results. With little to no upregulation of Cyp24A1 observed 
and no effect on the potency following hydroxylation, it was expected to see no change following 
etherification of the C-25 group. Intriguingly, 87 showed an increase in anti-Hh potency from an IC50 of 
~1.3 to 0.66 µM, as well an increase in Cyp24A1 levels from ~8 to 2,400-fold compared to 74 and 83 in 
ASZ cells.  
 
 
Table 31. In vitro evaluation of C-25 functionalized vitamin D analogues. 
 
C3H MEFsa ASZ 
Hh Activityb Cyp24A1c IC50  (Gli1, µM)d 
IC50  
(Gli1, µM)d Cyp24A1
c,e 
OHCs 100 --- --- --- --- 
DMSO --- 1.0 --- --- 1.0 
GDC-
0449 0.88 ± 0.01 1.0 ± 0.02 0.082 ± 0.007 0.040 ± 0.01 0.9 ± 0.2 
46 36 ± 0.3 8,300 ± 40 4.1 ± 0.3 1.1 ± 0.01 2,200 ± 200 
47 9.2 ± 0.4e >30,000e 0.40 ± 0.1 0.48 ± 0.07 11,000 ± 400 
48f 30 ± 0.1 >30,000 0.0031 ± 0.001 0.089 ± 0.04 >30,000 
77 5.9 ± 0.9 >30,000 1.3 ± 0.2 0.11 ± 0.001 >30,000 
78 11 ± 0.9 15,000 ± 2,000 0.89 ± 0.03 0.22 ± 0.01 >30,000 
81 3.3 ± 0.7 89 ± 8 2.3 ± 0.1 0.62 ± 0.07 11, 000 ± 2,000 
83 4.1 ± 0.7 34 ± 1 1.7 ± 0.1 1.3 ± 0.07 8.4 ± 2 
84 5.6 ± 2 6.1 ± 0.4 0.42 ± 0.04 0.51 ± 0.09 140 ± 8 
87 3.7 ± 0.7 27 ± 4 1.1 ± 0.02 0.66 ± 0.09 2,400 ± 800 
89 2.9 ± 0.5 27,000 ± 800 1.1 ± 0.01 0.39 ± 0.08 >30,000 
90 0.7 ± 0.1 14 ± 2 1.6 ± 0.1 1.0 ± 0.2 14 ± 2 
aAnalogue evaluated at 5  µM unless otherwise indicated. bValue represents % Gli1 mRNA expression 
compared to OHC control (set to 100). cValue represents Cyp24A1 mRNA expression compared to DMSO 
control (set to 1.0). dIC50 values represent average Mean ± SEM of at least two separate experiments performed 
in triplicate. eAnalogue evaluated at 2.5 µM. fAnalogue evaluated at 1 µM. 
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D. Pharmacokinetic Studies of Vitamin D Analogues  
Select analogues were then sent to Pharmaron, Inc. for pharmacokinetic (PK) studies (Table 12).  The 
first take-away from this study was the overall poor solubility of the compounds, which were essentially 
insoluble at pH 4.0 and 7.4. This was not too surprising given the hydrophobic nature of the compounds. 
Overall, the most soluble compound at pH 4.0 was analogue 78 with a single-atom amine seco-B and C-25 
hydroxylation, but showed a significant decrease in solubility at pH 7.4. Analogue 52 with the amide seco-
B region was the second most soluble compound at pH 4.0 and maintained solubility at pH 7.4.  
Comparing the PK properties of 56, 57, 75 and 78, general conclusions can be made for the amine 
series of analogues as all compounds contain the 4-hydroxyl phenolic A-ring moiety. Looking at 
compounds 56 and 57, the only structural difference is the orientation of the seco-B region at C-9, where 
56 maintains the a-orientation. While both compounds maintain similar solubility, the a-orientation 
appears to be less stable in human liver microsomes (HLMs) and has a higher clearance rate compared to 
the b-orientation of 57. Similarly, the extended amine seco-B analogue 75 maintains b-orientation at C-9 
and shows a very similar PK profile to the single atom seco-B analogue 57. Addition of the C-25 
hydroxylation to 56 (analogue 78) decreased the half-life and increased the clearance rate while increasing 
Table 14. Pharmacokinetic properties determined by Pharmaron, Inc. 
 
Pharmacokinetic Properties 
T1/2 
(HLM, min)a 
Clearance 
(mL/min/mg 
protein) 
Solubility (mg/mL) 
pH 4.0 pH 7.4 
48 >120* ND ND ND 
51 >231 < 3 1.6 x 10-4 6.7 x 10-4 
52 >231 < 3 2.7 x 10-4 6.8 x 10-4 
56 57 ± 0.1 12 ± 0.2 6.2 x10-7 2.6 x 10-6 
57 >231 < 3 7.5 x 10-7 2.6 x 10-7 
75 >231 < 3 1.3 x 10-7 2.7 x 10-6 
78 31 ± 0.5 22 ± 0.4 2.4 x 10-3 4.2 x 10-6 
81 >231 < 3 1.7 x 10-5 1.4 x 10-5 
87 43 ± 7 16 ± 3 6.0 x 10-5 1.2 x 10-4 
89 47 ± 1 15 ± 0.3 4.8 x 10-5 3.1 x 10-5 
90 49 ± 7 15 ± 0.3 2.7 x 10-6 2.3 x 10-6 
a Metabolic stability in human liver microsomes (HLM), time until 50% of 
compound disappeared. *Metabolic stability in rat liver homogenate, time until 
50% of compound disappeared [Ref 141]. 
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the solubility at pH 4.0. Although 81 has a 3-hydroxyl phenolic A-ring, masking of the C-25 hydroxyl group 
as the methyl-ether increased the half-life significantly and reduced clearance to values similar to the non-
functionalized C-25 analogues. Furthermore, the solubility of 81 was reduced compared to 78, but was 
greater than 56 – 57.  
Although not completely conclusive due to issues with obtaining results in their experiments, these 
studies have provided great insight into the best ways to proceed in analogue development. Taken together 
with the cellular data, it is becoming clearer that the orientation of the seco-B region is flexible and either 
the a- or b-orientation may be utilized for analogue development. Secondly, masking the C-25 
hydroxylation may be the best way to find a balance between biological activity and stability.  
  
Conclusion  
Following reports that VD3 (46) inhibits Hh signaling in multiple cell lines, initial analogue 
development focused on increasing the selectivity for Hh signaling over canonical vitamin D receptor 
(VDR) signaling. Previous SAR studies indicated that the CD-rings and alkyl side chain (50) were required 
for Hh signaling,129 and that incorporation of a phenolic A-ring and ester seco-B ring (51) increased both 
selective and potency over VD3.131 Follow up studies suggested that the natural alkyl side chain was 
preferred,132 and the use of an amine seco-B region yielded more potent analogues and greater consistency 
across cell lines.133  
With the specific protein target and mechanism of action unclear, a series of analogues were developed 
with modifications to the C-ring to probe the binding pocket for additional interactions and determine if 
this position would be useful for labeling studies.134 These additions were made to the C-11 position and 
ranged in size from ethyl to benzyl to propargyl groups. Overall, no significant gains in potency were 
achieved, but there was an immediate loss in activity as the size of the functional group changed from ethyl- 
(61a) to cyclohexyl- (61c). This suggests a narrow binding pocket, which would not be surprising as the 
theorized Hh binding partner is the transmembrane protein, Smo. As hydrophilic characteristics were 
introduced with 63–67, inhibitory activity was restored suggesting that the binding pocket may not be as 
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narrow as originally thought, but flexibility and rigidity of the functional group may play a primary role for 
SAR at this location of the scaffold. The ethyl addition (61a) did increase selectivity compared to 51, 
suggesting that the C-11 position may be useful to gain selectivity but not potency. The drop-off in activity 
calls for additional studies to determine the cause of the immediate activity loss. These studies could include 
computational modeling and binding studies within the potential binding pockets. Furthermore, the 
reduction in Cyp24A1 levels and the ability of 67 to inhibit Hh signaling suggests that the C-11 position 
may serve as a label attachment point for target elucidation studies that selectively identify non-VDR 
proteins.  
The incorporation of an amine seco-B has provided the most potent and selective VD3 analogues to 
date with sub-micromolar IC50 values and low Cyp24A1 levels in both cell lines. Combining these results 
with previous SAR studies, it is clear that the free hydroxyl group of the A-ring is required to maintain anti-
Hh activity. The preferred position of the hydroxyl group shifted from the 3-position of the esters and amide 
series (50 - 54) to the 4-poistion for the amine seco-B analogues (56 - 57, 72, 75). Additionally, extension 
of the initial single atom amine seco-B (55 – 57) by a methylene (CH2) group (74 – 75) showed the same 
preference for the 4-hydroxyl over the 3-hydroxyl position. This shift may be due to the flexibility of the 
seco-B region and how it orients the hydroxyl group within the binding site. The more rigid ester and amide 
seco-B analogues are similar to the diene system of the vitamin D compounds, whereas the -CH2NH- seco-
B region is more flexibly and allows the same interactions to be obtained.  These observations still need to 
be studied by computational studies, but with the mechanism of action unclear, the binding target remains 
in question.  
As expected, addition of a C-25 hydroxyl group significantly upregulated Cyp24A1 mRNA expression 
across cell lines, with analogues 83 – 84 being the exception to this trend. Compared to the non-C-25 
hydroxylated analogues, there were little differences in the anti-Hh activity in C3H cells; however, varying 
potency increases where observed in ASZ cells. Masking of the C-25 hydroxyl group via a methyl ether 
successful decreased Cyp24A1 expression for the single atom amine and ester seco-B analogues (80 and 
89). Interestingly, the extended amine analogue 87 had greater anti-Hh potency and higher Cyp24A1 
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mRNA levels than the non-hydroxylated or C-25 hydroxylated versions, 74 and 83 respectively. Taken 
together, these results suggest that addition of the C-25 hydroxyl or methoxy increases the binding 
interactions to increase potency. Another potential reason for the increase in potency is an increase in cell 
permeability, but additional studies need to be performed to understand the increase.  It was clear that as 
Cyp24A1 levels increased, so did anti-Hh activity. This observation suggests that VDR plays a role in 
controlling analogue activity and crosstalk with Hh signaling may exists. Studies to further understand these 
observations will be discussed in the following chapter.  
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Experimental Section 
General Information 
VD3 used for chemical synthesis was purchased from HBC Chem, Inc. Other chemicals were purchased 
from Sigma–Aldrich or Fisher Scientific. ACS or HPLC grade methanol, acetone, and tetrahydrofuran 
(THF) were purchased from Fisher Scientific. Anhydrous DCM and THF were purchased from Sigma-
Aldrich. Column chromatography was performed using silica gel purchased from Sorbtech (Sorbent 
Technologies). NMR data was performed on a Bruker AVANCE 500 MHz spectrometer and analysis with 
MestReNova version 8.0.0. HRMS data was analyzed at the Mass Spectrometry Facility at the University 
of Connecticut, performed by Dr. You-Jun Fu. 
 
Synthesis Procedures 
Ester 51.127 Grundmann’s alcohol 50 (0.19 mmol), dicyclohexylcarbodiimide (3 eq, 0.57 mmol), and 
dimethylaminopyridine (3 eq, 0.57 mmol) were dissolved in anhydrous DCM (4 mL) in an oven-dried 
round bottom flask. The benzyl protected 3-hydroxy benzoic acid was added and the reaction mixture 
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stirred overnight at RT. The crude mixtures were loaded directly on a silica column and purified with flash 
chromatography (4% EtOAc in Hexanes) to yield protected the ester, 60%. The protected ester (0.1 mmol) 
was dissolved in MeOH:THF (2:1, 6 mL). Pd(OH)2 (10% on carbon, 10 mg) was then added. The flask was 
sealed with a rubber septum and charged with an atmosphere of hydrogen gas. The reaction was stirred 
overnight at RT. The reaction mixture was passed through a celite pad, rinsed with ethyl acetate (10 mL), 
and concentrated under reduced pressure. The crude residue was purified using flash chromatography over 
a packed silica column (10% EtOAc in hexanes) to yield analogue 51 in good yield (70%). 1H NMR (500 
MHz, CDCl3) δ 7.70 (m, 1H), 7.64 (m, 1H), 7.34 (m, 1H), 7.11 (m, 1H), 6.63 (br s, 1H), 5.43 (m, 1H), 2.08 
(m, 1H), 2.01 (m, 1H), 1.84 (m, 2H), 1.56 (m, 5H), 1.37 (m, 3H), 1.26 (m, 3H), 1.15 (m, 4H), 1.04 (s, 3H), 
0.95 (d, J = 6.5 Hz, 3H), 0.90 (dd, J = 6.6, 1.9 Hz, 6H). 13C NMR (126 MHz CDCl3) δ 166.9, 156.1, 132.0, 
129.7, 121.7, 120.2, 116.5, 72.2, 56.4, 51.5, 41.9, 39.8, 39.5, 35.9, 35.4, 30.5, 28.0, 27.0, 23.7, 22.8, 22.6, 
22.5, 18.6, 18.0, 13.5. IR (film) vmax 3385 (bs), 3019, 2951, 2935, 2868, 1689, 1599, 1589, 1466, 1453, 
1366, 1344, 1295, 1215, 1157, 1106, 1075, 1062, 982, 946, 886, 755, 680, 668. DART-HRMS: a) m/z 
calcd. for C25H37O3: 385.2743 [M-H]+. Found: 385.2745.  
 
A. C-Ring Analogues 53-61134 
Enone 59. Lithium diisopropylamine (2 eq, 1 M, 6.8 mL) was cooled to -78ºC in anhydrous THF (5 mL). 
Grundmann’s ketone 58 (900 mg, 3.4 mmol) was dissolved in anhydrous THF (8 mL) and added dropwise 
over 15 min to the cooled LDA solution. The reaction stirred at -78ºC for 1 hr plus an additional 1 hr at RT. 
After 2 hr, the reaction mixture was cooled back to -78ºC and TMSCl (2 eq, 0.87 mL) was added. The 
mixture was warmed to 0ºC and stirred for 2.5 hr warming to RT. The reaction was quenched by slow 
addition of cold H2O and saturated NaHCO3. The organics were extracted with diethyl ether, dried over 
anhydrous NaSO4, and concentrated. The crude silyl-enol ether was dissolved in anhydrous MeCN (30 mL). 
Pd(OAc)2 (0.8 eq, 600 mg) was added followed by p-benzoquinone (0.5 eq, 185 mg) and allowed to stir 
overnight (16 hr) at RT. The reaction was filtered through celite and concentrated. Enone 59 was obtained 
via column chromatography (3% EtOAc in hexanes, 78%, 695 mg). 1H NMR (500MHz, CDCl3) δ 6.78 (m, 
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1H), 6.01 (dd, 1H), 2.64 (dd, 1H), 2.58 (t, 1H), 2.43 (d, 1H), 1.98 9m, 1H), 1.77 (m, 2H), 1.54 (m, 2H), 1.5-
1.0 (10H), 0.96 (d, 3H), 0.89 (d, 6H), 0.77 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 202.1, 147.7, 129.7, 
59.4, 56.9, 47.7, 43.2, 39.6, 36.1, 35.6, 28.2, 27.6, 23.9, 22.9, 22.7, 19.6, 18.6, 12.1. Previously reported: 
Okamura, W. H; et al. J. Org. Chem. 2002, 67, 1637-1650.  
 
General Procedure for C-11 additions (60a-e) 
CuI (2 eq, 365 mg) was suspended in anhydrous THF (5 mL) under argon and cooled to 0ºC. Ethyl-MgBr 
(10 eq, 1M, 9.5 mL) was added to the suspension and stirred for 1 hr. Enone 59 (250 mg, 0.95 mmol) was 
dissolved in anhydrous THF (5 ml) under argon and added to the Grignard-cuprate mixture at 0ºC. The 
reaction was monitored by TLC and quenched with cold H2O upon completion (~2 hr). The mixture was 
diluted with ethyl acetate (20 mL) and washed with 0.1N HCl (15 mL). The organics were extracted, dried 
over anhydrous NaSO4 and concentrated. The product 60a was purified by column chromatography (3% 
EtOAc in hexanes, 90 %, 250 mg). 1H NMR (500 MHz, CDCl3) δ 2.45 (m, 2H), 2.07 (m, 2H), 1.92 (m, 
2H), 1.80 (m, 1H), 1.67 (m, 1H), 1.53 (m, 2H), 1.37 (m, 5H), 1.25 (m, 1H), 1.17 (m, 4H), 1.11 (s, 3H), 1.04 
(m, 1H), 0.96 (t, 3H), 0.93 (d, 3H), 0.91 (m, 6H) .13C NMR (126 MHz, CDCl3) δ 215.27, 60.02, 56.52, 
47.48, 45.57, 45.29, 39.48, 35.46, 34.83, 34.10, 29.72, 29.51, 28.51, 28.02, 24.22, 22.81, 22.56, 22.33, 
22.04, 19.21, 11.35. HRMS: m/z calculated for C26H36O, [M+H]+, calc. 293.2844, obs. 293.2831; [M-OH]+, 
calc. 275.2739, obs. 275.2730. 
 
Vinyl-substituted analogue 60b.  150 mg, 71%. 1H NMR (500 MHz, CDCl3) δ 5.81 (m, 1H), 5.03 (m, 
2H), 2.77 (m, 1H), 2.48 (m, 1H), 2.36 (dd, 1H), 2.22(m, 1H), 2.13 (t, 1H), 1.94 (m, 1H), 1.73 (m, 1H), 1.6-
1.3 (9H), 1.15 (m, 3H), 1.06 (m, 1H), 0.99 (d, 3H), 0.89 (d, 6H), 0.70 (s, 3H). 13C NMR (126 MHz, CDCl3) 
δ 210.6, 142.2, 113.5, 67.2, 56.8, 49.2, 46.9, 45.9, 40.8, 39.6, 36.1, 35.7, 28.2, 27.9, 23.9, 22.9, 19.1, 19.0, 
13.3. HRMS: m/z calculated for C20H34O, [M+H]+, calc. 291.2688, obs. 291.2715; [M+NH4]+, calc. 
308.2953, obs. 308.2951. 
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Cyclohexyl-substituted analogue 60c. 72 mg, 62%. 1H NMR (500 MHz, CDCl3) δ 2.43 (q, 1H), 2.32 (dd, 
1H), 2.16 (dd, 1H), 1.95 (m, 4H), 1.8-1.6 (11H), 1.52 (m, 3H), 1.3-1.1 (9H), 1.04 (m, 4H), 0.94 (m, 3H), 
0.89 (m, 9H), 0.64 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 212.3, 62.1, 56.9, 49.1, 45.0, 43.4, 43.3, 42.1, 
39.6, 36.2, 35.6, 30.9, 30.2, 28.2, 27.9, 27.2, 26.8, 23.9, 22.9, 22.7, 19.1, 19.0, 13.4. HRMS: m/z calculated 
for C24H43O, [M+H]+, calc. 374.3140, obs. 347.3340.   
 
Phenyl-substituted analogue 60d. 100 mg, 78%. 1H NMR (500 MHz, CDCl3) δ 7.35 (m, 5H), 3.34 (m, 
1H), 2.65 (m, 1H), 2.50 (m, 2H), 2.36 (m, 1H), 1.99 (m, 1H), 1.87 (m, 2H), 1.58 (m, 5H), 1.40 (m, 4H), 
1.29 (s, 2H), 1.15 (m, 4H), 1.08 (m, 1H), 0.95 (d, 3H), 0.90 (m, 6H), 0.81 (s, 3H).13C NMR (126 MHz, 
CDCl3) δ 210.5, 128.9, 127.1, 126.8, 62.0, 56.9, 49.5, 49.1, 47.7, 42.9, 39.6, 35.7, 29.9, 28.2, 27.9, 23.9, 
22.9, 22.7, 19.2, 19.0, 13.4. HRMS: m/z calculated for C24H36O [MH]+, calc. 341.2844, obs. 341.2859.  
 
Benzyl-substituted analogue 60e. 95 mg, 88%. 1H NMR (500 MHz, CDCl3) δ 7.25 (m, 5H), 2.77 (dd, 
1H), 2.61 (m, 1H), 2.36 (m, 1H), 2.27 (m, 1H), 2.27 (m, 2H), 1.97 (m, 2H), 1.75 (m, 1H), 1.55 (m, 2H), 
1.38 (m, 8H), 1.1-1.0 (6H), 0.95 (d, 3H), 0.90 (d, 6H), 0.66 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 137.34, 
130.97, 130.58, 128.81, 127.95, 126.31, 71.96, 56.48, 53.20, 48.14, 41.64, 41.20, 39.50, 35.96, 35.24, 
29.71, 28.02, 27.35, 23.84, 22.82, 22.55, 19.61, 18.28, 13.48. HRMS: m/z calculated for C25H39O, [M+H]+, 
calc. 355.3001, obs. 355.3011. 
 
General Procedure for synthesis of esters 61a-61e. NaBH4 (5 eq, 40 mg) was added to a solution of 
ketone 60e (75 mg, 0.21 mmol) in MeOH (8 mL) and allowed to stir for 4 hr at RT. The reaction was 
quenched with H2O (10 mL), extracted with EtOAc (3 x 20 mL) and concentrated. The crude alcohol was 
dissolved in DCM (8 mL). DCC (2.5 eq, 108 mg), DMAP (4 eq, 103 mg) and 3-MOM-benzoic acid (4 eq, 
153 mg) were added and stirred at RT overnight (12-16 hr). The reaction was concentrated in vacu and 
purified via column chromatography. The 3-OMOM-protected ester was purified (5% EtOAc in hexanes) 
and immediately moved forward for deprotection. To remove the MOM-protecting group, (±)-CSA (5 eq, 
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170 mg) was added to a solution of the protected ester in MeOH (5 mL) and stirred at RT until the reaction 
was complete by TLC (16 hr). The reaction mixture was concentrated and purified via column 
chromatography. (8% EtOAc in hexanes).  
 
Ethyl-substituted analogue 61a. 18 mg, 32% over three steps. 1H NMR (500 MHz, CDCl3) δ 7.67 (d, 1H), 
7.54 (s, 1H), 7.37 (t, 1H), 7.07 (m, 1H), 5.45 (m, 1H), 5.04 (bs, 1H), 2.14 (m, 1H), 2.10 (m, 1H), 1.93 (m, 
1H), 1.82 (m, 1H), 1.6-1.4 (5H), 1.38 (m, 3H), 1.26 (m, 2H), 1.19 (m, 5H), 1.09 (s, 3H), 1.07 (m, 1H), 0.99 
(d, 3H), 0.92 (m, 10H). 13C NMR (126 MHz, CDCl3) δ 155.55, 132.51, 129.69, 122.13, 119.81, 116.26, 
72.34, 56.36, 52.01, 46.66, 42.66, 39.52, 37.17, 35.95, 35.44, 30.75, 29.85, 29.73, 28.04, 27.58, 23.78, 
22.83, 22.58, 22.43, 18.74, 14.49, 11.56. HRMS: m/z calculated for C27H42O3, [MNH4]+, calc. 432.3478, 
obs. 432.3475. 
 
Cyclohexyl-substituted analogue 61c. 22 mg, 20 % over three steps. 1H NMR (500 MHz, CDCl3) δ.66 
(dd, 2H), 7.36 (t, 1H), 7.11 (m, 1H), 6.26 (s, 1H), 5.47 (s, 1H), 2.05 (m, 2H), 1.92 (m, 1H), 1.78 (m, 3H), 
1.70 (m, 3H), 1.55 (m, 3H), 1.39 (m, 5H), 1.30 (m, 2H), 1.18 (m, 8H), 1.06 (s, 3H), 1.03 (m, 3H), 1.00 (m, 
3H), 0.92 (m, 6H).13C NMR (126 MHz, CDCl3) δ 166.79, 156.05, 132.16, 129.71, 121.80, 120.14, 116.49, 
72.87, 56.47, 52.00, 43.55, 42.97, 42.63, 39.53, 35.96, 35.42, 34.23, 34.19, 30.34, 30.16, 28.05, 27.59, 
26.91, 26.87, 26.83, 23.77, 22.84, 22.59, 22.46, 18.80, 14.40. HRMS: m/z calculated for C31H48O3, 
[MNH4]+, calc. 480.3478, obs. 480.3464.  
 
Phenyl-substituted analogue 61d. 7 mg, 17% over three steps. 1H NMR (500 MHz, CDCl3) δ 7.71 (d, 
1H), 7.58 (s, 1H), 7.39 (t, 1H), 7.35 (t, 2H), 7.28 (m, 2H), 7.24 (t, 1H), 7.12 (d, 1H), 5.57 (m, 1H), 5.03 (s, 
1H), 3.23 (m, 1H), 2.26 (m, 2H), 1.96 (m, 1H), 1.85 (m, 1H), 1.75 (m, 1H), 1.75 (m, 1H), 1.65 (m, 1H), 
1.6-1.3 (10H), 1.28 (m, 2H), 1.22 (s, 3H), 1.16 (m, 3H), 1.07 (m, 1H), 0.95 (s, 3H), 0.91 (dd, 6H). 13C NMR 
(126 MHz, CDCl3) δ 155.66, 146.42, 132.32, 129.76, 128.46, 127.19, 126.17, 122.10, 119.98, 116.31, 
72.12, 56.50, 51.55, 48.08, 43.02, 39.50, 38.41, 35.92, 35.81, 35.45, 29.72, 28.04, 27.58, 23.76, 22.82, 
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22.57, 22.50, 18.76, 14.38. HRMS: m/z calculated for C31H42O3, [M-H]+, calc. 467.3525, obs. 467.3523. 
 
Benzyl-substituted analogue 61e. 25 mg, 23% over three steps. 1H NMR (500 MHz, CDCl3) δ7.64 (d, 
1H), 7.59 (s, 1H), 7.35 (t, 1H), 7.31 (m, 2H), 7.19 (m, 3H), 7.03 (m, 1H), 5.59 (s, 1h), 5.47 (s, 1H), 2.58 (d, 
2H), 2.26 (m, 1H), 2.15 (m, 1H), 2.07 (m, 1H), 1.91 (m, 1H), 1.58 (m, 3H), 1.49 (s, 2H), 1.45-1.3 (7H), 
1.17 (m, 4H), 1.05 (s, 3H), 1.01 (m, 1H), 0.91 (m, 9H). 13C NMR (126 MHz, CDCl3) δ 166.44, 155.82, 
140.49, 132.19, 129.70, 129.15, 128.17, 125.82, 121.93, 120.03, 116.41, 72.21, 56.33, 51.90, 46.68, 43.70, 
42.63, 39.50, 37.28, 35.91, 35.32, 31.17, 30.36, 28.03, 27.52, 23.74, 22.83, 22.58, 22.37, 18.66, 14.42. 
HRMS: m/z calculated for C32H44O3, [MNH4]+, calc. 494.3534, obs. 494.3552. 
 
Ethyl hydroxyl alcohol 62. Ketone 60b (280 mg, 0.96 mmol) was dissolved in anhydrous THF (5 mL) 
under argon. A solution of 9-BBN (0.5 M, 4 eq, 4 mL) was added and stirred for 3.5 hr at RT. Water was 
slowly added until the solution became cloudy. NaOH (12 eq, 2 M, 6 mL) was added followed by MeOH 
(5 mL) and H2O2 (~30%, 2.5 eq, 1.5 mL) and stirred for 16 hr. The reaction mixture was washed with 
diethyl ether (2 x 15 mL), dried with anhydrous NaSO4 and concentrated. Diol 62 was purified via column 
chromatography (25% EtOAc in hexanes, 195 mg, 65%). 1H NMR (500 MHz, CDCl3) δ 4.10 (s, 1H), 3.67 
(m ,2H), 2.64 (s, 1H), 2.13 (m, 1H), 2.00 (d, 2H), 1.18 (m, 1H), 1.6-1.4 (4H), 1.3 (m, 6H), 1.2-1.0 (6H), 
0.97 (s, 3H), 0.91 (d, 3H), 0.88 (dd, 6H).13C NMR (126 MHz, CDCl3) δ 69.20, 60.35, 56.72, 53.23, 48.25, 
42.84, 40.20, 39.68, 39.52, 36.13, 35.45, 28.18, 27.78, 24.70, 23.95, 22.98, 22.73, 22.42, 18.82, 14.54. 
HRMS: m/z calculated for C20H38O2, [M+NH4]+, calc. 328.3216, obs. 328.3218; [M-OH]+, calc. 298.2844, 
obs. 298.2869. 
 
Analogue 63. Diol 62 (95 mg, 0.31 mmol) was dissolved in anhydrous DCM (5 mL) under argon. TBSCl 
(1.05 eq, 51 mg) was added followed by imidazole (1.8 eq, 39 mg). After 1 hr, the reaction was quenched 
with H2O (10 mL) and washed with DCM (2 x 10 mL). The organic layer was collected, dried over 
anhydrous NaSO4 and concentrated. Mono-protected alcohol was collected via column chromatography 
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(3% EtOAc in hexanes, 118 mg, 90%). The TBS-protected alcohol (70 mg, 0.16 mmol) was dissolved in 
DCM (5 mL). DCC (3 eq, 102 mg), DMAP (4 eq, 20 mg) and 3-OMOM-benzoic acid (4 eq, 120 mg) were 
added and the mixture stirred for 16 hr at RT. The reaction was concentrated, and the protected ester was 
purified via column chromatography (2% EtOAc in hexanes). The protected ester (25 mg, 0.52 mmol) was 
dissolved in MeOH (5 mL) to which (±)-CSA (5 eq, 50 mg) was added and stirred at RT until the reaction 
was complete by TLC (18 hr). The solution was concentrated and ester 63 was purified via column 
chromatography (25% EtOAc in hexanes, 15 mg, 65%). 1H NMR (500 MHz, CDCl3) δ 7.62 (d, 1H), 7.58 
(s, 1H), 7.32 (m, 1H), 7.10 (dd, 1H), 6.56 (s, 1H), 3.76 (t, 2H), 2.11 (m, 3H), 1.91 (m, 3H), 1.57 (m, 5H), 
1.5-1.2 (7H), 1.17 (m, 4H), 1.06 (s, 3H), 0.97 (d, 3H), 0.91 (dd, 6H).13C NMR (126 MHz, CDCl3) δ 166.58, 
156.07, 132.04, 129.70, 121.76, 120.15, 116.33, 72.14, 60.74, 56.33, 51.84, 46.98, 42.60, 39.91, 39.51, 
37.48, 35.92, 35.41, 27.50, 25.75, 23.77, 22.83, 22.58, 22.42, 18.73, 14.37. HRMS: m/z calculated for 
C27H42O4, [M+H]+, calc. 431.3161, obs. 431.3166; [M+NH4]+, calc. 448.3427, obs. 448.3437. 
 
Ketone 64. Tetrabutyl ammonium bromide (0.5 eq, 200 mg) was added to a slurry of IBX (3 eq, 1.1 g) in 
DCM:H2O (3:1, 8 mL) and the mixture was stirred until a yellow color appeared. A solution of diol 62 (350 
mg, 1.1 mmol) in DCM (2 mL) was added to the IBX mixture and stirred at RT for 4 hr. The mixture was 
filtered and thoroughly washed with diethyl ether. The filtrate was washed with saturated sodium thiosulfate 
(15 mL), water (2 x 15 mL) and brine (15 mL). The organic layer was dried with anhydrous NaSO4 and 
concentrated. Ketone 64 was purified via column chromatography (20% EtOAc in hexanes, 260 mg, 75%). 
1H NMR (500 MHz, CDCl3) δ 3.69 (s, 2H), 2.45 (m, 2H), 2.22 (m, 2H), 1.93 (m, 3H), 1.71 (m, 2H), 1.52 
(m, 3H), 1.34 (m, 6H), 1.14 (m, 5H), 0.96 (m, 3H), 0.88 (m, 6H), 0.66 (s, 3H).13C NMR (126 MHz, CDCl3) 
δ 211.33, 61.89, 60.37, 56.55, 49.21, 47.49, 46.40, 40.11, 39.40, 35.95, 35.46, 33.30, 27.98, 27.71, 23.75, 
22.77, 18.91, 13.19. HRMS: m/z calculated for C20H36O2,  [M+H]+, calc. 309.2794, obs. 309.2776. 
 
Amine analogue 65. Ketone 64 (100 mg, 0.32 mmol) was dissolved in dichloroethane (DCE, 6 mL). 4-
aminophenol (1.5 eq, 45 mg) and NaBH(OAc)3 (1.6 eq, 90 mg) were added, and the solution was stirred at 
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RT for 14 hr. The mixture was quenched with saturated NaHCO3 (10 mL) and washed with ethyl acetate 
(2 x 15 mL). The organic layers were dried over anhydrous NaSO4 and concentrated. Amine 65 was purified 
via column chromatography (25% EtOAc in hexanes, 15 mg, 12%). 1H NMR (500 MHz, CDCl3) δ 6.66 (d, 
2H), 6.45 (d, 2H), 3.68 (m, 2H), 2.58 (m, 1H), 2.53 (m, 1H), 2.20 (m, 2H), 2.05 (m, 4H), 1.82 (m, 1H), 1.7-
1.3 (10H), 1.27 (m, 1H), 1.23 (s, 3H), 1.2-1.1 (6H), 0.99 (d, 3H), 0.92 (d, 6H).  13C NMR (126 MHz, CDCl3) 
δ 148.47, 139.98, 116.68, 116.02, 74.24, 62.01, 55.64, 51.57, 47.33, 39.40, 39.20, 38.63, 36.70, 33.47, 
33.16, 32.45, 28.01, 27.99, 25.68, 22.72, 22.58, 22.49, 21.30, 16.17. HRMS: m/z calculated for 
C27H45NO2, [MH]+, calc. 402.3372, obs. 402.3376. 
 
Ketone 66. Ketone 64 (170 mg, 0.57 mmol) was dissolved in anhydrous DCM (5 mL). DCC (3 eq, 353 
mg), DMAP (3 eq, 210 mg) and 4-pentynoic acid (3 eq, 155 mg) were added to the solution and it was 
stirred at RT for 16 hr. The reaction mixture was concentrated. Ketone 66 was purified via column 
chromatography (10% EtOAc in hexanes, 201 mg, 91%). 1H NMR (500 MHz, CDCl3) δ 4.16 (m, 3H), 2.52 
(m, 5H), 2.45 (m, 1H), 2.38 (m, 1H), 2.21 (m, 2H), 1.95 (m, 4H), 1.71 (m, 5H), 1.53 (m ,3H), 1.37 (m, 9H), 
1.2-1.0 (6H), 0.97 (m, 3H), 0.87 (m, 8H), 0.66 (s, 3H).13C NMR (126 MHz, CDCl3) δ 210.50, 171.66, 
82.36, 69.13, 62.54, 61.86, 56.55, 49.06, 47.37, 46.07, 39.40, 35.95, 35.45, 33.65, 33.36, 27.98, 27.71, 
23.75, 22.78, 22.53, 18.91, 18.86, 14.39, 13.17. HRMS: m/z calculated for C25H40O3, [M+H]+, calc. 
389.3056, obs. 389.3067; [M+NH4]+, calc. 406.3321, obs. 406.3300. 
 
Ester analogue 67. Ketone 66 (200 mg, 0.51 mmol) was dissolved in MeOH (5 mL). NaBH4 (2 eq, 38 mg) 
was added and the mixture stirred at RT for 2 hr. The reaction was quenched with cold H2O (10 mL) and 
washed with EtOAc (2 x 15 mL). The organic layers were dried over anhydrous NaSO4 and concentrated. 
The crude alcohol was dissolved in anhydrous DCM (5 mL). DCC (3 eq, 214 mg), DMAP (3 eq, 130 mg) 
and 3-OMOM-benzoic acid (3 eq, 190 mg) were added and the solution was stirred at RT for 20 hr. The 
reaction mixture was purified via column chromatography (5% EtOAc in hexanes) to yield the MOM-
protected ester in modest yield, 115 mg, 60%. (±)-CSA (5 eq, 200 mg) was added to a solution of the MOM-
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protected ester (100 mg, 0.18 mmol) in MeOH (5 mL). The reaction was stirred at RT until complete 
consumption of the starting material by TLC (8 hr). The reaction mixture was diluted with H2O (5 mL), 
saturated NaHCO3 (10 mL), and extracted with ethyl acetate (2 x 15 mL). The organic layers were dried 
over anhydrous NaSO4 and concentrated. Ester 67 was purified via column chromatography (10% EtOAc 
in hexanes, 27 mg, 26%). Ester 63 was also collected (25 mg) demonstrating that these deprotection 
conditions were capable of cleaving the propargyl ester as well. 1H NMR (500 MHz, CDCl3) δ 7.66 (d, 1H), 
7.57 (s, 1H), 7.37 (t, 1H), 7.09 (dd, 1H), 5.46 (s, 2H), 4.22 (t, 2H), 2.54 (m, 4H), 2.10 (m, 3H), 2.00 (t, 1H), 
1.91 (m, 1H), 1.6-1.3 (13H), 1.19 (m, 4H), 1.08 (s, 3H), 0.98 (d, 3H), 0.91 (dd, 6H).13C NMR (126 MHz, 
CDCl3) δ 166.24, 155.76, 132.24, 129.75, 121.99, 120.03, 116.30, 82.58, 71.97, 69.12, 63.01, 56.34, 51.79, 
46.76, 42.61, 39.50, 37.41, 35.91, 35.68, 35.40, 33.45, 29.73, 28.04, 27.51, 26.45, 23.77, 22.83, 22.58, 
22.41, 18.77, 14.41. HRMS: m/z calculated for C32H46O5, [M]+, calc. 510.3345, obs. 510.3367; [M+NH4]+, 
calc. 528.3689, obs. 528.3695. 
 
B. Amine containing seco-B Analogues 52, 55-57, 68-72 
Amide 52133 
Ketone 58 (1.0 g, 2.5 mmol) was dissolved in 4 mL of pyridine. Hydroxylamine hydrochloride (XX mg, 
9.42 mmol) was then added with stirring and was left to stir at RT for 12 h and the mixture was diluted with 
H2O (10 mL) and benzene (10 mL). The mixture was washed with H2O followed by saturated CuSO4, and 
concentrated. Column chromatography (SiO2, 100% Hex to 10% EtOAc in hexanes) yielded Grundmann’s 
oxime (98%, 1.0 g). 1H NMR (500 MHz, CDCl3) δ 9.41 (bs, 1H) 3.27 (m, 1H), 2.09 (m, 2H), 1.93 (m, 1H), 
1.78 (m, 1H), 1.67 (m, 4H), 1.54 (m, 1H), 1.35 (m, 5H), 1.28 (s, 1H), 1.16 (m, 3H), 1.05 (m, 1H), 0.96 
(d, J = 6.0 Hz,3H), 0.89 (d, J = 6.1 Hz, 6H), 0.67 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 160.5, 56.1, 54.2, 
46.6, 39.6, 39.5, 36.2, 36.0, 28.1, 28.0, 24.0, 23.9, 22.9, 22.7, 21.9, 20.8, 18.9, 12.4. HRMS-ESI: m/z calcd. 
for C18H34NO: 280.2640 [MH]+. Found: 280.2647. Oxime (380 mg, 1.36 mmol) was dissolved in 
anhydrous THF (10 mL) and cooled to 0 °C. LiAlH4 (1.0 M; 9.50 mL, 9.52 mmol) was added drop-wise to 
the solution. Once all LiAlH4 was added, the reaction was refluxed for 12 h. The mixture was then worked 
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up according to the Fieser method: the reaction was cooled to 0 °C, water (30 mL) was added, followed by 
75 mL of 15% aqueous NaOH, and then 200 mL water. The mixture was warmed to RT, stirred for 0.5 h, 
and filtered over a celite pad. Following this protocol, the solution was washed with EtOAc (3 × 100 mL). 
The combined organic layers were dried over MgSO4, filtered, and concentrated. The crude mixture was 
then dissolved in glacial acetic acid (12 mL) and zinc powder (3 mmol) was added. The mixture was 
refluxed until the starting material was completely consumed (5 h, by TLC). The mixture was cooled to 
0 °C, quenched with saturated NaHCO3, washed with EtOAc (2 × 50 mL), and concentrated. Crude 
Grundmann’s amine was used directly in the next step. EDCI (0.689 mmol), DMAP (0.123 mmol) and 3-
(benzyloxy) benzoic acid (0.679 mmol) were dissolved in 5 mL anhydrous CH2Cl2 and stirred for 20 min. 
Crude amine (120 mg, 0.45 mmoL) in 3 mL anhydrous CH2Cl2 was added to the reaction mixture and 
stirred at RT for 16 h. Column chromatography (SiO2, 100% Hex to 5% EtOAc in hexanes) afforded the 
protected amide in 26 % (∼6:1) yield, 55 mg . 1H NMR (500 MHz, CDCl3) δ 7.44 (m, 5H), 7.36 (m, 2H), 
7.12 (m,1H), 6.31 (m, 1H), 5.14 (s, 2H), 4.46 (m, 1H), 2.06 (m, 1H), 1.97 (m, 1H), 1.91 (m, 1H), 1.62 (m, 
6H), 1.39 (m, 4H), 1.26 (m, 4H), 1.16 (m, 4H), 1.03 (m, 1H), 0.95 (m, 6H), 0.90 (m, 6H). 13C NMR 
(101 MHz, CDCl3) δ 166.9, 159.2, 136.9, 136.8, 129.8, 128.8, 128.3, 127.8, 127.7, 118.9, 118.4, 113.4, 
70.4, 56.8, 51.2, 47.9, 42.3, 39.9, 39.7, 36.1, 35.5, 31.2, 29.9, 28.2, 27.2, 23.9, 23.1, 23.0, 22.7, 18.7, 18.2, 
13.9. HRMS-ESI: m/z calcd. for C32H46NO2: 476.3528 [MH]+. Found: 476.351.  
To a solution of the protected amide (0.11 mmol) in MeOH:THF (3:1, 12 mL) under argon was added Pd/C 
(10%, 50 mg). The vessel was purged with H2 and the mixture stirred for 12 h. The mixture was filtered 
through celite, rinsed with copious EtOAc (100 mL), and the filtrate was concentrated. Amide 52 was 
isolated by column chromatography (SiO2, 100% Hex to 30% EtOAc in Hex) in 67% yield (∼6:1), 30 
mg. 1H NMR (500 MHz, CDCl3) δ 8.08 (s, 1H), 7.79 (s, 1H), 7.10 (m, 1H), 7.05 (m, 1H), 6.49 (m, 1H), 
4.46 (s, 1H), 2.06 (m, 1H), 1.97 (m, 1H), 1.90 (m, 1H), 1.62 (m, 5H) 1.56 (m, 2H), 1.38 (m, 5H), 1.16 (m, 
5H), 1.03 (m, 1H), 0.97 (s, 3H), 0.94 (d, J = 6.1 Hz, 3H), 0.90 (d, J = 6.4 Hz, 6H). 13C NMR (101 MHz, 
CDCl3) δ 167.6, 157.7, 136.0, 129.9, 119.3, 116.9, 115.6, 56.8, 51.1, 48.3, 42.3, 39.8, 39.7, 36.1, 35.5, 31.1, 
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28.2, 27.2, 23.9, 23.1, 23.0, 22.7, 18.7, 18.2, 13.9. IR(neat) vmax 3338, 2953, 1652, 1585, 1522, 1450, 
1258, 1277, 1239,1146, 938, 809. HRMS-ESI: m/z calcd. for C25H40NO2: 386.3059 [MH]+. Found: 
386.3037. 
 
General Reductive Amination Procedure133 
Ketone 58 (160 mg, 0.6 mmol) and 4-aminophenol (130 mg, 1.2 mmol) were dissolved in 1,2-
dichloroethane (8 mL). Sodium triacetoxyborohydride (380 mg, 1.8 mmoL) was added followed by acetic 
acid (50 µL) and titanium (IV) isopropoxide (370 µL, 1.2 mmol). The mixture was left to stir at RT or 
reflux for 24 - 48 h. The reaction was quenched with saturated sodium bicarbonate (20 mL) and diluted 
with diethyl ether (60 mL). The aqueous layer was washed with diethyl ether (3 × 60 mL) and the organic 
layers combined, dried over MgSO4, filtered, and concentrated. Crude residue was purified by column 
chromatography (SiO2, 100% Hex to 25% EtOAc in hexanes) affording recovery of the starting 
ketone 58 (20-60%), and the desired amine (15 - 80%). 
 
Amine 55133 
Reductive amination of 58 with 3-aminophenol was described previously to afford 55 as a clear oil in good 
yield; 80%, 170 mg. 1H NMR (500 MHz, CDCl3) δ 6.98 (m, 1H), 6.15 (m, 1H), 6.10 (m, 1H), 6.06 (m, 1H), 
4.78 (bs, 1H), 3.68 (m, 1H), 1.98 (m, 2H), 1.85 (m, 1H), 1.63 (m, 3H), 1.50 (m, 4H), 1.32 (m, 10H), 1.15 
(m, 6H), 0.99 (m, 2H), 0.94 (s, 3H), 0.89 (m, 9H). 13C NMR (126 MHz, CDCl3) δ 156.7, 150.0, 130.0, 
105.8, 103.3, 99.1, 56.8, 51.6, 51.1, 42.1, 40.2, 39.4, 35.9, 35.3, 31.5, 30.5, 28.0, 27.0, 23.7, 23.1, 22.7, 
22.6, 22.5, 18.5, 17.8, 14.1, 13.5. IR(neat) vmax 3388, 2986, 2866, 1614, 1506, 1464, 1371, 1333, 1272, 
1179, 1155, 1077, 977, 828, 757, 686. ESI-HRMS: m/z calcd. for C24H40NO: 358.3110 [MH]+. Found: 
358.3115. 
 
 
 
81 
  
Amine 56133 
Reductive amination of 58 with 4-aminophenol was described previously to afford 56 (40%, 28 mg) and 
57 (14%, 10 mg) as a clear oil in low yield. 1H NMR (500 MHz, DMSO) δ 8.34 (s, 1H), 6.48 (m, 4H), 4.13 
(m, 1H), 3.48 (m, 1H), 1.93 (m, 1H), 1.76 (m, 3H), 1.51 (m, 4H), 1.37 (m, 7H), 1.13 (m, 7H), 1.00 (m, 2H), 
0.90 (m, 6H), 0.87 (d, J = 2.3 Hz, 3H), 0.86 (d, J = 2.3 Hz, 3H). 13C NMR (126 MHz, DMSO) δ 148.0, 
142.1, 115.4, 113.6, 56.1, 51.8, 51.5, 41.6, 40.0, 38.9, 35.4, 34.7, 30.7, 27.3, 26.8, 23.1, 23.0, 22.6, 22.3, 
18.3, 17.5, 13.2. IR(neat) vmax 3441, 3161, 2927, 2866, 1610, 1512, 1466, 1241, 1192, 976, 795, 691. ESI-
HRMS: m/z calcd. for C24H40NO: 358.3110 [MH]+. Found: 358.3107. 
 
Amine 57133 
1H NMR (500 MHz, DMSO) δ 8.30 (bs, 1H), 6.51 (m, 2H), 6.41 (m, 2H), 4.33 (m, 1H), 2.83 (m, 1H), 1.95 
(m, 1H), 1.87 (m, 2H), 1.81 (m, 1H), 1.66 (m, 1H), 1.54 (m, 2H), 1.47 (m, 2H), 1.37 (m, 4H), 1.20 (m, 6H), 
1.02 (m, 1H), 0.94 (d, J = 6.5 Hz, 3H), 0.89 (s, 3H), 0.88 (d, J = 2.1 Hz, 3H), 0.86 (d, J = 2.2 Hz, 3H). 13C 
NMR (126 MHz, DMSO doped with a drop of CDCl3) δ 126.4, 118.2, 115.8, 115.5, 56.1, 55.2, 45.1, 44.9, 
44.6, 38.9, 35.9, 35.8, 34.9, 34.7, 34.4, 29.0, 27.4, 27.0, 24.2, 24.0, 22.6, 22.3, 19.2, 19.1. IR(neat) vmax 
3441, 3161, 2927, 2866, 1610, 1512, 1466, 1241, 1192, 976, 795, 691. DART-HRMS: m/z calcd. for 
C24H40NO: 358.3110 [MH]+. Found: 358.3102. 
 
Amine 68 
Reductive amination of 58 with aniline yielded amine 68; 65%, 69 mg.  1H NMR (500 MHz, CDCl3) δ 7.19 
(t, 2H), 6.68 (m, 1H), 6.62 (m, 2H), 3.77 (s, 1H), 2.04 (m, 2H), 1.9-1.5 (9H), 1.41 (m, 3H), 1.31 (m, 3H), 
1.17 (m, 5H), 1.07 (m, 1H), 1.00 (m, 3H), 0.97 (d, J = 6.7 Hz, 3H), 0.92 (m, 6H). 13C NMR (126 MHz, 
CDCl3) δ 148.5, 129.2, 129.2, 116.4, 112.5, 56.9, 51.7, 51.1, 45.7, 42.2, 40.3, 39.5, 35.9, 35.4, 30.6, 28.0, 
27.1, 23.8, 23.2, 22.8, 22.5, 18.5, 17.9, 13.6. IR(neat) vmax 2926, 1600, 1502, 1466, 1428, 1313, 1249, 
863. DART-HRMS: m/z calcd. for C24H39NO: 342.3161 [MH]+. Found 342.3132. 
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Amine 69 
Reductive amination of 58 with m-anisidine yielded amine 68; 45%, 23 mg. 1H NMR (500 MHz, CDCl3) δ 
7.09 (m, 1H), 6.24 (m, 2H), 6.16 (m, 1H), 3.81 (s, 3H), 3.75 (s, 1H), 2.03 (m, 2H), 1.9-1.5 (8H),1.40 (m, 
3H), 1.31 (m, 2H), 1.17 (m, 4H), 1.06 (m, 1H), 0.99 (m, 3H),0.96 (m, 3H), 0.92 (m, 6H). 13C NMR 
(126 MHz, CDCl3) δ 160.9, 149.9, 129.9, 129.8, 105.9, 101.5, 98.4, 56.9, 55.1, 51.7, 51.1, 45.6, 42.2, 40.2, 
39.5, 39.4, 36.4, 35.9, 35.4, 35.2, 30.6, 28.04, 28.01, 27.7, 27.1, 24.5, 24.4, 23.8, 23.2, 22.8, 22.5, 20.2. 
IR(neat) vmax 2927, 1611, 1493, 1463, 1208, 1159, 1208, 1159, 1050, 829, 750, 686. DART-
HRMS: m/z calcd. for C25H41NO: 372.3266; [MH]+. Found 372.3233. 
 
Amine 70 
Reductive amination of 58 with p-anisidine yielded amine 70; 42%, 32 mg. 1H NMR (500 MHz, CDCl3) δ 
6.81 (d, J = 8.9 Hz, 2H), 6.59 (d, J = 8.8 Hz, 2H), 3.79 (s, 3H), 3.68 (s, 1H), 2.04 (m, 2H), 1.92 (m, 1H), 
1.9-1.5 (7H), 1.39 (m, 3H), 1.31 (m, 2H), 1.17 (m, 5H), 1.06 (m, 1H), 1.00 (s, 3H), 0.96 (m, 3H), 0.92 (m, 
6H). 13C NMR (126 MHz, CDCl3) δ 151.5, 143.0, 115.0, 113.8, 56.9, 55.9, 52.2, 51.9, 42.2, 40.3, 39.5, 
35.9, 35.4, 30.1, 28.0, 27.1, 23.8, 23.2, 22.8, 22.6, 18.5, 17.9, 13.7.  IR(neat) vmax 2928, 2864, 1508, 1464, 
1262, 1172, 1041, 814. DART-HRMS: m/z calcd. for C25H41NO: 372.3266; [MH]+. Found 372.3249. 
 
Amine 71 
Reductive amination of 58 with (3,4-methylenedioxy)-aniline yielded amine 71; 20%, 24 mg. 1H NMR 
(500 MHz, CDCl3) δ 6.68 (d, J= 8.3 Hz, 1H), 6.26 (s, 1H), 6.05 (m, 1H), 5.87 (m, 2H), 3.65 (s, 1H), 2.03 
(m, 2H), 1.90 (m, 1H), 1.8-1.5 (8H), 1.38 (m, 4H), 1.29 (m, 2H), 1.19 (m, 5H), 1.06 (m, 1H), 0.98 (s, 3H), 
0.95 (d, J = 6.5 Hz, 3H), 0.92 (m, 6H). 13C NMR (126 MHz, CDCl3) δ 148.3, 144.5, 108.6, 100.4, 95.6, 
56.9, 52.2, 51.8, 42.2, 40.3, 39.5, 35.9, 35.4, 30.6, 28.0, 27.1, 23.8, 23.2, 22.8, 22.5, 18.5, 17.8, 
13.6.IR(neat) vmax 3378, 2920, 2860, 1714, 1635, 1600, 1504, 1465, 1377, 1094, 875. DART-
HRMS: m/z calcd. for C25H39NO2: 386.3059 [MH]+. Found 386.3048. 
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Amine 72 
Reductive amination of 58 with 4-hydroxybenzylamine yielded amine 72; 32%, 10 mg. 1H NMR 
(500 MHz, CDCl3) δ 7.05 (d, J = Hz, 2H), 6.78 (d, J = Hz, 2H), 5.17 (s, 1H), 3.40 (s, 1H), 3.02 (m, 1H), 
2.54 (m, 2H), 2.37 (m, 1H), 2.1-1.9 (3H), 1.75 (m, 2H), 1.67 (m, 5H), 1.55 (m, 2H), 1.48 (m, 2H), 1.35 (m, 
3H), 1.15 (m, 3H), 1.06 (s, 3H), 0.90 (m, 9H). 13C NMR (126 MHz, CDCl3) δ 153.9, 131.6, 130.1, 115.2, 
59.8, 55.0, 48.8, 39.4, 36.9, 36.7, 35.3, 34.2, 29,7, 28.3, 28.0, 26.2, 24.3, 22.8, 22.5, 22.4, 22.1, 19.1.  
IR(neat) vmax 2953, 2922, 2854, 1732, 1685, 1553, 1515, 1455, 1259, 1090, 1011, 799. DART-
HRMS: m/z calcd. for C25H42NO: 372.3266 [MH]+. Found 372.3248.  
 
Aldehyde 73133 
A mixture of methoxymethyl triphenylphosphonium chloride (2.1 g, 6 mmol) in THF (30 mL) was cooled 
to 0 C. With vigorous stirring, sodium t-butoxide (640 mg, 5.7 mmol) was added. The heterogeneous 
mixture immediately changed color to yellow and on to deeper yellow and finally deep red at 0 ºC. After 
30 min, a solution of 58 (400 mg, 1.5 mmol) in THF (10 mL) was added to the above mixture. TLC indicated 
consumption of 33 after 20 min. Water (80 mL) was added and the mixture and was washed with ethyl 
acetate (3 x 80 mL). The organic layers were combined, dried over MgSO4, filtered, and concentrated. The 
crude material was purified using column chromatography (SiO2, 100% hexanes to 2% EtOAc in hexanes) 
to yield the vinyl ether; 89%, 390 mg as a clear oil. 1H NMR (500 MHz, CDCl3) d5.84 (m, 1H), 3.43 (s, 
3H), 1.97 (m, 3H), 1.77 (m, 4H), 1.52 (m, 3H), 1.42 (m, 3H), 1.33 (m, 3H), 1.25 (m, 1H), 1.19 (m, 5H), 
1.01 (m, 1H), 0.92 (d, J = 6.5 Hz, 3H),0.87 (d, J = 6.6 Hz, 3H), 0.86 (d, J = 6.6 Hz, 3H), 0.68 (s, 3H). 13C 
NMR (126 MHz, CDCl3) d 138.9, 118.2, 59.3, 56.0, 52.1, 44.4, 40.4, 39.5, 36.2, 28.0, 27.9, 25.1, 23.8, 
22.8, 22.5, 22.4, 21.9, 18.8, 11.6. DART-HRMS: m/z calcd. for C20H37O: 293.2844; [MH]+ Found: 
293.2849.  
The vinyl ether refluxed in methanol (10 mL) and 3N HCl (5 mL) for 12 h. The reaction was neutralized 
by the addition of 2 M NaOH, and the aqueous fraction washed with ethyl acetate (3 x 50 mL). The organic 
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layers were combined, dried over MgSO4, filtered, and concentrated. The crude material was purified using 
column chromatography (SiO2, 100% hexanes to 2% EtOAc in hexanes) to yield 73 in 75%, 280 mg yield 
as a clear oil. 1H NMR (500 MHz, CDCl3) d 9.55 (m, 1H), 2.30 (m, 1H), 1.99 (m, 1H), 1.86 (m, 1H), 1.78 
(m, 1H), 1.66 (m, 2H), 1.53 (m, 2H), 1.30 (m, 8H), 1.12 (m, 5H), 1.02 (m, 1H), 0.93 (d, J = 46.5 Hz,3H), 
0.87(d, J = 2.1 Hz, 3H), 0.86 (d, J = 2.0 Hz, 3H), 0.71 (s, 3H). 13C NMR (126 MHz, CDCl3) d 205.1, 55.4, 
50.6, 49.4, 42.7, 39.4, 39.4, 36.1, 35.6, 28.0, 27.8, 25.7, 24.2, 23.7, 22.8, 22.5, 20.7, 18.7, 11.6. DART-
HRMS: m/z calcd. for C19H35O: 279.2688; [MH]+ Found: 279.2684.  
 
Amine 74 
Reductive amination of 3-aminophenol with aldehyde 73 afforded amine 74; 46%, 8.3 mg. 1H NMR 
(500 MHz, CDCl3) δ 7.05 (t, J = 8.0 Hz, 1H), 6.22 (dd, J = 16.9 Hz, 2H). 6.13 (s, 1H), 4.50 (bs, 1H), 3.17 
(m, 1H), 2.79 (m, 1H), 2.03 (m, 1H), 1.92 (m, 2H), 1.72 (m, 2H), 1.60 (m, 3H), 1.42 (m, 3H), 1.32 (m, 1H), 
1.19 (m 5H), (m, 2H), 0.99 (d, J = 6.5 Hz, 3H), 0.94 (dd, J = 6.6, 2.1 Hz, 6H), 0.74 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 156.8, 150.2, 130.1, 105.9, 104.1, 99.6, 56.2, 53.7, 49.0, 43.2, 40.0, 39.6, 39.5, 36.5, 36.4, 
36.2, 35.7, 31.2, 28.1, 28.0, 27.9, 24.6, 24.5, 23.8, 22.8, 22.6, 21.9, 18.7, 11.9. IR(neat) vmax 2948, 2923, 2864, 
1614, 1508, 1467, 1438, 1333, 1186, 1157, 838. DART-HRMS: m/z calcd. for C25H42NO: 372.3266 [MH]+. 
Found 372.3270. 
 
Amine 75  
Reductive amination of 4-aminophenol with aldehyde 73 afforded amine 75; 38%, 6.2 mg. 1H NMR 
(500 MHz, CDCl3) δ 6.72 (m, 2H), 6.59 (m, 2H), 4.33 (m, 2H), 3.20 (m, 1H), 2.71 (m, 1H), 1.90(m, 4H), 
1.72 (m, 2H), 1.57 (m, 3H), 1.41 (m, 5H), 1.30 (m, 2H), 1.18 (m 6H), 1.06 (m, 1H), 0.99 (m, 3H), 0.93 (m, 
6H), 0.73 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 116.2, 114.1, 56.2, 53.7, 52.1, 50.1, 45.5, 44.0, 43.1, 39.5, 
36.4, 34.8, 31.2, 28.0, 27.6, 25.7, 24.4, 23.8, 22.8, 22.5, 21.9, 20.5, 19.5, 18.7, 11.8. IR(neat) vmax 2950, 2923, 
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2865, 1512, 1468, 1232, 1215, 818. DART-HRMS: m/z calcd. for C25H42NO: 372.3266 [MH]+. Found 
372.3268. 
 
C. C-25 functionalized Analogues  
25-OH Ketone 76 
RuCl3 (100 mg, 0.48 mmol) and NaIO4 (1.5 g, 7.0 mmol) were suspended in H2O (20 mL) with pyridine 
(40 µL, 0.49 mmol). A solution of Ketone 58 (600 mg, 2.3 mmol) in MeCN (20 mL) was added to the 
reaction mixture and heated at 60 ºC for 48 h. The mixture was diluted with saturated sodium thiosulfate 
(20 mL) and filtered through celite. The filtrate was washed with EtOAc (50 mL x 3), dried with anhydrous 
sodium sulfate, and concentrated in vacu. Ketone 76 was purified with column chromatography (22 % 
EtOAc in hexanes), 420 mg, 67%. 1H (500MHz, CDCl3) δ 2.48 (m, 1H), 2.35-2.23 (2H), 2.15 (m, 1H), 2.06 
(m, 1H), 1.93 (m, 2H), 1.77 (m, 1H), 1.65-1.55 (2H), 1.51-1.35 (7H), 1.30 (m, 1H), 1.26 (s, 6H), 1.13 (m, 
1H), 1.01 (d, J = 6.0Hz, 3H), 0.68 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 212.0, 71.0, 62.0, 56.6, 49.9, 
44.3, 41.0, 39.0, 36.2, 35.5, 29.4, 29.2, 27.5, 24.0, 20.7, 19.1, 18.7, 12.5. 
 
Amine 77  
Reductive amination of 3-aminophenol with ketone 76 afforded amine 77; 34%, 12 mg. 1H NMR 
(500 MHz, CDCl3) δ 7.01 (t, J = 8.0 Hz, 1H), 6.19 (m, 2H), 6.12 (m, 1H), 3.04 (m, 1H), 2.20 (m, 1H), 1.98 
(m, 2H), 1.77 (m, 2H), 1.50 (m, 10H), 1.31 (m, 1H), 1.28 (s, 6H), 1.13 (m, 2H), 1.01 (d, J = 6.5 Hz, 3H), 
0.98 (s, 1H), 0.96 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 156.9, 149.8, 130.1, 106.0, 103.5, 99.3, 71.4, 
56.5, 53.4, 45.6, 45.3, 44.3, 36.7, 35.2, 35.2, 33.1, 29.4, 29.3, 29.2, 29.1, 27.7, 24.3, 24.2, 21.3, 20.2, 19.4. 
IR(neat) vmax 3492, 3252, 2916, 1510, 1404, 1245, 1210, 1184, 1155, 962, 816. DART-HRMS: m/z calcd. 
for C24H39NO2: 374.3059 [MH]+. Found 374.3068. 
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Amine 78 
Reductive amination of 4-aminophenol with ketone 76 afforded amine 78; 29%, 19 mg. 1H NMR 
(500 MHz, CDCl3) δ 6.71 (m, 2H), 6.53 (m, 2H), 2.96 (m, 1H), 2.17 (m, 1H), 1.97 (m, 2H), 1.80 (m, 2H), 
1.68 (m, 1H), 1.58 (m, 1H), 1.47 (m, 6H), 1.27 (s, 6H), 1.11 (m, 1H), 1.00 (d, J = 6.6 Hz, 3H), 0.95 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 147.4, 116.2, 114.8, 109.9, 71.2, 56.4, 54.9, 45.7, 45.3, 44.3, 36.7, 35.3, 
35.2, 33.2, 29.7, 29.4, 29.2, 27.7, 24.5, 24.2, 21.4, 20.2, 19.4. IR(neat) vmax 3520, 3250, 2915, 1514, 
1373,1241, 1189, 1162, 1105, 910, 822. DART-HRMS: m/z calcd. for C24H39NO2: 374.3059 [MH]+. Found 
374.3058. 
 
Ketone 79 (25OMe) 
Ketone 76 (100 mg, 0.38 mmol) was dissolved in 3 mL anhydrous DMF and capped with a rubber septum. 
MeI (250 µL, 3.9 mmol) was added followed by NaH (70 mg, 1.1 mmol). The reaction stirred at 0ºC and 
warmed to RT overnight. After 16 h, the reaction was quenched with H2O and extracted with EtOAc (10 
mL x 3). The organics were concentrated and purified via column chromatography (4% EtOAc in hexanes). 
The reaction yielded both starting material 76 (50 mg, 50 %) along with ketones 79 (27 mg, 25%) and 80 
(20 mg, 17%). 1H NMR (500 MHz, CDCl3) δ 3.21 (s, 3H), 2.49 (m, 1H), 2.30 (m, 2H), 2.14 (m, 1H), 2.03 
(m, 1H), 1.95 (m, 2H), 1.73 (m, 2H), 1.6 – 1.2 (12H), 1.18 (s, 6H), 1.12 (m, 1H), 1.00 (d, J = 6.2 Hz, 3H), 
0.67 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 212.1, 74.6, 62.0, 56.6, 49.9, 49.1, 40.9, 40.2, 39.0, 36.3, 35.5, 
27.5, 25.1, 25.0, 24.0, 20.2, 19.1, 18.7, 12.5. 
 
Ketone 80 (9-Me, 25OMe) 
1H NMR (500 MHz, CDCl3) δ3.21 (s, 3H), 2.72 (m, 1H), 2.46 (m, 1H), 2.11 (m, 1H), 1.96 (m, 2H), 1.73 
(m, 4H), 1.43 (m, 8H), 1.22 (d, J = 7.4 Hz, 3H), 1.18 (m, 6H),1.08 (m, 1H), 1.00 (d, J = 6.3 Hz, 3H), 0.68 
(s, 3H). 13C NMR (126 MHz, CDCl3) δ 216.0, 74.6, 57.3, 56.6, 49.6, 49.1, 43.7, 40.2, 36.2, 35.5, 35.1, 30.3, 
29.7, 27.6, 25.0, 20.1, 19.0, 18.7, 18.5, 13.1. 
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Amine 81 (4-70) 
Reductive amination of 3-aminophenol with ketone 79 afforded amine 81; 15%, 14 mg. 1H NMR 
(500 MHz, CDCl3) δ 7.02 (m, 1H), 6.16 (m, 3H), 3.73 (s, 1H), 3.23 (m, 3H), 2.02 (m, 2H), 1.9-1.3 (20H), 
1.25 (m, 3H), 1.19 (s, 6H), 1.09 (m, 5H), 0.97 (m, 6H), 0.89 (m, 2H). 13C NMR (126 MHz, CDCl3) δ 156.8, 
150.1, 130.0, 105.3, 103.3, 99.0, 74.7, 56.7, 51.6, 51.1, 49.1, 42.2, 40.3, 40.2, 36.2, 35.3, 30.6, 29.7, 27.1, 
25.0, 23.2, 20.2, 18.5, 17.8, 13.6. IR(neat) vmax 2993, 2923, 2852, 1725, 1611, 1559, 1509, 1455, 1363, 
1261, 1188, 1085, 814. DART-HRMS: m/z calcd. for C25H42NO2: 388.3216 [MH]+. Found. 388.3243. 
 
Aldehyde 85 (25OH CHO) 
Aldehyde 82 was synthesized following the same procedure as aldehyde 73 from ketone 76; 70% over two 
steps, 390 mg. Although a mixture of a- and b-aldehydes were formed (2:1 mixture based on the aldehyde 
proton peak), a single isomer was obtained for each reductive amination procedure. 1H NMR (500 MHz, 
CDCl3) δ 9.60 (m, 0.5H), 9.53 (m, 1H), 3.47 (m, 0.5H), 3.42 (m, 1H), 1.97 (m, 2H), 1.83 (m, 4H), 1.75 (m, 
2H), 1.62 (m, 6H), 1.48 (m, 12H), 1.34 (m, 2H), 1.27 (m, 10H), 1.00 (m, 6H), 0.96 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 205.3, 71.0, 55.4, 52.1, 50.7, 49.5, 47.6, 45.7, 44.3, 43.4, 39.4, 36.6, 35.6, 35.0, 29.7, 
29.3, 29.2, 27.5, 25.9, 25.7, 24.2, 23.8, 21.2, 20.7, 19.7, 19.2, 18.7, 11.6. 
 
Amine 83  
Reductive amination of 3-aminophenol with aldehyde 82 afforded amine 83; 48%, 15 mg. 1H NMR 
(500 MHz, CDCl3) δ 7.04 (t, J = 8.0 Hz, 1H), 6.22 (m, 2H), 6.12 (s, 1H), 4.21 (bs, 1H), 3.20 (m, 1H), 2.77 
(m, 1H), 2.02 (m, 1H), 1.89 (m, 2H), 1.70 (m, 2H), 1.57 (m, 3H), 1.39 (m, 3H), 1.31 (m, 1H), 1.18 (m, 8H), 
0.98 (d, J = 6.5 Hz, 3H), 0.91 (m, 6H), 0.74 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 156.7, 150.3, 130.1, 
105.9, 103.9, 99.3, 56., 53.7, 48.9, 43.1, 40.0, 39.5, 36.5, 36.2, 35.7, 31.2, 28.0, 27.9, 24.6, 23.8, 22.8, 22.5, 
21.9, 18.7, 11.9. IR(neat) vmax 2629, 1617, 1510, 1466, 1157, 755, 686. DART-HRMS: m/z calcd. for 
C25H42NO2: 372.3266 [M-O+H]+. Found 372.3380. 
 
88 
  
Amine 84 
Reductive amination of 4-aminophenol with aldehyde 82 afforded amine 84; 59%, 16 mg. 1H NMR 
(500 MHz, CDCl3) δ 6.73 (m, 2H), 6.60 (m, 2H), 4.12 (bs, 1H), 3.189 (m, 1H), 2.78 (m, 1H), 1.98 (m, 1H), 
1.90 (m, 2H), 1.71 (m, 2H), 1.57 (m, 3H), 1.38 (m, 4H), 1.18 (m, 7H), 1.05 (m, 1H), 0.97 (d, J = 6.5 Hz, 
3H), 0.91 (m, 6H), 0.73 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 116.2, 114.4, 56.2, 53.7, 43.1, 40.0, 39.5, 
36.4, 36.2, 35.7, 31.2, 28.0, 27.9, 24.6, 23.8, 22.8, 22.5, 21.9, 18.7, 11.8. IR(neat) vmax 2703, 1635, 1508, 
1415, 1155, 804. DART-HRMS: m/z calcd. for C25H42NO2: 388.3215 [MH]+. Found 388.3214. [M-O+H]+ 
calcd. 372.3266. Found 372.3249.  
 
Enol ether 85 
A mixture of methoxymethyl triphenylphosphonium chloride (1.1 g, 3 mmol) in THF (30 mL) was cooled 
to 0 C. With vigorous stirring, sodium t-butoxide (300 mg, 2.8 mmol) was added. The heterogeneous 
mixture immediately changed color to yellow and on to deeper yellow and finally deep red at 0 ºC. After 
30 min, a solution of 76 (210 mg, 0.8 mmol) in THF (10 mL) was added to the above mixture. After 1 hr, 
TLC indicated consumption. Water (30 mL) was added and the mixture and was washed with EtOAc (3 x 
30 mL). The organic layers were combined, dried over MgSO4, filtered, and concentrated. The crude 25-
OH enol ether was re-suspended in DMF (8 mL) and cooled to 0 ºC. MeI (0.5 mL, 8.0 mmol) was added 
followed by NaH (100 mg, 1.6 mmol).  The reaction stirred for 4 h warming to RT. The reaction was 
quenched by slow addition of water (20 mL), and washed with EtOAc (3 x 20 mL). The organics were 
combined, dried and concentrated. Enol ether 85 was purified via column chromatography 3% EtOAc in 
hexanes; 145 mg, 62%.  1H NMR (500 MHz, CDCl3) δ 5.58 (s, 1H), 3.59 (s, 3H), 3.22 (s, 3H), 2.78 (m, 
1H), 2.02 (m, 1H), 1.89 (m, 3H), 1.43 (m, 13H), 1.30 (m, 9H), 1.18 (s, 6H), 1.10 (m, 2H), 0.98 (m, 3H), 
0.93 (m, 2H), 0.61 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 139.0, 118.3, 74.7, 59.4, 55.9, 52.1, 49.1, 44.4, 
40.4, 40.3, 36.5, 36.2, 29.7, 27.9, 25.1, 25.0, 22.5, 22.0, 20.3, 18.8, 11.7.  
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Aldehyde 86  
Enol ether 85 (100 mg, 0.3 mmol) was dissolved in MeOH (10 mL) and HCl (2N, 5 mL). The reaction 
stirred at RT for 6 h till TLC indicated consumption. After which, the reaction as quenched by slow addition 
of 2M NaOH, and washed with EtOAc (3 x 15 mL). The organics were combined, dried and concentrated. 
Aldehyde 86 was purified via column chromatography, 4% EtOAc in hexanes; 75%, 72 mg. 1H NMR 
(500 MHz, CDCl3) δ 9.60 (s, 1H), 3.42 (m, 2H), 3.22 (s, 3H), 2.35 (m, 1H), 2.1 – 1.8 (4H), 1.71 (m, 3H), 
1.61 (m, 3H), 1.43 (m, 8H), 1.18 (s, 6H), 1.09 (m, 6H), 0.99 (m, 4H), 0.93 (m, 4H), 0.89 (m, 4H), 0.76 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 205.1, 108.8, 74.6, 55.4, 50.7, 49.5, 49.1, 40.3, 39.4, 36.5, 35.7, 31.9, 
29.7, 29.3, 27.9, 25.7, 25.0, 24.2, 22.7, 20.7, 20.2, 18.7, 14.1, 11.6. DART-HRMS: m/z calcd. for C25H36O2: 
291.2688 [MH]+. Found 291.2696. 
 
Amine 87 
Reductive amination of 3-aminophenol with aldehyde 86 afforded amine 87; 32%, 18 mg. 1H NMR 
(500 MHz, CDCl3) δ 7.04 (m, 1H), 6.21 (m, 2H), 6.15 (m, 1H), 3.23 (s, 3H), 3.17 (m, 1H), 2.79 (m, 1H), 
2.02 (m, 1H), 1.89 (m, 2H), 1.71 (m, 2H), 1.58 (m, 3H), 1.42 (m, 7H), 1.24 (m, 2H), 1.19 (s, 6H), 1.1 - 1.0 
(4h), 0.99 (m, 3H), 0.92 (m, 3H), 0.73 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 156.9, 130.1, 105.9, 104.1, 
99.5, 74.8, 56.1, 53.6, 49.0, 43.1, 40.3, 39.9, 36.5, 36.4, 35.7, 31.2, 29.7, 27.9, 25.0, 24.6, 21.9, 20.2, 18.7, 
11.9. IR(neat) vmax 3490, 2947, 2875, 1780, 1620, 1572, 1512, 1495, 1453, 1365, 1205, 1170, 895. DART-
HRMS: m/z calcd. for C26H43NO2: 402.3372 [MH]+. Found 402.3366. 
 
Alcohol 88  
Ketone 76 (50 mg, 0.18 mmol) was dissolved in DMF (5 mL) and cooled to 0 ºC. Triethylsilyl chloride (48 
mg, 0.44 mmol) was added followed by imidazole (37 mg, 0.54 mmol). The reaction was quenched by slow 
addition of water (15 mL) and washed with EtOAc (3 x 10 mL). The organics were combined, dried and 
concentrated. The 25-OTES ketone was purified via column chromatography, 5 % EtOAc in hexanes; 94%,  
66 mg. Sodium borohydride (15 mg, 0.38 mmol) was added to a solution of 25-OTES ketone (60 mg, 0.15 
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mmol) in DCM:MeOH (2:1, 6 mL) at 0 ºC. The reaction stirred for 4 h warming to RT. The reaction was 
quenched by slow addition of water (10 mL) and washed with EtOAc (3 x 15 mL). The organics were 
combined, dried and concentrated. Alcohol 88 was purified via column chromatography, 5% EtOAc in 
hexanes; 90%, 60 mg. 1H NMR (500 MHz, CDCl3) δ 4.12 (m, 1H), 2.04 (m, 1H), 1.84 (m, 3H), 1.7 – 1.3 
(13H), 1.23 (s, 6H), 1.11 (m, 3H), 0.99 (m, 11H), 0.94 (m, 3H), 0.60 (m, 6H). 13C NMR (126 MHz, CDCl3) 
δ 73.5, 69.5, 56.7, 52.6, 45.5, 41.8, 40.4, 36.3, 35.3, 33.6, 30.0, 29.8, 27.2, 22.5, 20.8, 18.5, 17.4, 13.5, 7.1, 
6.8. 
 
Ester 89 (25OH, 3-101) 
Ester 89 was synthesized following the same esterification procedure as the C-11 modified analogues (61a-
e). Ester 89 was purified via column chromatography, 15% EtOAc in hexanes; 75% 13 mg. 1H NMR 
(500 MHz, CDCl3) δ 7.62 (m, 2H), 7.34 (t, J = 7.9 Hz,1H), 7.11 (m, 1H), 5.42 (s, 1H), 2.05 (m, 2H), 1.84 
(m, 3H), 1.6 – 1.4 (10H), 1.28 (s, 6H), 1.23 (m, 2H), 1.16 (m, 1H), 1.04 (s, 3H), 0.96 (d, J = 6.5 Hz, 3H).  
13C NMR (126 MHz, CDCl3) δ 166.7, 156.2, 132.1, 129.6, 121.6, 120.2, 116.3, 72.7, 71.6, 56.4, 51.5, 44.2, 
41.9, 39.9, 36.1, 35.4, 30.5, 29.3, 29.2, 27.0, 22.6, 20.8, 18.5, 18.0, 13.6. IR(neat) vmax 2939, 1717, 1687, 
1588, 1452, 1291, 1215, 1156, 1102, 1072, 946, 917, 883, 804, 752. DART-HRMS: m/z calcd. for 
C25H38O4: 420.3114 [MNH4]+. Found 420.3104. 
 
Ester 90 (25OMe, 3-151) 
Sodium borohydride (13 mg, 0.32 mmol) was added to solution of ketone 79 (25 mg, 0.08 mmol) in MeOH 
(5 mL). After 2 h, the reaction was quenched and washed with EtOAc (3 x 15 mL). The organics were 
concentrated in vacu. 25-OMe Grundmann’s alcohol (25-OMe GA) was purified via column 
chromatography, 8% EtOAc in hexanes; 92%, 23 mg. 1H NMR (500 MHz, CDCl3) δ 4.11 (m, 1H), 3.21 (s, 
3H), 2.05 (m, 1H), 1.87 (m, 3H), 1.59 (m, 1H), 1.40 (m, 12H), 1.21 (m, 1H), 1.17 (s, 6H), 1.07 (m, 2H), 
0.97 (s, 3H), 0.94 (d, J = 6.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 74.7, 69.4, 56.6, 52.6, 49.0, 41.8, 
40.4, 40.3, 36.3, 35.2, 33.6, 27.1, 25.04, 25.02, 22.5, 20.2, 18.5, 17.4, 13.5.  
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25-OMe GA (20 mg, 0.07 mmol) was dissolved in DCM (10 mL). 3-OMOM-benzoic acid (42 mg, 0.23 
mmol) was added followed by DMAP (27 mg, 0.21 mmol) and DCC (37 mg, 0.18 mmol). The reaction 
stirred at RT overnight (16 h). The reaction was purified directly via column chromatography, 5 % EtOAc 
in hexanes; 68%, 21 mg. 1H NMR (500 MHz, CDCl3) δ 7.78 (m, 1H), 7.75 (m, 1H), 7.40 (t, J = 7.9 Hz, 
1H), 7.26 (m, 1H), 5.44 (m, 1H), 5.25 (s, 2H), 3.53 (s, 3H), 3.22 (s, 3H), 2.10 (m 1H), 2.02 (m, 1H), 1.87 
(m, 2H), 1.57 (m, 5H), 1.42 (m, 6H), 1.30 (m, 4H), 1.18 (s, 6H), 1.09 (s, 3H), 0.99 (d, J = 6.5 Hz, 3H).  13C 
NMR (126 MHz, CDCl3) δ 166.1, 157.2, 132.3, 129.4, 123.1, 120.8, 117.2, 94.5, 74.6, 72.4, 56.4, 56.0, 
51.6, 49.1, 41.9, 40.3, 39.9, 36.3, 35.4, 30.5, 27.1, 25.0, 22.6, 20.2, 18.6, 18.0, 13.5. 
(±) Camphor sulfonic acid (CSA, 30 mg, 0.13 mmol) was added to a solution of MOM-protected ester (20 
mg, 0.04 mol) in MeOH (5 mL) and stirred at RT overnight (16 h). The reaction was concentrated and 
purified via column chromatography, 8% EtOAc in hexanes; 65%, 14 mg. 1H NMR (500 MHz, CDCl3) δ 
7.66 (m, 1H), 7.61 (s, 1H), 7.35 (t, J = 7.9 Hz, 1H), 7.10 (m, 1H), 6.48 (s, 1H), 5.42 (s, 1H), 3.25 (s, 3H), 
2.08 (m, 2H), 1.84 (m, 2H), 1.56 (m, 5H), 1.42 (m, 5H), 1.30 (m, 3H), 1.21 (s, 6H), 1.05 (s, 3H), 0.97 (d, J 
= 6.5 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 166.6, 156.1, 132.2, 129.6, 121.7, 120.1, 116.2, 75.1, 72.7, 
56.4, 51.5, 49.0, 41.9, 40.4, 39.9, 36.2, 35.4, 30.5, 27.0, 25.0, 24.8, 22.7, 20.3, 18.6, 18.0, 13.6. 
IR(neat) vmax 2982, 2940, 1715, 1686, 1588, 1450, 1290, 1216, 1157, 1098, 1066, 946, 918, 881, 805, 
753.  DART-HRMS: m/z calcd. for C26H40O4: 434.3270 [MNH4]+. Found 434.3276. 
 
Biological Assay Protocols 
General Information 
Protocols for general cell culture, qPCR (Hh pathway and VDR), and VDR binding assays are as previously 
described.127, 131 20α-Hydroxycholesterol and 22(S)-hydroxycholesterol (OHCs) were purchased from 
Sigma-Aldrich. VD3 for biological studies was purchased from Sigma-Aldrich and calcitriol was purchased 
from Caymen Chemical. Data was analyzed using GraphPad Prism 5, and reported values represent mean 
± SEM for at least two separate experiments performed in triplicate. 
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Introduction 
When vitamin D3 and its metabolites were identified as inhibitors of Hh signaling, initial reports 
suggested that inhibition was a result of direct binding to the Smoothened (Smo) receptor.124 Additional 
studies have suggested a mechanism of action where the vitamin D receptor interacts with the Hh pathway 
to inhibit signaling.142 The activity of the most recent analogues developed within the Hadden lab, discussed 
in Chapter 3, suggests that at least some of the Hh inhibitory activity is due to activation of vitamin D 
signaling. This hypothesis is based on similar activity to calcitriol observed for C-25 functionalized 
analogues. An additional trend was observed between Cyp24A1 mRNA expression and anti-Hh activity, 
where both appeared to increase together. This may be coincidental and a result of increased interactions 
with a component of the Hh pathway, but additional mechanism of action studies need to be performed to 
further evaluate this observation. With contradictory mechanisms of action reported, follow-up studies were 
designed to provide insight into the mechanism of action of vitamin D analogues.  
 
I. Vitamin D Receptor  
The vitamin D receptor (VDR) is a member of the steroid hormone nuclear receptor family and a ligand-
dependent transcription factor most commonly associated with calcium and phosphorous homeostasis in 
the bone.142 It is comprised of three domains: (1) N-terminal DNA binding domain (DBD) with two zinc 
fingers, (2) C-terminal ligand binding domain (LBD), and (3) hinge region connecting the two binding 
domains.121 Crystal structures of both the ligand and DNA binding domains have been solved separately in 
the last 20 years,143-144 adding greater insight into the multiple functions of VDR.  
As a nuclear receptor and transcription factor, ligand bound (“active”) VDR interacts with a number of 
coregulatory proteins such as the coactivators, DRIP (vitamin D receptor interacting protein)145 and RXR 
(retinoid X receptor).146 Unliganded (“inactive”) VDR associates with corepressors, such as NCoR (nuclear 
receptor corepressor) and the silencing mediator of retinoic acid and thyroid hormone receptor (SMRT), 
and histone deacetylases (Figure 18).147-148 In addition to regulation by coregulatory proteins, VDR 
function is tissue specific. Using three different cell types, sChIP-seq (chromatin immunoprecipitation-
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sequencing) assays identified 1,600 – 2,700 specific VDR-binding sites, with only 20% of those sites found 
in all three assays.149 This suggests that VDR activity is highly cell type specific and that the 20% conserved 
sites represent important cellular functions for all VDR expressing tissues.  
II. Vitamin D and Cancer 
As noted above, the primary functions of VDR are associated with proper bone formation where 
vitamin D deficiency has been linked for multiple decades to increased risk of fractures and bone disease, 
such as rickets.150-151 In addition, studies in the past 15-20 years have associated vitamin D deficiency with 
a variety of cancers. This correlation was notably seen in the Garland and Garland report that correlated 
colon cancer mortality rates and UV-B exposure, as evident by the highest mortality rates observed in the 
 
Figure 18.147 Regulation of vitamin D receptor activity by coregulatory proteins. Unliganded 
(inactive) VDR associates with corepressor proteins (CoRs) by complex formation with histone 
deacetylases (HDACs). Ligand bound (active) VDR associates with coactivator proteins (CoAs) 
and histone acetyltransferases (HATs). The specific complex regulates the primary target genes for 
transcription, such as protein coding genes (Cyp24A1) or miRNAs (miR-214). Some miRNAs 
regulate mRNA expression of protein encoding genes, as will be discussed later in Chapter 4. 
CEBPA (CCAAT enhancer-binding protein alpha) and SPI1 (PU.1) represent additional 
transcription factors that enhance VDR activity.147,149  Reprinted from Steroids, 78, Carlberg, C.; et 
al. Vitamin D receptor signaling mechanisms: Integrated actions of a well-defined transcription 
factor, 127-136, 2013, with permission from Elsevier. 
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northeastern United states and decreased rates in the south and west.152 This study suggested that increased 
exposure to UV-B (sunlight) lead to higher rates of vitamin D synthesis that could reduce the risk of 
colorectal cancer. In follow-up epidemiological studies,153 low serum 25-OH VD3 (the accepted clinical 
measure for vitamin D levels) was associated with increased risk of prostate, breast, and colorectal cancer. 
Multiple associations have also been made between vitamin D metabolism enzymes and cancer incidences. 
In these studies, increased expression of Cyp24A1, or decreased expression of Cyp27B1, lead to a reduction 
in calcitriol production and increased cancer risk/occurance.153 Taken together, these studies would suggest 
a role for calcitriol in regulating tumor growth.  
Most studies of VDR and calcitriol have been performed using keratinocytes, the primary cell type of 
the epidermis, or outermost layer of skin cells. VDR plays a critical role in their differentiation, so these 
cells maintain tight control over VDR and calcitriol activity by expressing all the enzymatic machinery 
required for production and metabolism of calcitriol.153 Additionally, VDR expression and activity is 
distinct depending on the differentiation status of the cells, with decreased VDR activity as the cells age.142 
Skin cancers, such as BCC and squamous cell carcinoma (SCC), are some of the most common 
malignancies and all express VDR. Even with this relationship, there is a lack epidemiological evidence for 
a positive role of vitamin D and VDR in preventing skin cancer development.154 Animal studies however 
suggest a protective role exists. Administration of dimethylbenzanthracene,155 or UV-radiation,156 to VDR 
null mice resulted in skin tumors formation, while no tumors were observed in control mice. In addition, 
Cyp27B1 null mice, which lack the ability to produce calcitriol, did not show increased susceptibility to 
tumor formation.156 This study suggests that a protective role may exists for VDR itself and not calcitriol.  
A few mechanisms have been proposed for this protective role. First and as previously mentioned, 
vitamin D signaling plays an integral and critical role in the proliferation and differentiation of 
keratinocytes. Secondly, vitamin D signaling regulates DNA damage repair, where VDR null mice show 
slowed DNA damage repair induced by UV-radition.157 Therefore, dysregulation of VDR signaling could 
result in poorly differentiated cells and accumulation of mutations leading to tumor formation.  
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III. VDR and Signaling Pathways 
Both SHh and Wnt/b-catenin signaling are associated with increased proliferation and decreased 
differentiation of keratinocytes, where activation of both pathways are associated with skin tumor 
formation.158 In the absence of VDR, b-catenin expression increased and induced tumors resembling 
BCCs.159-160 Follow-up studies indicated that many b-catenin target genes contain vitamin D response 
elements (VDREs) are many of the genes induced independent of canonical TCF/Lef expression. Activation 
of VDR shifted b-catenin target genes away from canonical TCF/Lef target genes and to VDR controlled 
genes, suggesting that VDR is an independent transcriptional effector of Wnt signaling. 160-161 A follow up 
study indicated that inactive (unliganded) VDR interacted with Lef1 and addition of calcitriol (liganded 
VDR) resulted in VDR-b-catenin binding.161 More recently, several long non-coding RNAs associated with 
tumor formation, such as H19, are overexpressed in VDR null keratinocytes in vitro and in vivo.162 
Overexpression of H19 has been associated with dysregulation of Wnt/b-catenin signaling,163 but this 
potential interaction remains to be investigated. Interactions between Hh and VDR signaling appear to be 
much more complicated and remain to be investigated.  
 
A. VDR and Hedgehog Signaling 
Both Hh and VDR signaling have been suggested to play a role in tumor formation, where VDR null 
mice show overexpression of Hh components and tumor formation.165 However, interactions between VDR 
and Hh signaling are complicated as results have been contradictory. Initial reports looked to investigate 
the endogenous regulation of Smo and suggested that a 3b-hydroxysteroid, VD3 or 7-DHC, was secreted 
by Ptch and interacted with the extracellular domain of Smo to inhibit downstream signaling.124 Based on 
this model, binding of Hh ligands to Ptch prevents secretion of VD3/7-DHC (Figure 19a). Interestingly, 
follow-up studies suggested that VD3 (46) was more active than any of the other vitamin D metabolites – 
7-DHC (45), 25-OH VD3 (47), and calcitriol (48).126 Additional studies have supported a mechanism of 
action of direct binding to Smo and independent of VDR,  where calcitriol independently inhibited Hh 
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signaling and activated VDR signaling  resulting in concomitant antiproliferative effects on BCC growth 
stronger than cyclopamine, Hh-specific inhibition.166 It has also been suggested that the binding site is 
distinct from the trans-membrane (TM) region or the cysteine-rich domain (CRD).167 In agreement with 
this proposal, previous studies in the Hadden lab have shown an inability of VD3 (46) to displace BODIPY-
cyclopamine.131 
Contradictory to these reports, evidence has also suggested VDR-dependent inhibition of Hh signaling. 
First, experiments performed in the Hadden lab show an increase in potency progressing down vitamin D 
metabolism, with calcitriol (48) being the most potent (Ch3, Table 11).  Secondly, increases in analogue 
potency were observed with the incorporation of a C-25 hydroxyl group, the next metabolic step of VD3. 
Another recent report has proposed a crosstalk mechanism for VDR and Hh signaling (Figure 19b).  
Comparing VDR knockout (VDR-/-) and wild-type (WT) breast cancer cells, VDR was shown to regulate a 
 
Figure 19. Interactions of VDR with Wnt and Hh signaling pathways. (A) Proposed interactions where 
activation of VDR alters or repressed pathway target genes and specific vitamin D metabolites inhibit 
downstream signaling.164 (B) Proposed VDR-dependent mechanism for Hh inhibition where VDR 
activation repressed miR-214 expression to increase SuFu mRNA and protein expression.168 
(A) (B) 
VDR-/- VDR+
Dmn3os
miR-214
SuFu
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decrease
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number of micro-RNAs (miRNAs), including miR-214 which was upregulated over 40-fold in VDR-/- 
cells.168 Further studies indicated that VDR and miR-214 were inversely correlated, and miR-214 
suppressed SuFu protein expression.168-169 This study ultimately proposed that VDR indirectly regulates 
SuFu mRNA and protein expression to inhibit Hh signaling through miR-214. Their results suggest that 
activation of VDR increased SuFu protein expression. The determined that this increase was a result of 
indirect repression of miR-214 expression by repressing the expression of Dnm3os, a non-coding RNA 
transcript of the dynamin-3 gene encoding the miR-214 cluster.168 
 
IV. Mechanism of Action Studies  
Based on multiple differences between published reports and experimental evidence in the Hadden lab, 
a series of experiments were designed to elucidate more information on the specific mechanism of action 
that our synthetic analogues utilize to inhibit Hh signaling. Previous studies performed by former lab 
members (Albert M DeBerardinis, PhD, Upasana Banerjee, PhD, and Vibhavari Sail, MS) suggested that 
our synthetic analogues acted independent of VDR. This interpretation was based on very low upregulation 
of the VDR target gene, Cyp24A1, and single concentration studies with VDR-/- cells and VDR-specific 
RNAi (interfering RNA), Figure 20.131  
In these studies, ester 51 maintained inhibitory activity at 5 µM following the addition of VDR RNAi, 
while VD3 (46) lost all inhibitory activity under the same conditions. Calcitriol (48) however showed little 
loss in inhibitory activity, suggesting that VD3 may act through a distinct mechanism. Furthermore, VDR 
RNAi abolished Cyp24A1 upregulation of VD3 and calcitriol, which was not unexpected as VDR RNAi 
was only able to knockdown approximately half of the endogenous VDR mRNA expression.131 Combining 
these results with the inability of VD3 or 51 to displace BODIPY-Cyc (Figure 20c), suggested that VD3 
may act through VDR signaling while our analogues may act through a separate mechanism. In VDR-/- 
cells, there was no loss in anti-Hh activity for VD3 or calcitriol, which further complicated results 
suggesting that all compounds may act independent of VDR (Figure 20d).   
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Figure 20. Initial mechanism of action studies in the Hadden lab. Relative expression of VDR, Gli1 and 
Cyp24A1 in response to non-targeting (filled) and VDR-specific (open) RNAi transfection. Relative 
expression of Gli1 (B), and Cyp24A1 (C) following RNAi and compound treatment. Statistical analysis 
one-way ANOVA with Tukey post-test performed with GraphPad Prism5; ***p<0.001, **p<0.01, 
*p<0.05, compared with corresponding RNAi treatment; # p<0.01, compared between RNAi treatments; 
ns, not statistically significant. (D) Comparison of Gli1 expression in VDR-/- (open) and C3H (closed) 
cells; Statistical analysis one-way ANOVA with Tukey post-test performed with GraphPad Prism5; 
***p<0.001, compared with corresponding OHC treatment; #p<0.01, compared between cell lines; ns, 
not statistically significant. (E) BODIPY-Cyc displacement studies indicate VD3 (46) and ester 51 are 
unable to displace BODIPY-Cyc from Smo.131 
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A. Determining the Necessity of VDR  
A new hypothesis was formed based on previous mechanism of action studies (Figure 20) and the trend 
that Cyp24A1 levels and anti-Hh activity increased together for vitamin D metabolites and the new 
analogues. This new hypothesis is that vitamin D-based compounds may be able to directly inhibit Hh 
signaling but also be able to further inhibit via crosstalk through VDR signaling. To evaluate this 
hypothesis, Cyp24A1 EC50 (half maximal effective concentration) values were collected in ASZ001 (ASZs) 
cells due to obtaining the highest Cyp24A1 values at single concentrations in ASZs, Table 13. A strong 
correlation was observed between Gli1 IC50 and Cyp24A1 EC50 values for nearly all analogues. For 
example, an IC50 value of 110 nM and an EC50 value of 130 nM were obtained for 78 suggesting little “true” 
selectivity for Hh over VDR signaling and a potential role for VDR signaling in the regulation of Hh 
signaling. 
To further investigate potential crosstalk between the two signaling pathways, cellular-knockout 
models were utilized to evaluate VD3 (46), calcitriol (48), and amines 56 and 78. These specific analogues 
(56 and 78) were chosen because even though 78 is the C-25 hydroxylated version of 56 they had 
comparable IC50 values across cell lines, but had significantly different Cyp24A1 expressions (2 – 45-fold 
for 56 and >15,000-fold for 78). With such significant Cyp24A1 differences, we hypothesized that these 
Table 13. Comparison of Hh inhibitory and VDR agonistic potency in ASZ001 BCC cells.  
 IC50 (Gli1, µM)a Cyp24A1b EC50 (Cyp24A1, µM)a 
46 1.1 ± 0.01 2,200 ± 200 0.95 ± 0.05 
47 0.48 ± 0.07 11,000 ± 400c 0.59 ± 0.07 
48 0.089 ± 0.04 >30,000c 0.13 ± 0.001 
77 0.11 ± 0.001 >30,000 0.13 ± 0.003 
78 0.22 ± 0.01 >30,000 0.60 ± 0.08 
81 0.62 ± 0.07 11, 000 ± 2,000 0.65 ± 0.05 
83 1.3 ± 0.07 7.8 ± 2 > 10 
84 0.51 ± 0.09 140 ± 8 1.3 ± 0.7 
87 0.66 ± 0.09 2,400 ± 800 0.56 ± 0.01 
89 0.39 ± 0.08 >30,000 0.44 ± 0.06 
90 1.0 ± 0.2 14 ± 2 >10 
a IC50 and EC50 values represent average Mean ± SEM of at least two separate experiments performed 
in triplicate. bValue represents Cyp24A1 mRNA expression at 2.5 µM compared to DMSO control (set 
to 1.0). cAnalogue evaluated at 1 µM. 
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two analogues may utilize differing mechanisms to inhibit Hh signaling that may be exposed through the 
studies.  
As a follow-up to previous studies, these four analogues were full evaluated in VDR-/- cells, obtained 
from a VDR-/- mouse model in the Sun lab at Rush University.  These cells were upregulated by OHCs 
similar to C3H cells and compared to C3H and ASZ cells, Table 14.  A non-secosteroidal VDR agonist, 
LG190178,169 was kindly provided by Alexander (Leggy) Arnold, PhD, at the University of Wisconsin-
Milwaukee, and used an additional method to evaluate the role VDR plays in Hh inhibition. LG190178 is 
selective for VDR against other nuclear receptors and no additional activities have been reported.  
When the full concentration-dependent analysis was performed, all compounds except VD3 (48, 56 
and 78) showed both a significant loss in potency and, the expected decrease in Cyp24A1 expression. 
Calcitriol showed the greatest difference in activity going from an IC50 of 3 nM in C3H cells to 6 µM in 
VDR-/- cells with Cyp24A1 levels dropping from over 30,000 to about 500-fold. This result was unexpected 
for 56 as low Cyp24A1 levels were previously observed suggesting a VDR-independent mechanism.  
It was originally hypothesized that the significant differences in Cyp24A1 levels for 56 and 78 was a 
result of opposing mechanisms where 56 acted independent of VDR and 78 acted in a VDR-dependent 
mechanism. The overall loss in potency suggested that all vitamin D analogues acted at least in part through 
Table 14. Comparison of inhibitory activity of compounds 46, 48, 56, and 78. 
 C3H
a ASZ001e VDR-/- a 
Cyp24A1b IC50 (µM)c Cyp24A1b IC50 (µM)c EC50 (µM)d Cyp24A1b IC50 (µM)c 
VD3 8,300 ± 40 4.1 ± 0.3 2,200 ± 200 1.1 ± 0.01 0.98 ± 0.06 5.5 ± 0.1 4.5 ± 1.0 
Calcf >30,000 0.0031 ± 0.001 >30,000 
0.089 ± 
0.04 0.13 ± 0.001 530 ± 200 6.3 ± 1.0 
56 45 ± 20 0.40 ± 0.02 2.7 ± 0.7 067 ± 0.02 -- 8.1 ± 2 3.9 ± 0.2 
78 15,000 ± 2,000 0.89 ± 0.03 >30,000 0.22 ± 0.01 0.60 ± 0.08 140 ± 30 4.9 ± 0.01 
LGf >30,000 0.00025 ± 0.04 
13,000 ± 
2,000 
0.00025 ± 
0.0001 
0.0077 ± 
0.003 250 ± 100 1.9 ± 0.2 
aAll analogues evaluated at 5 µM unless otherwise indicated. bValues represent Cyp24A1 mRNA expression 
compared to DMSO control (set to 1.0). c IC50 (Gli1, µM) and dEC50 (Cyp24A1, µM) values represent mean ± SEM 
for at least two separate experiments performed in triplicate.  eEvaluated at 2.5 µM unless otherwise indicated. 
fEvaluated at 1 µM. Calc = calcitriol.  
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VDR. The potent activity and Gli1 expression of LG190178 across cell lines provides additional evidence 
for the Hh inhibitory activity of VDR.  
 
 
B. Evaluation of Potential VDR-Hh Signaling Crosstalk  
Based on reports by Alimirah suggesting that VDR activation induced SuFu expression to inhibit Hh 
signaling,167 the same four compounds were evaluated in SuFu-/- MEF cells. If this proposed mechanism of 
Hh inhibition is correct, then a complete loss in inhibitory activity would be observed in SuFu-/- cells. This 
complete loss would be due to the inability of VDR to upregulate SuFu, as the SuFu gene is inactivated. 
When the four compounds were tested, a similar activity profile for Hh inhibition and VDR activation were 
observed, Table 15. Combining data from these two cell lines provides a few key insights into possible 
mechanism(s) of action. 
First, the ability of calcitriol (48), 56 and 78 to maintain moderate Hh inhibitory activity in SuFu-/- cells 
suggests that these compounds in part inhibit downstream or independently of SuFu, potentially at the 
transcriptional level. A comparison of baseline mRNA expression (Figure 21b) suggests interplay between 
VDR and Hh may exist. When comparing the normalized mRNA values cross these cell lines, a relationship 
between VDR and SuFu mRNA expression appears to exist. The relative mRNA expression of VDR and 
Table 15. Evaluation in Hh component knockout (KO) cells to determine the potential level of 
crosstalk. 
 
C3Ha Ptch-/- a Smo-/- a SuFu-/- a 
Cyp24A1b IC50 (µM)c Cyp24A1
b IC50 
(µM)c Cyp24A1
b IC50 
(µM)c Cyp24A1
b IC50 (µM)c 
46 8,300 ± 40 4.1 ± 0.3 19 ± 2 7.6 ± 2 590 ± 100 
4.4 ± 
0.05 2.9 ± 1.3 > 10 
48d >30,000 0.0031 ± 0.001 
1,400 ± 
500 ND* 
3,600 ± 
200 
0.15 ± 
0.07 590 ± 70 8.5 ± 3 
56 45 ± 20 0.40 ± 0.02 4.7 ± 2 
1.9 ± 
0.06 2.1 ± 0.8 7.0 ± 4 1.2 ± 0.1 
3.1 ± 
0.4 
78 15,000 ± 2,000 
0.89 ± 
0.03 
3,500 ± 
300 
7.1 ± 
0.8 2,600 ± 60 
0.64 ± 
0.4 51 ± 5 
2.9 ± 
0.3 
aAll analogues evaluated at 5 µM unless otherwise indicated. bValues represent Cyp24A1 mRNA expression 
compared to DMSO control (set to 1.0). cGli1 IC50 values represent mean ± SEM for at least two separate 
experiments performed in triplicate. dEvaluated at 1 µM. *IC50 for calcitriol undetermined as concentration-
dependence yielded two inflection points (See Appendix). 
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SuFu appeared to change similarly and opposite Gli1 expression. Looking at the baseline mRNA 
expressions, we found the VDR-/- cells to be more of knockdown model and not a full knockout model due 
to residual expression levels, further complicating interpretations. Taking this into consideration, a 
mechanism of action completely dependent on VDR cannot be ignored. As both cell lines show a significant 
decrease in VDR expression and a loss in anti-Hh activity compared to both C3H and ASZ cells, it can be 
proposed that part of Hh inhibition is due to activation of VDR.  
Since a loss of inhibition was observed in the SuFu-/- cells, additional studies were performed in Ptch-/- 
and Smo-/- cells to determine a potential level at which crosstalk between Hh and VDR may occur (Table 
15). In the Ptch-/- cells, a loss in activity was observed for all compounds, suggesting that the analogues 
     
 
 
 
Figure 21. Evaluation of select analogues (A) in knockout cell lines. Comparison of baseline (B) cycle 
numbers and (C) mRNA expression of Gli1, VDR, and SuFu normalized to ActB across cell lines. 
Statistical analysis performed with GraphPad Prism5, one-way ANOVA with Tukey post-test; 
***p<0.001, compared with C3H expression of corresponding mRNA; ns, not statistically significant 
compared to C3H expression. (D) Relative Gli1 mRNA expression across MEF cell lines.  
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Evaluation in KO cell lines. (A) Analogues  
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interact before or with Ptch, and is contradictory to the previously obtained data from the SuFu-/- cells. Also 
contradictory, 48 and 78 maintained comparable activity in Smo-/- cells to C3H cells suggesting that they 
inhibit downstream of Smo. Due to very little differences observed between the control and treated cells 
and low the baseline expressions of the Smo-/- cells (Figure 21b), data from the Smo-/- cells is not taken as 
conclusive evidence.   
An IC50 for 48, calcitriol, could not be determined (ND*) in the Ptch-/- cells because the concentration-
dependence curve yielded two inflection points (see end of chapter, page 110). It is unknown if this is a 
result of experimental error due to a limit number of concentrations evaluated or indicative of two potential 
mechanisms, such as a VDR-independent and dependent mechanisms. Based on multiple trials resulting in 
the same response, the latter cannot be ruled out. If two mechanisms exist, it may suggest that direct 
inhibition by binding to Smo and a VDR-dependent mechanism, such as that proposed by Alimirah.167 The 
loss of activity for 78 in Ptch-/- cells was slightly unexpected as it maintained relatively high upregulation 
of Cyp24A1, which may suggest that VDR crosstalk occurs at or before Ptch; however, additional studies 
need to be performed to evaluate this interpretation. 
Taken together, the results have led us to propose a new hypothesis with regards to how vitamin D 
structures regulate Hh inhibition. It is hypothesized that Hh inhibition is partially obtained through a VDR-
dependent mechanism where the activation of VDR prevents Hh target gene expression. The differences in 
Cyp24A1 expression can be explained by varying abilities of analogues to recruit specific coactivators to 
induce Cyp24A1 expression. Additionally, a VDR-independent mechanism likely exists due to inhibitory 
activity observed across all knockout cell lines, but the contradictory activities make it hard to determine a 
specific level and target.  
 
V. Computational Modeling 
Based on the intriguing and unexpected results following cellular evaluation of the synthetic analogues, 
an initial computational modeling study was performed with select analogues. Using the Schrödinger 
software, two models were generated.  The first model generated was of the ligand binding domain (LBD) 
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of VDR (PDB file 1DB1). As previously mentioned, VDR is a nuclear receptor that interacts with multiple 
coregulatory proteins to influence its transcriptional activity. Based on the results from our cellular 
evaluation of the synthetic analogues, it is hypothesized that the majority of analogues do interact with 
VDR. We hypothesized that the differences in Cyp24A1 expression result from differing abilities to recruit 
coactivating proteins, such as SRC2, to induce Cyp24A1 expression. A second model generated contained 
the VDR-LBD and a peptide of SRC2-3, steroid receptor coactivtor 2 (PDB file 5H1E). We hoped that 
comparing the binding scores of both models with the cellular activity could help explain the cellular 
differences observed, Table 16.  
Following the modeling studies, the compounds could be placed into four categories: (1) high VDR 
and high coactivator, (2) high VDR and low coactivator, (3) low VDR and low coactivator, and (4) low 
VDR and high coactivator docking scores. Category 1 would suggest strong binding to VDR and a stable 
Table 16. Comparing cellular activity with initial computational modeling of vitamin D analogues 
arranged by docking score to VDR alone. 
 C3H10T1/2 ASZ001 Docking Score
f 
IC50 (µM)a Cyp24A1b,c IC50 (µM)a Cyp24A1b,d VDRg Coact.h 
48 0.0031 ± 0.001 >25,000e 0.089 ± 0.04 >25,000e -15.573 -13.808 
47 0.40 ± 0.1 >25,000d 0.48 ± 0.07 11,000 ± 400e -14.332 -12.681 
83 1.7 ± 0.1 34 ± 0.7 1.4 ± 0.07 8.4 ± 2.0 -13.611 -11.318 
90 1.6 ± 0.1 14 ± 2 1.01 ± 0.2 6.7 ± 2 -13.384 -10.865 
46 4.1 ± 0.3 8,300 ± 40 1.1 ± 0.01 2,200 ± 200 -13.269 -12.176 
87 1.1 ± 0.02 26 ± 4 0.66 ± 0.09 2,400 ± 800 -13.189 -11.139 
89 1.1 ± 0.01 >25,000 0.39 ± 0.08 >25,000 -12.992 -12.201 
77 1.3 ± 0.2 >25,000 0.11 ± 0.0004 >25,000 -12.756 -11.648 
81 3.3 ± 0.7 90 ± 7 0.62 ± 0.07 11, 000 ± 2,000 -12.668 -10.691 
52 0.98 ± 0.04 7.0 ± 0.9 1.8 ± 0.3 1.8 ± 0.2c -12.603 -10.400 
53 3.9 ± 0.8 3.0 ± 0.5 6.3 ± 1.1 1.6 ± 0.2c -12.459 -11.412 
84 0.42 ± 0.04 6.1 ± 0.4 0.51 ± 0.09 140 ± 8 -12.423 -10.953 
56 0.40 ± 0.02 45 ± 20 0.67 ± 0.02 2.7 ± 0.7c -11.846 -10.337 
51 0.74 ± 0.1 22 ± 5 5.2 ± 0.2 1.9 ± 0.1c -11.843 -10.648 
61a 0.92 ± 0.09 3.6 ± 2 5.2 ± 0.5 1.3 ± 0.3c -11.531 -11.714 
55 1.0 ± 0.1 17 ± 4 1.7 ± 0.1 1.8 ± 0.1c -11.208 -10.928 
78 0.89 ± 0.03 15,000 ± 2,000 0.22 ± 0.01 >25,000 -11.094 -10.674 
63 2.0 ± 0.2 9.0 ± 4 4.1 ± 2 1.1 ± 0.09c -11.052 -10.558 
72 3.1 ± 0.1 24 ±0.8 0.34 ± 0.02 1.1 ± 0.7 -8.468 -12.607 
aIC50 values represent average Mean ± SEM of at least two separate experiments performed in triplicate. bValue 
represents Cyp24A1 mRNA expression compared to DMSO control (set to 1.0). cAnalogue evaluated at 5 µM. 
dAnalogue evaluated at 2.5 µM. eAnalogue evaluated at 1 µM. fDocking scores represent predicted binding 
energy generated by Autodock 4.0. gVDR structure PDB file 1DB1. hVDR structure bound to SRC2-3 peptide, 
PDB file 5H1E. 
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complex with the coactivator peptide, which would theoretically lead to increased Cyp24A1 expression. 
Category 2 would suggest strong binding to VDR but a “non-stable” coactivator complex resulting in low 
Cyp24A1 expression. Category 3 would suggest low binding to VDR and therefore low Cyp24A1 
expression.  
Importantly, both calcitriol (48) and 25-hydroxy vitamin D3 (47) had the highest docking scores in both 
models suggesting strong binding to VDR itself and stable binding in the presence of the SRC2-3 
coactivator peptide. Overall the docking scores correlated well with the observed cellular VDR agonism of 
the compounds; i.e., analogues that induce the highest levels of Cyp24A1 mRNA expression were also 
predicted to bind best in both models. Only three compounds did not follow this trend – analogues 78, 83, 
and 89.   
Overall, the models found the 3-hydroxyl position, which would explain the high scores for 83 and 90 
and the low score for 78. Analogues 83 and 90 did have lower docking scores with the presence of the 
coactivator peptide consistent with the low Cyp24A1 levels. Along similar lines, 78 had a relatively low 
docking score in both models, contradictory to the cellular data. Another puzzling result was the docking 
scores of 72.  Based on our hypothesis and as one of the most potent analogues, we expected 72 to have 
one of the highest docking scores for VDR alone and a low score for the coactivator model, but it had the 
opposite results.  
The narrow range of scores in both models does further complicate interpretation of the results. The 
relatively narrow range for the VDR alone model is consistent with the hypothesis that all compounds 
possess the ability to bind to VDR. The narrow range for the coactivator model suggests that all compounds 
would have the ability to induce Cyp24A1 expression, whereas the analogues show a wide range of 
Cyp24A1 levels.  
 
 
 
Conclusion 
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The complexity of Hh signaling has left multiple questions open, specifically the endogenous regulation 
of Smo, and provided multiple targets for therapeutic purposes. Multiple reports have proposed sterols as 
endogenous regulating small molecules, both agonists70,73,75 and antagonists.124 To date, the proposed 
antagonistic regulators of Smo are of the vitamin D scaffold, 45 – 48. Contradictory reports exist for the 
specific mechanism of action utilized by vitamin D-based compounds to inhibit Hh signaling. Multiple 
reports propose direct inhibition of Hh signaling by binding to Smo in a VDR-independent manner.124, 136, 
165-166 In these reports, all metabolites of vitamin D signaling demonstrated the ability to inhibit Hh signaling 
to varying degrees.125 More recently, a VDR-dependent mechanism was suggested. The proposed 
mechanism involves indirect regulation of a specific micro-RNA, miR-214, that controls the regulation of 
SuFu, an endogenous inhibitory protein of Hh signaling. 167,168 In this mechanism, activation of VDR 
downregulates the production of miR-214 resulting in upregulation of SuFu protein and mRNA, resulting 
in Hh inhibition.  
Initial mechanistic studies performed in the Hadden lab were inconclusive, and the biological activity 
data for the lead analogues (51 – 57) suggested a VDR-independent mechanism due to strong inhibition of 
Hh signaling and VDR activation.131, 133 It was also determined that VD3 (46) and 51, our lead ester 
analogue, were unable to displace BODIPY-Cyclopamine, ruling out one known binding site on Smo.131 
Newly developed analogues (Chapter 3) have suggested more of a VDR-dependent mechanism based on 
significant upregulation of Cyp24A1 mRNA and increased inhibitory activity following the addition of a 
C-25 hydroxyl group. To further evaluate these analogues, EC50’s were obtained in ASZ cells, which 
showed the most robust Cyp24A1 upregulation, Table 13. A strong correlation was observed between the 
Gli1 IC50 and Cyp24A1 EC50 values further suggesting potential crosstalk between VDR and Hh signaling, 
and a VDR-dependent mechanism of action.  
 A series of experiments were performed utilizing knockout cell lines to probe the specific 
mechanism(s) of action. These knockout (KO) lines included VDR, Ptch, Smo, and Sufu-/- cell lines to fully 
evaluate the necessity of VDR and determine which level of signaling crosstalk occurs. Unfortunately, 
baseline analysis of these cell lines (Figure 21b) indicated a few issues with this method. It was determined 
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that our VDR-/-was not a complete knockout cell line. One possibility is that the method used to “knockout” 
the VDR gene resulted in the formation of non-functional VDR and not complete removal. If the binding 
region of Taqman primer used was not altered, this would explain the baseline VDR readings. Because 
Cyp24A1 levels are still upregulated similar to the SuFu-/- cell line, it is hypothesized that a small amount 
of functional VDR remained after “knockout.” Another issue was that Gli1 levels were very low in our 
Smo-/- line making it hard to make any conclusions based on very little difference between control and 
treated cycle numbers.  
Overall, comparing C3H and ASZ cell data with the KO cell studies suggests that a VDR-dependent 
mechanism(s) exists for Hh inhibition. Even though our VDR-/- cells were more of a knockdown cell line, 
a positive correlation can be seen between VDR levels and Hh inhibitory activity. Overall, the anti-Hh 
activity decreased with decreases in VDR expression and activation. These studies also provided a few key 
insights into potential mechanism(s) of action and lay a foundation for those studies and provided a new 
hypothesis to be evaluated. The decrease, but not complete loss, in inhibitory activity across KO cell lines 
suggests that multiple mechanisms, both VDR-independent and –dependent exists. Additionally, the 
decrease in activity for 56 in VDR-/- cells was unexpected based on little upregulation of Cyp24A1 observed 
in C3H and ASZ cells, which had suggested a VDR-independent mechanism of action. The decrease in 
activity is the foundation for a new proposed mechanism of action for Hh inhibition.  
Based on these studies, it is believed that both VDR - dependent and – independent mechanisms exist 
and work synergistically to inhibit Hh signaling. With multiple reports suggesting contradictory 
mechanisms, it is hard to ignore the potential for different inhibitory mechanisms to exist that are cell type 
specific. In this proposed mechanism, it is hypothesized that vitamin D-based compounds interact directly 
with the Hh pathway but also activate VDR to reduce Hh target gene expression. Furthermore, as a nuclear 
receptor, VDR is known to interact with multiple coregulatory proteins to regulate target gene expression. 
This is important because the loss in activity for 56 suggests that compounds that have low Cyp24A1 values 
may still inhibit through VDR without upregulating Cyp24A1. Taken together, it is suggested that vitamin 
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D based compounds utilize both VDR-dependent and independent mechanisms, and may not interact 
strongly enough with VDR to upregulate Cyp24A1 via specific coactivator recruitment. 
Initial computational studies to further probe potential mechanism(s) of action through VDR suggest 
that all analogues have the ability to bind to VDR with differing abilities in the presence of a coactivator 
peptide. The results of these studies however were not as conclusive as we had hoped with a relatively 
narrow range of scores in both models. This narrow range suggests that all compounds have the ability to 
bind in both model systems and do not explain the major differences observed with the Cyp24A1 expression 
levels. The simple docking and non-flexible models may explain these observations, and suggests the need 
for more thorough and in-depth modeling studies.  
 
Experimental Procedures 
General Information. Protocols for general cell culture, qPCR (Hh pathway and VDR), and VDR binding 
assays are as previously described.127, 131 20α-Hydroxycholesterol and 22(S)-hydroxycholesterol (OHCs) 
were purchased from Sigma-Aldrich. VD3 for biological studies was purchased from Sigma-Aldrich and 
calcitriol was purchased from Caymen Chemical. Data was analyzed using GraphPad Prism 5, and reported 
values represent mean ± SEM for at least two separate experiments performed in triplicate.  
 
Fluorescence Binding Assays.131 For flow cytometry experiments, HEK293T cells were seeded in 10 cm 
cell culture dishes (2.5 × 106 cells) and incubated overnight (37 °C, 5% CO2). Cells were transfected with 
Smo-Myc3 expression plasmid
 (24 µg) using Lipofectamine 2000 reagent (60 µL) was added and the cells 
returned to the incubator overnight. The next day, cells were split into a single 6-well plate and incubated 
overnight. The next day (2 days post- transfection) cells were incubated in DMEM containing 10% FBS, 
BODIPY-Cyc (5 nM), and various concentrations of Cyc, VD3, or 5 at 37 °C for 4 h. Cells were trypsinized, 
centrifuged, and resuspended in 500 µL of phosphate buffered saline (PBS) for flow cytometry analysis. 
To determine transfection efficiency, cells were fixed with 2% PFA (15 min), permeabilized with 90% 
ethanol (30 min, 4 °C), and blocked for nonspecific binding with 10% FBS in PBS (15 min, RT). Cells 
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were incubated with anti-Myc antibody (1:800, Cell Signaling Technology) for 1 h at RT, followed by 
Alexa Flour-647 donkey anti-rabbit antibody (1:1000, Invitrogen) for 30 min at RT. Finally, cells were 
analyzed for green fluorescence using flow cytometry.  
 
VDRi Assay. C3H10T1/2 cells were seeded into 24-well tissue culture treated plates 24 h prior to 
transfection. Lipofectamine 2000 (2.1 µL, Invitrogen) was mixed with mouse VDR-specific siRNA (2.5 µL 
of a 20 µM stock solution, Dharmacon) in OptimMEM reduced serum media (95.4 µL, Life Technologies). 
Transfection solution (100 µL/well) was added dropwise to cells supplemented with BME (400 µL/well) 
containing 0.5% fetal bovine serum (Atlanta Biologicals) and 1% penicillin/streptomycin/L-glutamine 
(Cellgro) and plates returned to the incubator (37 °C, 5% CO2). Following a 6 h incubation period, 
transfection media was replaced with complete growth media and cells incubated overnight. Cells were 
treated with VD3 (46, 5 µM), calcitriol (48, 0.5 µM), 51 (5 µM), or control 24 h post-transfection. RNA 
isolation and cDNA synthesis was performed 24 h post-treatment (48 h post- transfection) using the Cells-
to-Ct kit (Ambion) following the manufacturer’s protocol and qPCR analysis of target genes followed 
standard procedures.  
 
Calcitriol concentration-dependent graph assay in Ptch-/- cells appears to have two inflection points. 
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Introduction 
As discussed in Chapter 1, the Hedgehog (Hh) pathway is an embryonic signaling pathway primarily 
inactive in adult cells. Since its initial discovery as a key pathway responsible for embryonic patterning and 
development, our understanding of Hh signaling and the key components of the pathway has grown. In 
adult tissues, the pathway is responsible for maintaining homeostasis of stem cell populations, primarily in 
the skin and central nervous system.1 Abnormal regulation of the pathway, specifically constitutive 
activation through mutations or irregular expression, has been linked to a variety of cancers, most notably 
BCC and MB. Hh signaling has since emerged as a therapeutic target with multiple components of the 
pathway serving as targets of interests (Figure 22). Among the Hh pathway components under 
investigation, the trans-membrane protein Smoothened (Smo) has been the most studied and targeted.  
 
Figure 22.16 Representative targets and inhibitors of Hh signaling under investigating. Tumor 
suppressors (red) and oncogenes (green) that have been reported in preclinical and some clinical settings 
to cause or maintain basal cell carcinoma (BCC) and medulloblastoma (MB) are shown. Stars (activating 
or inactivating mutations) and arrows (genomic amplifications) indicate pathway components 
implicated in resistance to Smo inhibitors. Additional inhibitors do exist that are not indicated in this 
image such as Ptch inhibitors and PKA agonists. Reprinted from Developmental Cell, 38, Pak, E.; et al. 
Hedgehog signal transduction: Key players, oncogenic drivers and cancer therapy, 333-344, 2016, with 
permission from Elsevier.  
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Small molecule modulators of Smo have been investigated as both agonists and antagonists of Hh 
signaling. Among the scaffolds under investigation, two sterol scaffolds have shown therapeutic potential 
as anti-cancer chemotherapeutics (vitamin D) and treatment options for osteo- and neurodegenerative 
disorders (oxysterols) (Figure 23). Oxysterols (OHCs) have been well characterized as agonists of Hh 
signaling by direct binding to Smo, specifically the extracellular cysteine-rich domain (CRD).2, 71-74 The 
specific mechanism(s) of action by which vitamin D inhibits Hh signaling is unclear. However, questions 
remain about their ability to treat degenerative disorders in humans.  
In 2006, a 3b-hydroxysteroid, ultimately proposed to be pro-vitaminD3 or vitamin D3, was identified 
as an inhibitor of Hh signaling.125 The specific mechanism of action was later proposed to be through direct 
binding to Smo.118 Follow up studies have since confirmed inhibition of Hh signaling by the vitamin D 
family – pro-vitamin D3 (45), vitamin D3 (46), 25-hydroxyvitamin D3 (47) and calcitriol (48) – and 
analogues of vitamin D3.126-134   However, contradictory mechanisms of action by which these compounds 
inhibit Hh signaling have been proposed. Similar to initial reports, multiple studies have proposed a 
mechanism independent of the vitamin D receptor (VDR).124, 165-166 Other studies have proposed a VDR-
dependent mechanism,167 including the studies discussed here.  
 
Figure 23. (A) Representative oxysterol agonists of Hh Signaling; (B) Vitamin D family and 
representative analogues. 
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The initial mechanism of action studies discussed in the previous chapter (Chapter 4) suggested that 
crosstalk between Hh signaling and VDR exists. First, correlation between the Gli1 IC50 and Cyp24A1 EC50 
values in ASZ001 cells (Ch4, Table 13) suggested that VDR may play a role in regulating Hh signaling. 
Secondly, knockdown of baseline VDR levels in multiple cell lines (Ch4, Figure 21) resulted in decreases 
in anti-Hh activity for the four compounds tested – 46, 48, 56, and 78.  
Simple docking studies, described in the previous chapter, suggested that all analogues have the ability 
to bind to VDR. These studies looked to compare the ability of analogues to bind to VDR alone and in the 
presence of a coactivator peptide, SRC2-3. These studies were not conclusive due to a narrow range of 
docking scores and limitations with the studies. These limitations include not allowing complete flexibility 
of the VDR ligand binding domain (LBD) and the coactivator peptide. By not allowing flexibility in these 
regions, a true ranking list of the analogues could not be determined. The docking studies appeared to favor 
the 3-hydroxyl phenolic A-ring moiety contradictory to cellular studies where the 4-hydroxyl position 
yielded greater Cyp24A1 mRNA expression (Ch4, Table16).  
Combining the results obtained in the Hadden lab, a hypothesis has been proposed to describe the 
mechanism of action by which vitamin D - based compounds inhibit Hh signaling. Based on our studies, 
we believe that these compounds inhibit Hh signaling at least in part through a VDR-dependent mechanism. 
To explain the significant differences in observed Cyp24A1 mRNA levels, we hypothesize that these 
differences result from different abilities to recruit coactivators of VDR to induce Cyp24A1 expression. 
Describe herein are proposed studies to further elucidate the mechanism by which vitamin D compounds 
inhibit Hh signaling and study this proposed mechanism of action.  
 
I. Induction of Osteogenesis by Oxysterols  
Studies in the Hadden lab to date have focused on the ability of OHCs to induce osteogenic 
differentiation in bone-marrow derived stromal cells, M2-10B4 cells. In these studies, OHCs 20 and 28 
showed comparable abilities to induce osteogenic differentiation through a similar mechanism.108 OHC 32 
however appeared to induce differentiation through a different mechanism. The ability of these analogues 
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to induce differentiation was determined through qPCR analysis of osteogenic genes, osterix and alkaline 
phosphatase. To further evaluate the ability of these compounds to induce differentiation, bone-marrow 
derived human mesenchymal stem cells can be used to determine the ability of OHCs to induce osteogenesis 
in human cells (ATCC PCS-500-012). A commercially available osteocyte differentiation kit (ATCC PCS-
500-052) can be used to compare the ability of OHCs to induce osteogenesis. Additionally, staining 
protocols may be utilized to visualize complete differentiation to osteoblasts.   
Two different staining techniques can be used to compare differentiation abilities. The first staining 
techniques is Alizarin Red S. Alizarin Red stains extracellular calcium deposits. In contrast to 
undifferentiated cells, differentiated osteoblasts accumulate extracellular calcium deposits. Osteoblasts – 
mediated accumulation is indicative of the formation of bone mass. The second staining procedure 
visualizes alkaline phosphatase activity to indicate differentiation into osteoblasts. This protocol uses 5-
bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT) as a substrate to stain cells blue-
violet when alkaline phosphatase is present.     
 
II. Vitamin D Receptor Binding Assays 
Although the docking studies showed the potential for all the developed vitamin D-based analogues to 
bind VDR, the limitations of the studies make the results inconclusive. To follow up with these studies, 
biochemical assays may be utilized to determine the ability of analogues to bind to VDR. These studies 
would allow for flexibility in both the small molecule and protein that could not be accounted for in the 
docking studies.  Two commercially available kits could be utilized to compare the binding affinities similar 
to the two docking models.  
The first kit is the fluorescence polarization (FP) based PolarScreenTM Vitamin D Receptor Competitor 
Assay Kit from ThermoFisher Scientific. This kit utilizes full-length human VDR and a proprietary 
fluorescent VDR ligand. The kit is also optimized for a 384-well format allowing for multiple compounds 
and concentrations to be evaluated in a single assay. If the analogue binds to VDR in the LBD, the analogue 
would displace the fluorescent ligand to ultimately give an IC50 value.  
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By utilizing full-length VDR, this assay also allows for potential allosteric sites to be explored. If one 
of the analogues binds to an allosteric site, it may also displace the fluorescent ligand to indicate binding. 
Unfortunately, the analogues may not be able to displace the fluorescent ligand whether they bind in the 
LBD or an allosteric site. To address this possibility, a modification of the assay could be performed. Under 
the standard assay format, VDR and the fluorescent ligand incubate prior to administration of the compound 
of interest. If the compound of interest incubates with VDR or the incubation step is removed and adding 
all three components simultaneously, the potential issue of “weaker” binding can be reduced by removing 
the need to displace the fluorescent ligand.  
As the first kit can be utilized to determine and measure the ability of compounds to bind to VDR, the 
second kit can be used to determine if the compounds are capable of recruiting a coregulatory protein. This 
second kit is the LanthaScreenTM TR-FRET VDR Coactivator Assay Kit from ThermoFisher Scientific. 
Unlike the first kit, this kit only uses the VDR-LBD tagged with glutathione-S-transferase (GST) and a 
fluorescein-labeled TRAP220/DRIP-2 coactivator peptide. The tagged VDR-LBD is added to the 
compound of interest followed by addition of the coactivator peptide and a terbium (TB)-labeled anti-GST 
antibody. If the compound binds to the VDR-LBD, a conformational change allows for the coactivator 
peptide to be recruited and bind to VDR (Figure 24). When the Tb-labeled antibody binds to the GST tag 
and is excited at 340 nm, an energy transfer to the fluorescein - coactivator peptide can be detected at 520 
nm. If the compound of interest does not bind to the VDR-LBD, this energy transfer does not occur and the 
antibody emission can be detected at 495 nm. A TR-FRET ratio of 520:495 can then be calculated to provide 
an EC50 dose-response curve.  
 
Figure 24. Principle of the TR-FRET coactivator assay (LanthaScreen). NR = Nuclear Receptor (VDR) 
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Similar to comparing the two docking studies, comparing the experimental values of these two kits will 
give a greater understanding towards analogue binding to VDR and the validity of our proposed hypothesis. 
Based on the proposed hypothesis, the four analogues utilized in the knockout studies would give potent 
IC50 and EC50 values in both assays for calcitriol (48) and 78, while VD3 (46) and 56 would show moderate 
IC50 values for the VDR assay and weak EC50 values for the coactivator assay. If all compounds show 
similar profiles in both assays, more in-depth studies can be proposed to determine the reason for the cellular 
activity differences.  
  
III. Knockdown Studies  
With inconclusive results from the knockout cell line studies discussed in Chapter 4, another method 
may be utilized to provide insight into the specific mechanism of action that vitamin D-based compounds 
use to inhibit Hh signaling. Similar to previously utilized techniques in the initial mechanism studies,131 
RNA knockdown of the protein of interest in a single cell line should provide greater insight than the use 
of multiple knockout cells with varying baseline expressions.  
Previously, siRNA knockdown of VDR was performed in C3H10T1/2 cells. These cells are well 
understood and have good baseline expression of all proteins of interest – Ptch, VDR, and SuFu. 
Additionally, C3H cells respond robustly to Hh pathway or VDR activation by small molecules. Typical 
PCR cycle numbers of 28 – 30 for Gli1 and 35 or more for Cyp24A1 are seen in DMSO controls compared 
to 22 – 25 for Gli1 and Cyp24A1 with compounds (Figure 25A). This robust response would allow for 
even small differences between concentrations and compounds to be seen more easily. Since C3H cells 
were previously utilized, a procedure already exists that resulted in at least 50% knockdown of VDR mRNA 
which resulted in a proportionate reduction in Cyp24A1 expression (Figure 25B).  
Unfortunately, knockdown of mRNA expression does not always correlate with protein expression. 
Combining the knockdown studies with Western blot analysis of the lysates would confirm any changes. 
When the baseline levels of the knockout cells were compared, a theoretical relationship between VDR and 
SuFu could be observed where the mRNA expression of each appeared to change in a similar manner. This 
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is most prominently seen in SuFu-/- cells which showed the lowest expression of VDR when normalized to 
ActB (Figure 25D). Similarly, Alimirah proposed that regulation of mi-RNA by VDR resulted in increases 
in the protein and mRNA expression of SuFu, which ultimately lead to Hh pathway inhibition. Based on 
the proposed mechanism of action by Alimirah,167 it is possible that protein expression may change without 
changes to mRNA expression. A comparison at the protein level would allow for a more in-depth look at 
changes following compound administration.  
 
Figure 25. (A) Non-normalized cellular response of C3H cells in response to pathway activation. (B) 
Initial mechanism of action studies with siRNA knockdown. Statistical analysis one-way ANOVA with 
Tukey post-test performed with GraphPad Prism5; **p<0.01, compared with non-targeting RNAi 
treatment; ns, not statistically significant. Baseline comparison of knockout cell lines non-normalized 
(C) and normalized (D) to ActB of DMSO. Statistical analysis performed with GraphPad Prism5 one-
way ANOVA with Tukey post-test; ***p<0.001, **p<0.01, compared with corresponding mRNA 
expression in C3H cells; ns, not statistically significant. 
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The increase in activity for 25-OH VD3 (47) and calcitriol (48) compared to VD3 (46) suggest a role 
for VDR in the anti-Hh activity of these compounds. This observation also suggests that VD3 may only be 
activity due to in vitro metabolism. To study this hypothesis, mRNA knockdown of Cyp2R1 and Cyp27B1 
could be performed. By knocking down these enzymes, metabolism of VD3 or 25-OH VD3 is halted 
leading to accumulate in cells. The activity of all three compounds could then be compared to non-
transfected cells allowing for any role of vitamin D metabolism to be determined.  
 
IV. Labeling Studies 
The series of experiments described above look to determine the level at which vitamin D-based 
compounds inhibit Hh signaling and gain an understanding of the cellular responses to compound 
administration. These studies do not confirm or specifically look to identify the cellular protein target, or 
targets. With multiple targets proposed in previous publications, the use of labeling studies would provide 
more concrete evidence to the protein target(s) and allow for those target(s) to be identified. The VDR 
binding assays allow for the potential of the analogues to bind to VDR to be quantified but are only 
biochemical assays. A labeled analogue would allow for any VDR binding to be determined in cells. The 
more important aspect of the labeling studies would be to determine if the analogues interact with Smo. 
If vitamin D-based compounds do interact directly with Smo, multiple binding sites have been proposed 
including the CRD and the trans-membrane region. Preliminary studies in the Hadden lab showed that 
neither VDR (46) or 51 were able to displace BODIPY-Cyc in intact cells or isolate membranes (Ch4 Figure 
 
Figure 26.167 Calcitriol mediated inhibition of Smo 
constructs. CP=cyclopamine 
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20E).131 In 2015, calcitriol was proposed to bind to the CRD region, which would explain the inability to 
displace BODIPY-Cyc; however, no direct binding studies were performed.128  
Similarly, Linder et al. showed an inability of calcitriol to displace BODIPY-Cyc.167 They also utilized 
wild-type Smo (Smowt) and DCRD Smo (SmoDCRD) constructs in a luciferase-based assay to try to identify 
a specific binding site on Smo (Figure 26). In these studies, they showed that similar to Cyc there was no 
difference in inhibitory activity between the two Smo constructs. This led them to suggest that calcitriol 
binds to a unique TM-region of Smo, although they did not show any direct interactions.167 Using a labeled 
version of vitamin D and similar Smo constructs, a binding site on Smo could be identified. 
The specific label can be placed on vitamin D in multiple positions (Figure 27). As shown by the C-11 
modified analogues (Ch3, 67),134 the attachment of a BODIPY or fluorescent label at the C-11 position 
should not interfere with binding. Additionally, when 51 and 61 – 67 are compared, modifications at this 
position appeared to increase selectivity for Hh signaling. Attaching a label to this position could therefore 
help identify a non-VDR target, such as Smo. A second position for label attachment is the C-22 position 
of the alkyl-side chain, accessible from vitamin D2 starting material. Finally, 
a third position that could be utilized is the C-2 position of the A-ring. 
Multiple synthetic papers have been published with C-2 modifications and 
shown that these modifications do not interfere with binding to VDR.170-172 
The C-2 position also provides a position opposite of the C-11 and C-22 
positions. This may be important and useful if the incorporation of the larger 
labeling group abolishes anti-Hh activity.  
 
V. Calcemic Effects  
As discussed in Chapter 3, VDR regulates a variety of cellular process. The most notable of these 
processes is the regulation of calcium, which limits the clinical utility of vitamin D-based compounds. 
Therefore, the usefulness of vitamin D-based compounds in a clinical setting is based on their ability to 
avoid hypercalcemic effects.  
 
Figure 27. Label 
attachment positions on 
VD3 where R1 = C-11; 
R2 = C-22; R3 = C-2. 
H
HO
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Based on the cellular data and mechanism studies for the analogues described in the previous chapters, 
some analogues may be devoid of the hypercalcemic effects seen with calcitriol. An initial way to determine 
the ability of compounds to regulate calcium levels through VDR activation is to measure the expression 
of VDR target genes associated with calcium regulation, such as TRPV6 (membrane calcium channel).174 
A more in-depth way to measure these effects is to use animal models. Animal models allow for calcium 
changes to be determined. The two changes that are typically measured are changes in serum calcium levels 
(bone calcium mobilization) and the serosal/mucosal calcium ratio (calcium transport), Figure 28.173-176 
Even if all analogues do interact with VDR to inhibit Hh signaling, if any compounds are devoid of calcemic 
effects they could be more clinically attractive.  We know that this to be possible based on multiple reports 
of both secosteroidal and non-steroidal noncalcemic vitamin D mimics reported.169, 175-176 
 
VI. Vitamin D Analogues  
With the calcemic activity of the previous synthetic analogues unknown, incorporating functionality 
known to have less or minimal calcemic activity would be beneficial. Among the functionalities shown to 
have less calcemic activity is C-20 hydroxylation. Both 20(R)- and 20(S)-OH VD3 were first isolated in 
2003 and determined to metabolites of Cyp11A1 metabolism of VD3.178 Additional studies determined that 
20(S)-OH VD3 was as potent, or more potent, than calcitriol in inhibiting the proliferation of normal or 
immortalized keratinocytes, as well as leukemia and melanoma cells.179-182  
 
Figure 28. Example figures of calcemic activity from Reference 174. Reprinted (adapted) with 
permission from Sibilska, I. K.; et al. Synthesis and biological activity of 2-methylene analogues of 
calcitriol and related compounds. J. Med. Chem. 2015, 58, 9653-9662. Copyright 2015 American 
Chemical Society. 
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There are currently two synthetic routes reported to synthesize these metabolites. The first synthetic 
route follows the endogenous metabolic pathway using commercially available pregnenolone acetate as the 
starting material (Scheme 10).180 Bromination at the C-7 position followed by dehydro-bromination yields 
7-dehydropregnenolone acetate. Grignard addition of freshly prepared 4-methylpentylmagnesium bromide 
will selectively yield 20(S)-OH VD3. Unlike the similar Grignard addition to form OHC analogues 32 - 33, 
the C-18 and C-21 methyl groups prevent front-side attack and the formation of 20(R)-OH VD3. Irradiation 
with UVB yielded a mixture of steroids that can be separated to provide 20(S)-OH VD3.  
 
Scheme 10.180 Reagents and conditions: (a) dibromantin, 2,2′-azobisisobutyronitrile, benzene/hexane 
(1:1), 100 °C, reflux; (b) Bu4NBr, Bu4NF, THF, RT; (c) Mg, 4-methylpentylbromide, THF, O°C - RT; 
(d) UVB irradiation, 5min followed by 3 days stirring in solution, RT. 
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Scheme 11.181 Reagents and conditions: (a) KMnO4, EtOH–H2O; (b) i. Pb(OAc)4, Na2CO3, DCM; 
ii. Red-Al, benzene; (c) Ac2O, Pyr, DMAP, DCM; (d) OsO4, NMO, acetone:t-BuOH; (e): NaIO4, 
H2O:THF; (f) morpholine, p-TsOH, PhH, reflux; (g) KMnO4/Al2O3, acetone; (h) Mg, 4-
methylpentylbromide, THF, O°C to RT; (i) PDC, DCM. 
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The second synthetic route allows for analogues to be developed and uses vitamin D2 as the starting 
material (Scheme 11).181 Regioselective dihydroxylation of the vitamin D2 triene followed by oxidative 
cleavage and reduction provides alcohol 91. Protection of the hydroxyl group followed by dihydroxylation 
with osmium tetroxide (OsO4) to triol 92 allows for oxidative cleavage of the side chain diol to yield 
aldehyde 94. Formation of aldehyde 95 is accomplished by oxidative cleavage of enamine 94 with alumina 
supported potassium permanganate (KMnO4/Al2O3). Similar to the previous route, Grignard addition of 4-
methylpentylmagnesium bromide yields diol 96 stereoselectively. Alcohol 96 can then be used to 
synthesize new analogues or oxidized with pyridinium dichromate (PDC) to ketone 97 to provide additional 
analogues.   
Vitamin D analogues should also be further evaluated as inhibitors of Hh signaling. The analogues can 
be evaluated against mutant models of Smo and in primary cancer cell lines dependent on Hh signaling, 
such as the MB MERP cells. These studies would be beneficial in providing additional evidence towards a 
mechanism of action as well as further demonstrating the ability to inhibit Hh signaling. If the compounds 
inhibit in a VDR-dependent manner, they should theoretically maintain potency against mutant models of 
Smo.  
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NMR Spectra 
I. Oxysterols (OHC) Analogues 
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H assignment S-MTPA-39 ester (ppm) R-MTPA-39-ester (ppm) DdSR (ppm) 
17 1.732 1.748 -0.016 
18 0.517 0.645 -0.128 
19 0.979 1.026 -0.047 
26/27 0.902 0.859 0.043 
7 1.965 1.995 -0.030 
20 5.146 5.165 -0.019 
12 1.759 1.772 -0.013 
22 1.898 1.861 0.037 
25 1.553 1.481 0.072 
4 2.375 2.390 -0.015 
4 2.218 2.236 -0.018 
Based on reference (Hoye, T. R., et al. Nature Protocols, 2007, 10, 2451), DdSR shift indicates R1 or R2 
moiety of the compound, where positive shift corresponds to R1 (side chain) and negative shift R2 
(tetracyclic body).  
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H assignment S-MTPA-40 ester (ppm) R-MTPA-40-ester (ppm) DdSR (ppm) 
18 0.744 0.708 0.036 
19 1.050 1.045 0.005 
26/27 0.838 0.887 -0.049 
7 2.018 1.999 0.019 
20 5.246 5.257 -0.011 
4 2.404 2.395 0.009 
4 2.241 2.238 0.003 
Based on reference (Hoye, T. R., et al. Nature Protocols, 2007, 10, 2451), DdSR shift indicates R1 or R2 
moiety of the compound, where positive shift corresponds to R1 (side chain) and negative shift R2 
(tetracyclic body).  
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-1.0-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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a. C-11 Modified Analogues 
 
 
 
 
-0.50.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
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1600
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28
1.
27
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b. Amine seco-B Analogues  
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c. C-25 Functionalized Analogues  
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